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Abstract 
Abstract 
The FK506-binding protein 51 (FKBP51) has an important role in several diseases and 
pathologic states like stress-related depressive disorder, obesity and cancer. Gaali et al. just 
recently developed the first series of selective FKBP51 inhibitors. All ligands known before 
bind to FKBP51 and the structurally very similar, but functionally opposing, FKBP52 with 
the same binding affinity. With the most advanced ligands SAFit1 and SAFit2 the first studies 
to assess the effects of pharmacological FKBP51 inhibition were finally realizable. In these 
studies FKBP51 was validated as a promising drug target and FKBP51 inhibition as possible 
treatment option.  
Scheme 1: Central coupling step of the FKBP ligand series. 
Nevertheless, both SAFit compounds are rather research tools than real drug candidates, since 
they don’t exhibit optimal drug-like parameters. The aim of this thesis is therefore to find 
more appropriate lead structures for further drug optimization studies, explore the FKBP51 
binding pocket by structure-affinity-relationship (SAR) analysis and to further assess the role 
of FKBP51 as a drug target. With this aim three structurally novel ligand series, classified on 
their chemical synthesis (Scheme 1), were developed and synthesized. The novel ligands were 
derived from the SAFit compounds, whereby either the “Bottom Group” (BG) or the “Top 
Group” (TG) was replaced by new moieties.  
Inspired by FK506 and previous FKBP ligands we assessed the role of a hydroxyl group in 
the binding pocket in the first BG series, whereby the building blocks were derived from a 
stereo-selective Aldol reaction. At the same time we developed a series of ligands to analyze 
the structural requirements for selective binding. In the second BG series a rigidification 
strategy was used and a series of bicyclic scaffolds were designed and synthesized via an 
asymmetric Diels Alder cyclization. In both series we were able to reproduce the selective 
binding mechanism. In the last series a SAR on various different amino acids as TG was 
performed that all contained the highly selective SAFit-derived BG. For this project an 
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efficient solid phase-based synthesis was developed and conducted in collaborative work. All 
three ligand series gave new insight into the FKBP51 binding pocket and valuable 
information for further drug research. Additionally, they represent the first systematic analysis 
on FKBP51 selective ligands after the discovery of the SAFit compounds.  
In order to further validate FKBP51 as a drug target in different indications an upscaling of 
the SAFit synthesis was performed. In several in vitro and in vivo studies it was possible to 
reproduce FKBP51 knock out results with pharmacological inhibition by SAFit1 or SAFit2. 
In these studies FKBP51 inhibition was either confirmed or even newly discovered as 
possible treatment, encouraging our attempts to further optimize FKBP51 selective ligands. 
 
Contents 
 
 
CONTENTS 
 A - INTRODUCTION 
1. FKBP51 as a promising drug target 1
1.1. The role of FKBP51 in diseases  1
1.2. Druggability of FKBP51 2
2. The biology of FKBP51  3
2.1. Structure and function 3
2.2. The important role of FKBP51 in HPA axis regulation 5
3. Development of FKBP51-selective ligands 6
3.1. The necessity of FKBP51 selectivity 6
3.2. Flipping Phenylalanine – the key to  selectivity 7
3.3. Open issues 8
4. Aim of this work 9
  
 B – RESEARCH ARTICLES 
5. Publication I: “Recent Progress in FKBP ligand development” 11
  Summary 11
  Original Publication 12
6. Publication/Manuscript II-V: Pharmacological effects of SAFit1 and SAFit2 30
6.1. II: “FKBP51 employs both scaffold and isomerase functions to promote NFκB 
activation in melanoma” 
30
  Summary 30
  Original Publication 31
6.2. III: “The stress regulator FKBP51 drives chronic pain by modulating spinal 
glucocorticoid signaling” (submitted manuscript) 
42
  Summary 42
6.3. IV: “Loss or inhibition of FKBP51 protects against diet-induced metabolic 
disorders by shaping insulin signaling” (manuscript in preparation) 
43
  Summary 43
  Original Manuscript 44
6.4. V: “The FKBP51 antagonist SAFit2 decreases basal ultradian corticosterone 
secretion in the rat”  (manuscript in preparation) 
56
  Summary 56
  
Contents 
 
 
  
  
7. Publication/Manuscript VI-VIII: Own publication 57
 VI: “Structure−Affinity Relationship Analysis of Selective FKBP51 Ligands” 57
  Summary 57
  An asymmetric aldol reaction as key synthesis step  58
  Original Publication 61
  Supporting Information 72
7.2. VII: “A novel decalin-based bicyclic scaffold for FKBP51-selective ligands” 
(manuscript in preparation)  
92
  Summary 92
  Prescreening of bycyclic aromating scaffolds 93
  An asymmetric intramolecular Diels-Alder (IMDA) reaction as key 
synthesis step 
93
  Original Manuscript 97
  Supporting Information 107
7.3. VIII: “Rapid, structure-based exploration of pipecolic acid amides as novel 
selective antagonists of the FK506-binding protein 51” (submitted manuscript) 
140
  Summary 140
  Original Manuscript 141
  Supporting Information 173
  
 C – SUMMARY AND OUTLOOK  179
  
 D – REFERENCES 182
  
 E – CURRICULUM VITAE 189
  
  
A. Introduction 
 
1 
 
A. INTRODUCTION 
1.  FKBP51 as a promising drug target 
1.1.The role of FKBP51 in diseases  
The immunophilin FK506-binding protein 51 (FKBP), among other FKBPs, is best known for 
its immunosuppressant-enabling properties due to its role as the binding target of the 
immunosuppressant FK506 (Tacrolimus) and also rapaymcin (Sirolimus) (Fig. 1). Even the 
name of this protein family is derived from this function. But beside this role, FKBPs are also 
enrolled in numerous other intracellular pathways and are therefore involved in different 
diseases.  
 
Fig. 1: Chemical structure of FK506 (Tacrolimus) and rapamycin (Sirolimus). 
In genetic studies single nucleotide polymorphisms in FKBP5, the gene encoding FKBP51, 
have repeatedly been associated with stress-related disorders. An upregulation of FKBP51, 
caused by genetic variations of FKBP5, were linked to numerous stress-related 
endophenotypes and affective disorders like depression or post-traumatic stress disorder.1, 2 
Studies in FKBP51 knockout mice showed enhanced active stress-coping behavior after 
stress. Also on the endocrine level the animals were protected from hyperactive stress 
responses, likely due to an improved feedback regulation of the hypothalamus-pituitary-
adrenal (HPA) axis. In behavioral studies FKBP51 deficiency led to enhanced recovery after 
stress exposure and actually an antidepressive-like effect, confirming the influence of 
FKBP51 on HPA axis regulation.3-6 FKBP51 is therefore an established risk factor for stress-
related disorders.  
Beside this a strong expression of FKBP51 was also observed in adipocytes during 
differentiation. It might therefore influence mitotic cell growth.7 Additionally, reduction of 
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the protein by knockout protected mice from weight gain after a high fat diet. In selected 
organs and pathways a loss of functional FKBP51 is supposed to create a hyperactivated 
glucocorticoid receptor that in the end induces fatty acid catabolism and better expenditure of 
energy.8 Generally, mice with reduced FKBP51 exhibited a slightly reduced weight.4 In this 
context an inhibition of FKBP51 is supposed to have positive effects on obese conditions. It 
has also been shown that a reduction of FKBP51 leads to chemoresistance in malignant 
melanoma by influencing NF-kB activation.9-11 However, also in several other cancers a 
strong expression of FKBP51 was found. An inhibition of the protein by rapamycin showed 
positive effects in, for example, glioma and  in childhood acute lymphoblastic leukemia.9, 10 
Another auspicious indication for FKBP51 inhibition is the treatment of muskoskeletal pain 
after trauma, like motor vehicle collision or sexual assault to improve recovery. Also here, it 
has been shown in genetic studies that single nucleotide polymorphisms in FKBP5 cause 
increased FKBP5 mRNA levels that are associated with increased pain development.14 
For all these diseases FKBP51 is a promising drug target and pharmacological inhibition 
could therefore be a possible treatment.15-17 
1.2. Druggability of FKBP51 
Since FK506 and rapamycin were known inhibitors of FKBP51, a principle druggability of 
FKBP51 was acknowledged. But to further go on with FKBP51-directed drug discovery for 
the treatment of FKBP1-related diseases two major hurdles had to be taken. The first one was 
to develop non-immunosuppressant inhibitors. The second obstacle was to selectively target 
FKBP51 without affecting other FKBPs, especially its closest homolog FKBP52, to avoid 
undesired side-effects. 
 
Fig. 2: Evolution of FKBP ligands and their characteristics. The calcineurin binding domain of FK506 is shown 
in green. 
A. Introduction 
 
3 
 
By removing and changing the immunosuppressive effector domain (calcineurin binding 
domain) a series of non-immunosuppressive FKBP ligands were developed. The development 
of FK1706, for example, was based on the chemical structure of FK506.18 Like several other 
non-immunosuppressive FKBP ligands, it was shown that FK1706 exhibits neurotrophic 
activity. This class of non-immunosuppressive FKBP ligands was therefore supposed to be 
promising for the treatment for neurodegenerative diseases upon binding to FKBP12. To find 
more binders for FKBP51 a high throughput screening of more than 380,000 compounds and 
chemical scaffold was conducted. Unfortunately, no promising hit was found after the 
screening.19 A more successful strategy was the use of structure-based rational design, 
whereby a crystal structure of FKBP51 and the non-immunosuppressive ligand SLF was used 
as starting point.20 With this method a series of novel non-immunosuppressive FKBP 
inhibitors were developed by Gopalakrishnan et al.20, 21, Wang et al.22 and Pomplun et al.23. 
Although novel scaffolds and highly efficient synthetic strategies were developed to obtain a 
variety of chemically different and highly affine ligands, all compounds bound to FKBP12, 51 
and 52 with almost the same binding affinity. No significant FKBP51 selectivity could be 
achieved. 
A milestone in FKBP51 drug development was reached when Gaali et al.24 discovered a first 
series of ligands that exhibited high binding affinities for FKBP51, but no binding towards 
FKBP52. The compounds SAFit1 and SAFit2 from this series are the best published FKBP51 
selective ligands so far. SAFit2, due to its more lipophilic structure and therefore better blood-
brain-barrier permeability, allowed the first in vivo pharmacological studies for FKBP51 in 
mice. In several animal models SAFit2 showed clear antidepressant-like and anxiolytic 
effects.24, 25 Additionally, a plausible mechanistic explanation of the selective binding mode 
was provided that, together with the first pharmacological data, represent a great progress in 
FKBP51-directed drug development.  
 
2. The biology of FKBP51 
2.1. Structure and function  
FKBP51 as well as the other members of the FKBP family exhibit rotamase activity. The 
proteins are peptidyl-prolyl isomerases (Fig. 3) and catalyze cis-trans conversion around 
peptidyl-prolyl bonds of proteins. Therefore it is assumed that they play an important role in 
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protein folding and intracellular trafficking. The enzyme activity can be inhibited by both 
FK506 and rapamycin.7 
N
O
NHR3
OR2
OR1
N
OR2
O
O
R1
NHR3
trans cis  
Fig. 3: Proline cis/trans isomerization 
FKBP51 (as well as FKBP52) belongs to the large FKBP homologs and are named after their 
size (in kD). As most FKBPs they are located in cytosolic cell compartments.26 The protein 
consists of three domains (Fig. 4): two consecutive structurally similar FKBP domains (FK1, 
FK2) and at the C-terminus a three-unit repeat of the TPR (tetratricopeptide repeat) domain. 
As typical FKBP domains the FK1 and FK2 domains of FKBP51 are composed of an α-helix 
enclosed by five β-sheets. In contrast, the TPR domain is all-helical.27 
 
Fig. 4: Crystal structure of human FKBP51 (pdb: 1KT0). TPR domain is shown in green; FK2 domain is shown 
in yellow; FK1 domain is shown in salmon; PPIase active site is shown in red.  
Although both FK domains are structurally similar, the FK2 domain has no PPIase activity. 
Double point mutations in FK1 almost abolished the enzyme activity in human FKBP5127, 
making this part of the protein the main target and focus in FKBP51-directed drug 
development. 
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2.2. The important role of FKBP51 in HPA axis regulation 
Although FK506 and rapamycin also show high binding affinity towards the large FKBPs (51 
and 52) the immunosuppressive effect is mainly mediated by FKBP12 and only partly by 
FKBP51, whereby the effect is independent from PPIase inhibition.26 The immunosuppressive 
effect is enabled by ternary complexes that are formed by FKBP51-FK506-calcineurin and 
FKBP51-rapamycin-mTOR, whereby a specific part of the ligands is responsible for binding 
the effector proteins. In the end both complexes, by different pathways, lead to an absence of 
important key regulators for T-cell activation, a major component of the human immune 
system.28 
Although this is the most prominent role of FKBPs, FKBP51 itself is mainly considered in 
context with stress-related diseases due to its important role in the stress regulating system, 
which is the hypothalamus-pituitary-adrenal (HPA) axis (Fig. 5). Stress is a trigger for the 
hypothalamus to produce CRH (corticotropin releasing hormone), which activates the 
pituitary gland to secrete ACTH (adrenocorticotropic hormone). This stimulates the 
production of cortisol in the adrenal glands.29 
 
Fig. 5: The hypothalamus-pituitary-adrenal axis regulation cascade. 
Upon binding to the glucocorticoid receptor (GR), cortisol activates energy metabolism in 
different tissues. At the same time it inhibits exaggerated CRH and ACTH release in the 
respective tissues to maintain a homeostasis of the HPA axis. FKBP51 is a negative 
modulator of GR activity by decreasing the affinity of GR for cortisol. Simultaneously, GR 
activation increases FKBP51 expression. Changes in these feedback loops can lead to an 
inappropriate reaction of the HPA axis to stress. Overactive FKBP51 leads to decreased GR 
sensitivity. In depressive patients this is a typical functional phenotype.29 Reduced GR 
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sensitivity is also associated with the evolvement of posttraumatic pain states.14 Enhancement 
of GR sensitivity to restore a balanced feedback mechanism by pharmacological inhibition of 
FKBP51 has already shown successful results in first in vivo studies in mice.24 
 
3. Development of FKBP51-selective ligands 
3.1. The necessity of FKBP51 selectivity 
A key issue in the drug discovery process is the development of preferably selective 
compounds to avoid undesired side-effects by interacting with different target proteins.30 In 
the field of FKBP51 research, achieving selectivity, especially over FKBP52, was a big 
hurdle. In a cellular model of neuronal differentiation in N2a cells it has been shown that 
FKBP52 has exactly the opposite effect of FKBP51. While FKBP52 exhibited a 
neuritotrophic effect by stimulating neurite outgrowth, FKBP51 showed an inhibitory effect 
(Fig. 6).24 Also on a physiological level opposing effects of FKBP51 and 52 have been 
reported. Both proteins affect the binding affinity of steroids on their respective steroid 
hormone receptors, for example the androgen receptor, progesterone receptor and the 
glucocorticoid receptor. In the presence of FKBP51 the binding affinity of the hormones, e.g. 
cortisol, are decreased. In contrast, FKBP52 enhances the binding affinity of the respective 
hormones.31-35 Therefore it is supposed that that a pharmacological regulation of both proteins 
at the same time would have no effect at all since it would cancel each other out.  
        
  
Fig. 6: Effect of FKBP51 (A) and FKBP52 (B) on neurite outgrowth of N2a cells.38 
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In addition to that, reduction of endogen FKBP52 in knockout mice had severe effects on the 
reproductive system. Female mice were complete sterile and male mice showed significant 
undesirable phenotypic changes in the secondary sex organs. Functional FKBP52 is essential 
for the formation of fully functional reproductive organs.32, 36, 37 A pharmacological inhibition 
of this protein should therefore be clearly avoided. 
In contrast, no severe phenotypic but even positive changes in the stress-regulating system 
were observed in FKBP51 knockout mice as described in the previous chapter, suggesting 
that inhibition of FKBP51 is probably well tolerated  
Although these issues have been known for a while, FKB51 drug discovery was hindered 
since it was not possible to pharmacologically differentiate between these proteins. Before 
2014 all known ligands showed virtually the same binding affinity on both proteins, like 
FK506 and rapamycin.  
3.2.Flipping Phenylalanine – the key to  selectivity 
The discovery of the first FKBP51 selective ligands was a serendipitous incident. iFit1, a 
ligand that was developed to only bind to mutated FKBP51, surprisingly showed weak 
binding to wildtype FKBP51. But, paradoxically, at the same time no binding towards 
FKBP52 was observed.24 
 
Fig. 7: X-ray structure of FK506 (A, green, pdb: 3O5R) and iFit1 (B, magenta, pdb: 4TW6) in the FK506 
binding domain of FKBP51. Phenylalanine 67 is shown in blue.  
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The cocrystal structure of FKBP51-iFit1 showed a significantly enlarged binding pocket 
compared to earlier published structures of FKBP51-ligand complexes (Fig. 7), like FK506, 
although the rest of the ligand adopts virtually the same binding conformation. The allyl 
substituent points into this enlarged cavity, which is in the apo-form of the protein occupied 
by Phe67. A comparison of this crystal structure with a FK506-FKBP51 crystal structure 
confirmed that Phe67 is flipped into a new position. It is hypothesized that this 
conformational change is energetically less favored in FKBP52 due to the sterically more 
hindered amino acids Thr58, Trp60, Val129 in the Phe67 surrounding. In FKBP51 Phe67 is in 
close proximity to Lys58 and Lys60 that are stabilized by Phe129.24 
Due to its orientation the allyl substituent seemed to be very important for this kind of binding 
mode. A structure affinity relationship analysis of this particular substituent was therefore 
performed by Gaali et al to explore the enlarged binding pocket. They could show a positive 
correlation between the size of the substituent and the binding affinity. Also the right 
stereochemistry was shown to be essential for binding. In this series the cyclohexyl-
substituted ligands SAFit1 and SAFit2 (Fig. 8) showed the highest binding affinities towards 
FKBP51 and at the same time > 10,000 fold selectivity over FKBP52. With these ligands it 
was, for the very first time, possible to assess the pharmacological effect of selective FKBP51 
inhibition (see 1.1.), representing a turning point in FKBP51 research.24 
 3.3. Open issues 
SAFit2, due to its more lipophilic structure and therefore better blood-brain-barrier 
permeability, has already shown promising pharmacological effects in animal studies. 
Although these effects are very intriguing and encouraging, both (SAFit1 & SAFit2) 
compounds should be rather considered as tool compounds for research than seen as drug-like 
inhibitors. Their physicochemical properties (Tab.1) are clearly outside the range of typical 
CNS-directed drugs (90 % of CNS drugs) and have clearly to be optimized.39 It was shown by 
Leeson et. al.40 that compounds, which match with the suggested drug-like parameters, have 
higher chances to pass the clinical trials and reach the market. 
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 SAFit1 SAFit2 typ. CNS drug 
molecular weight (g/mol) 743 803 < 426 
lipophilicity (clogD) 3.5 7.1 < 3.8 
polar surface area (Å2)  139 114 < 86 
hydrogen bond acceptors 14 12 < 7 
 
Tab. 1: Overview of the physicochemical parameters of SAFit1, SAFit2 and typical CNS drugs. 
Due to their high molecular weights, SAFit1 and SAFit2 are also not useful chemical starting 
points for further drug development. Towards this end, more suitable molecular entities have 
to be found that optimally further retain the just recently discovered selective binding 
characteristics.  
 
4. Aim of this work 
Derived from the open issues in current FKBP51 drug research the aim of this study was to 
identify molecular entities that can serve as starting points for improving drug-likeness of 
FKBP51 ligands. Using rational drug design methods novel ligands should be developed 
based on the knowledge about previous developed ligand series and on the information about 
the protein obtained from the respective crystal structures. To perform a structure-based 
approach, using SAFit1 and SAFit2 as starting points, we divided the compounds into three 
parts based on the chemical synthesis of the compounds. Hereby the (S)-pipecolic acid 
represents the “core group”, which we decided to keep constant in all compounds since a 
preliminary chemical exploration of this moiety has already been performed by Gaali.41 
 
Fig. 8: Chemical structure of SAFit1 and SAFit2. The chemical building blocks are shown in different colors 
(Top Group in green, Core Group in blue, Bottom Group in red).  
A. Introduction 
 
10 
 
First of all, the trimethoxyphenylring of the bottom group should be systematically replaced 
to analyze the structural requirements for the selective binding mechanism. Since we expect a 
significant loss of binding affinity during this step, potential methods to again increase the 
affinity will be tested. This includes incorporating a hydroxyl group in the bottom group that 
has proven to be important for previous developed ligands. Additionally, a scaffold should be 
designed that rigidifies the flexible cyclohexylring to decrease entropy loss during binding. 
Furthermore, we set out to find biologically more stable and smaller residues to replace the 
labile ester “Top Group”.  
A scale-up of the SAFit1&2 syntheses should be developed and conducted to provide 
sufficient of these compounds for further animal studies. The promising effects of 
pharmacological FKBP51 inhibition should be confirmed by more experiments to justify our 
drug optimization ambitions. 
B. Research Articles – Publication I 
 
11 
 
B. RESEARCH ARTICLES 
5. Publication I 
Recent Progress in FKBP ligand development 
(Xixi Feng, Sebastian Pomplun, Felix Hausch, Current Molecular Pharmacology 2015) 
 
Summary 
The review article “Recent Progress in FKBP ligand development” gives an overview of the 
latest achievements in FKBP ligand research. It provides information about the relevance of 
FKBPs, especially FKBP51, as potential drug targets and the structural and chemical 
development of different series of FKBP ligands.  
Within this article I contributed to the section “Development of the first FKBP51-selective 
ligands”, where the serendipitous discovery of the first FKBP51-ligand is described, and the 
section “Induced Fit-The Key to FKBP51 Selectivity”. In this part a detailed explanation of 
the selectivity mechanism is given and the development of the currently most advanced 
ligands SAFit1 and SAFit2 is explained. 
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ORIGINAL PUBLICATION 
Recent progress in FKBP ligand development 
Xixi Feng, Sebastian Pomplun, Felix Hausch 
Max Planck Institute of Psychiatry, Kraepelinstr. 2, 80804 Munich, Germany 
Abstract 
FK506-binding proteins have been implicated in numerous human diseases suggesting novel 
therapeutic opportunities. In particular, the large FKBP51 has emerged as an important 
regulator of the stress-coping system and as an established risk factor for stress-related 
disorders. The principal druggabilty of FKBPs is evidenced by the prototypical high affinity 
ligands FK506 and rapamycin but the development of more refined and selective chemical 
probes for FKBPs has been challenging. In this review we summarize recent advances in the 
development of FKBP ligands, which cumulated in the first highly selective ligands for 
FKBP51. The best ligand SAFit2 allowed the proof-of-concept in mice for FKBP51 inhibitors 
as potentially novel antidepressants. Finally, we discuss pending issues that need to be 
addressed for the further development of FKBP51-directed drugs. 
Introduction 
FK506-binding proteins (FKBPs) comprise a family of 16 proteins in humans that share 
sequence homology to the prototypic FKBP12, the first discovered and best characterized 
FKBP. Many members of the FKBP family possess a peptidyl-prolyl-isomerase activity and 
to bind to the natural products FK506 or rapamycin.[1,2]  
FKBPs are best known for their ability to enable the immunosuppressive effect of FK506 and 
rapamycin (Fig. 1).[3,4] Remarkably, this is a gain-of-function mechanism that is 
biochemically achieved by forming an FK506-induced ternary complex with the phosphatase 
calcineurin or a rapamycin-induced ternary complexes with the kinase mTOR. As a result the 
activity of calcineurin or mTOR is inhibited, leading to a blockade of pathways that are 
essential for allograph rejection after transplantation. While this immunosuppressant-enabling 
property was historically assigned to the prototypic FKBP12, it has recently become clear that 
other cytosolic FKBPs like FKBP12.6 and FKBP51 can also exert this effect, especially in the 
case of rapamycin, where direct contacts between FKBPs and mTOR are minimal within the 
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ternary complex.[5] Since the mTOR pathway is also critical for cell growth, rapamycin and 
its analogs are also clinically used to treat several types of cancer. 
A)          B) 
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Fig. 1: A) Chemcial structures of the prototypic immunosuppressive FKBP ligands FK506 and rapamycin. The 
conserved FKBP-binding part of the molecules is shadowed in gray. The effector part of the molecules that 
induces the inhibitory ternary complexes with calcineurin or with mTOR is circled. B) Crystal structure of the 
ternary complex of FBKP12-Rapamycin-FRB (FKBP/Rapamycin binding domain of mTOR; pdb code: 1FAP) 
FKBPs in disease  
In addition to their immunosuppressant-enabling properties, FKBPs on their own have been 
implicated in numerous intracellular signaling pathways. Early work focused on the role of 
FKBP12 in neurological disorders since FKBP12 were found to be highly expressed in the 
central nervous system and FKBP ligands showed neuroprotective and neuroregenerative 
properties. However, the relevant target of the in-vivo effects of those FK506-derived ligands 
could never be elucidated and it remained unclear if FKBPs were involved at all.[6] In 
consequence, drug discovery for FKBPs within the pharmaceutical industry largely stopped. 
Very recently, the development of more specific tools allowed to unambiguously show that 
inhibition of the large FKBP51 accounts, at least in part, for the neuritotrophic effect of FKBP 
ligands in vitro. 
Transgenic studies in mice have provided more direct evidence for the role of individual 
FKBPs in mammalian physiology. It is clear that FKBP12 and FKBP12.6 are important in the 
development of skeletal and heart muscle.[7] FKBP12 knockout mice display severe 
developmental heart defects that seem to be mediated at least in part by a stabilization of 
Notch1.[8] FKBP36 deficiency results in male infertility but FKBP36-/--mice are otherwise 
healthy.[9] Knockout of FKBP38 leads to lethal neurodevelopmental defects.[10] Several 
FKBP12 FRB Rap 
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studies have shown that deletion of FKBP51 protects mice from the negative consequences of 
stress exposure. FKBP52-/--mice display defects in male sexual development and female 
infertility, confirming the essential role of FKBP52 in sex hormone signaling.[11] 
More recently, genetic studies in humans have indicated a contribution of several FKBPs to 
human diseases. Germ-line mutations in the gene encoding FKBP37 (also known as AIP, 
XAP2 or ARA9) are a major cause for the development of pituitary adenomas.[12]  The gene 
encoding FKBP36 is part of a large genomic deletion that causes sporadic Williams 
syndrome.[13] Single nucleotide polymorphisms in FKBP5, the gene encoding FKBP51, have 
repeatedly been associated with numerous stress-related endophenotypes and affective 
disorders.[14] Recently, mutations in the ER-localized FKBP22 and FKBP65 have been 
associated with matrix disorders.[15,16] 
FKBPs are also present in many human pathogens, where they have been proposed to play an 
important role in the infection process.[17] The macrophage infectivity potentiator belongs to 
the FKBP family and has been pursued a an anti-infective target.[18] Inhibitors of FKBP35 
from plasmodium species have been suggested as anti-malaria agents.[19] Finally, the 
translocation of clostridial toxins seem to require co-chaperone assistance from immunophilin 
proteins (Cyp18 and FKBP51), which may therefore to be useful for detoxification of these 
pathogens.[20] 
FKBP51 as drug target 
The data gathered for FBKP51 over the last decade have converged to a compelling case 
suggesting FKBP51 inhibition as a novel drug target.[21] Single nucleotide polymorphisms in 
the FKBP5 gene have been shown to enhance the induction of FKBP51 expression by 
glucocorticoid stress hormones through transcriptional and epigenetic mechanisms.[22] The 
same single nucleotide polymorphisms have repeatedly been associated in humans with 
stress-coping, fear perception, cognition, aggression and emotionality. The genetic FKBP5 
variations have also been associated with the susceptibility for stress-related disorders like 
post-traumatic stress disorder, especially in combination with early life trauma.[14] 
Collectively, these results firmly established FKBP51 as risk factor for stress-related 
disorders. 
The spatial and temporal expression pattern of FKBP51 in the brain is consistent with its role 
as a regulator of stress-related behavior. Notably, the expression of FKBP51 is robustly 
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induced by glucocorticoids and by various forms of stress in several regions of the brain that 
are important for stress-coping behaviours.[23]   
Several studies have shown that FKBP51-knockout mice are protected from exaggerated 
stress responses. They display lower levels of the stress hormone corticosterone during the 
peak of the circadian glucocorticoid rhythm, reduced corticosterone secretion after acute or 
chronic stress, enhanced feedback regulation of the hypothalamus-pituitary-adrenal axis, 
enhanced cognitive flexibility and more active stress-coping behavior after stress.[24-29] 
Importantly, only very mild phenotypic alterations were observed in FKBP51-deficient mice 
beyond stress biology. In an analysis of peripheral processes controlled by the glucocorticoid 
receptor, blood and immune markers, glucose metabolism, and life span were found to be 
only marginally affected by FKBP51 deletion, suggesting that pharmacological inhibition of 
FKBP51 might be tolerated and devoid of target-based adverse side effects.[28]  
One of the few minor phenotypes of FKBP51-/- mice under basal conditions was slightly 
reduced weight.[25] This might be important, however, since FKBP51-/-- mice were described 
to be protected from excessive weight gain after a high-fat diet.[30] This is consistent with a 
pronounced expression of FKBP51 in adipocytes and in adipose tissue. FKBP51 expression in 
human omental adipose tissue correlated with reduced insulin responsiveness and single 
nucleotide polymorphism in the FKBP5 gene were associated with type 2 diabetes.[31] In the 
3T3 cellular model, FKBP51 knockdown affected a variety of markers of adipogenesis.[32] In 
vivo, FKBP51 might also affect metabolism via central mechanism, since higher FKBP51 
expression in the hypothalamus was associated with increased weight gain[33] and viral 
overexpression of FKBP51 in the hypothalamus promoted an obese phenotype after a high-fat 
diet.[34] It is therefore clear that FKBP51 plays an important role in metabolism. Metabolic 
disorders like obesity or diabetes might thus be an alternative indication for FKBP51 
inhibitors. 
An open question in FKBP51 drug development is the molecular mechanism by which 
FKBP51 exerts its physiological effects. While initially FKBP51 was largely viewed as an 
inhibitor of steroid hormone receptors, most importantly of the glucocorticoid receptor, it is 
now clear that FKBP51 has many other interaction partners. In addition to the established 
binding to Hsp90, FKBP51 was co-immunoprecipitated with transcription factors or 
coactivators like PPARγ,[Stechschulte Mol Endo 2014], NF-κB,[35,36] p300[37] or 
Smad2/3,[38], kinases like IKK, Akt and SGK1,[39-41], phosphatases like PHLPP and 
calcineurin,[41,42] TRAF scaffolding proteins,[43] or the miRNA/siRNA effector Ago2.[44] 
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More recently, 90 putative interaction partners of FKBP51 were identified in a proteomic 
analysis.[45] For most of these interactions, it is unclear if FKBP51 binds to these proteins 
directly or indirectly via a third partner such as Hsp90. Mirroring its broad protein binding 
potential, FKBP51 has also been implicated in several other cellular pathways beyond steroid 
hormone signaling such as the Akt/mTOR pathway, the IKK/ NF-κB pathway, TGF/Smad 
pathway, or the Tau phosphorylation. An important open question is how FKBP51 affects 
these pathways at the biochemically level. It is noteworthy that biochemical assays that 
reconstitute the effect of FKBP51 on a relevant substrate protein in a defined system are 
lacking in most cases. 
Medicinal Chemistry of FKBP inhibitors 
Early work on FKBP ligands focused on improving the properties of the natural products 
FK506 and rapamycin for their use in immunosuppression and related applications. This led 
to the development of the semisynthetic drugs pimecrolimus and everolimus. In addition, in 
the late 1990s many pharmaceutical companies pursued drug development programs for non-
immunosupressive FKBP ligands as potential neuroprotective or neuroregenerative agents.[3] 
These studies were mainly focused on FKBP12 ligands and resulted in the clinical candidates 
FK1706 and Biricodar. FK1706 was tested in a phase I clinical trial, where it was well 
tolerated.[46] Biricodar is a dual FKBP12/P-glycoprotein inhibitor that was tested as a 
chemosensitzer in several phase II clinical phases for several types of cancer.[47] Because of 
the lack of success of these clinical candidates and due to substantial controversies on the 
underlying mechanistic concept, by 2005 most FKBP drug discovery efforts were stopped. In 
recent years the field got some revival by the intriguing biological findings for FKBP38, 
FKBP52 and especially for FKBP51. 
FKBP inhibition can be determined by a peptidyl-prolyl-isomerase inhibition assay.[48,49] 
However, as this assay demands laborious experimental conditions (short time window, 
anhydrous reagents) the development of a practical assay was an important step for the 
development of new inhibitors. The synthetic non-immunosupressive FKBP12 inhibitor 1a 
(Fig. 2), first described by Keenan et al.,[50] was shown to retain binding affinity to the larger 
FKBP51 and FKBP52.[2] Compound 1a was coupled to a fluorescein derivative, affording 1b 
(also called FL-SFL[51]), which allowed competitive fluorescence polarization assay for most 
FK506 binding-competent FKBPs (FKBP12, 12.6, 13, 25, 51 and 52). This assay was used 
for a high throughput screening of more than 380,000 compounds for binders to the FK506-
binding pocket of FKB51. However, while FK506 and rapamycin were routinely identified in 
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an unbiased fashion, no other chemically tractable starting point could be identified for 
FKBP51. This suggests that FKBP51 might be rather difficult to target with the chemical 
scaffolds typically present in the contemporary screening libraries. 
 
Fig. 2: Progressive generations of FKBP ligands developed by rational design, with chemical structures of 
selected examples (left side) and crystal structures of complexes with the FK506-binding domain of FKBP51. 
Like for FKBP12, the most effective strategy to develop FKBP51 inhibitors turned out to be 
structure-based rational design. Towards this end, cocrystal structures of the FK506-binding 
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domain of FKBP51 with FK506 and 1a were generated[52,53]. This clarified the most 
important protein-ligand interactions, affording a suitable starting point for a further rational 
ligand development. The core interactions of FK506 in the FKBP51 binding domain (Fig. 3) 
are conserved for 1a: the pipecolate ring is situated over Trp90, the basement of the binding 
pocket. The C1-carbonyl of the pipecolate forms a hydrogen bond with Ile87 and the C8-
carbonyl (for numbering of FK506 see Fig.1) of the amide forms a hydrogen bond with 
Tyr113.  With 1a (KiFKBP51= 8µM, KiFKBP52= 10µM, KiFKBP12= 0.17µM) as starting point 
Gopalakrishnan et al. performed the first structure-activity-relationship analysis of small 
synthetic molecules for the human FKBP51 and FKBP52. This confirmed the important role 
of the pipecolate core of the ligands: substitution by proline or 4,5-dehydropipecolinic acid 
caused 4-6 fold decreased binding affinity of the ligands, while a thiomorpholine-3-carboxylic 
acid as core component completely abrogated the binding affinity to FKBP51 and 52. The 
successive attempt to substitute the α-keto amide tert-pentyl group of 1a with α-keto amide 
hydroxyl-cyclohexyl moieties, which were supposed to emulate the pyranose functionality of 
the highly affine FK506, did not afford substantially enhanced affinities of the inhibitors (2a, 
2b, Fig. 2).[53] 
 
Fig. 3 Cocrystal structure of FK506 (blue lines) in complex with the FKBP51 binding domain (grey cartoon, pdb 
code: 3O5R). The pipecolate core of FK506 is highlighted as blue sticks. Trp90 (orange sticks) forms the 
basement of the binding pocket, while Ile87 and Tyr113 (orange sticks) form hydrogen bonds with the C1- and 
C8-carbonyls FK506.[52] 
Tyr113
Trp90 
Ile87 
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In a second approach the α-ketoamide-moiety was bioisosterically replaced by an aryl 
sulfonamide moiety. With a solid phase synthetic strategy a small focused library of > 50 
ligands with the general structure 7 was prepared (Fig. 4).[54] 
 
Fig. 4: Solid phase-assisted reaction of the immobilized building block 6 with various sulfonyl chlorides and 
subsequent cleavage under acidic conditions afforded a focused library of > 50 sulfonamide FKBP ligands.[54] 
As revealed by the cocrystal structure of 3a, the ortho-hydrogens of the aryl-sulfonamides 
engage in aromatic hydrogen bonds with Asp68 and Tyr113 of FKBP51 and therefore 
functionalization of the ortho position caused loss of activity in this class of compounds. The 
m-halogen substituted aromatic sulfonamides showed the most promising binding affinities to 
FKBP51 and FKBP52 due to the formation of a halogen bond with Ser118 (Fig. 2, 3a). When 
the free acid of the pipecolate-ester-top group  was substituted by a morpholine-containing 
group, the m-dichloro, p-hydroxy sulfonamide analogue (Fig. 2, 3b) showed submicromolar 
affinities for FKBP51, 52 and 12 (456 nM, 710 nM, 115 nM respectively).  
The initial structure-activity relationship analysis showed minimal differences in affinity for 
FKBP51 or FKBP52, in line with the almost complete structural conservation of the active 
site residues between these two proteins.[52,55] There was also a general trend for higher 
affinities for FKBP12 (5-10 fold on average). Surprisingly, the benzothiazole-2(3H)-one 
sulfonamide analogue (Fig 2, 3c) showed a striking selectivity for FKBP12 over FKBP51 and 
FKBP52,[54] making it a useful tool compound probe to the specific role of FKBP12.[5] 
It became clear that simple substitutions or modifications of pipecolate-based ligands would 
be insufficient to provide drug-like ligands for FKBP51 or FKBP52. Due to the high 
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molecular weights (> 650) and the moderate binding affinities the ligand efficiencies (defined 
as free binding energy ΔG/Number of non-hydrogen atoms) were far away from values 
typically required for brain-penetrant drugs.[56] It was thus necessary to improve the core 
structure of the FKBP ligands. In all cocrystal structures up to that date the pipecolate core of 
the ligands occupied virtually superimposable positions. This suggested the idea to fix this 
active conformation by bridging the pipecolate scaffold from the carbonyl C1 to the C6 
position either with an ethylene or with a methylene linker to form a preorganized bicyclic 
core scaffold (Fig. 2d, examples 4a and 4b). As predicted by modelling studies the ethylene 
linker afforded considerably better results, preorganizing the pipecolic core exactly in the 
desired active conformation (Fig. 5).[57]  
 
Figure 5 The core scaffold of the monocyclic, pipecolated-based ligands (blue sticks) is converted from an ester 
to an amide and bridged by an ethylene linker (magenta sticks) connecting N3 and carbon C6. The resulting aza-
amido [4.3.1] bicycle rigidifies the active conformation of the pipecolate core maintaining exactly the same O1-
C1-C2-N7 / N3-C2-C1-N10 dihedral angles.  
The combination of the [4.3.1]-bicycles with sulfonamide moieties afforded a robust 
improvement of ligand efficiency (up to LE= 0.29). The cocrystal structures of the bicyclic 
sulfonamides partially explained this by revealing a very unusual hydrogen bond between the 
sulfonamide nitrogen (N10 in Fig. 5) and Tyr113. The pyramidalized geometry of this nitrogen 
resembles the postulated transition state of peptidyl-prolyl-peptide bond during the cis-trans 
isomerisation catalyzed by FKBPs. The [4.3.1]-bicyclic sulfonamides may thus be very 
efficient FKBP ligands because they are very close transition state analogs. 
The binding mode of the rigid bicyclic core scaffold suggested a further improvement of the 
ligands by rational design. The analysis of the cocrystal structure of bicyclic [4.3.1] aza-amide 
ligands with the binding domain of FKBP51 indicated that a substituent in the pro-(S)-C5 
position could fit into the binding pocket while offering the potential for further interactions 
with the protein(Fig. 2, 4b). For the construction of C5- substituted bicycles with defined 
stereochemistry two new synthetic strategies had to be developed. In the first approach, C5-
hydroxy substituted bicycles were prepared by an intramolecular epoxide opening followed 
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by a lactamization reaction (Fig. 6a).[58] In the second approach, [4.3.1] bicycles with a C5-
vinyl substituent were prepared by an intramolecular N-acyliminium cyclization (Fig. 6b).[59] 
Both approaches offered the possibility for further chemical variation of the new C5-
functionality, furnishing ligands with binding affinities in the low nanomolar range (< 50 nM) 
and highly improved ligand efficiencies (up to 0.38) (Figure 2, examples 5a and 5b). 
Substance 5b potently facilitated neurite outgrowth of N2a neuroblastoma cells.[59]   
 
Fig. 6 a) Retrosynthetic analysis for the synthesis of C5-hydroxy [4.3.1] bicycles: an intramolecular epoxide 
opening is followed by a lactamization step.[58] b) Mechanism of the intramolecular acyliminium cyclization, 
key step for the synthesis of C5-vinyl substituted [4.3.1] bicyclic FKBP ligands.[59] 
Development of the first FKBP51-selective ligands 
Although antagonists of FKBPs have been known for a while, selectivity within the FKBP 
family was regarded difficult.[60] The selectivity issue was particularly important for 
FKBP51 and FKBP52 since these proteins have opposite effects on glucocorticoid signaling 
in cells and partially also in vivo. However, achieving selectivity between FKBP51 and 
FKBP52 was also extremely challenging since their FK506-binding pockets are completely 
conserved. Until very recently, none of the tested FKBP ligands differentiated between 
FKBP51 and FKBP52. 
To solve this issue in model systems, a chemical genetics approach was used by Gaali et al. to 
generate artificial selectivity.[61] The FK506-binding sites of FKBP51 and 52 were enlarged 
via mutation, whereby the large hydrophobic Phe67 is replaced by a smaller valine, leading to 
a new cavity in the mutant protein. A similar method had been previously used by Clackson et 
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al.,[62] who introduced a F36V mutation in FKBP12 fusion proteins. The aim of such a 
mutation in the binding pocket is to allow designing complementary ligand that fit into the 
new binding pocket but clash with the wildtype protein. This way artificial selectivity for the 
mutant FKBP can be achieved (Fig. 7). For the FKBP51F67V/FKBP52F67V system ligand 1 was 
designed and synthesized, showing IC50 values of 60 nM and 80 nM, respectively. The 
binding affinities for the wild type proteins were >30 µM. In this ligand the allyl substituent 
in the Cα-position is responsible for the artificial selectivity towards the mutant proteins 
compared to the wildtype proteins. 
N
O
O
O
MeO
MeO
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OMe
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C
Ligand 1  
Fig. 7: A) Ligand mutant pair for artificial selectivity. B) The FKBP51/52F67V mutant-selective ligand 1 
The FKBP51/52F67V mutant-ligand system was tested in murine N2a neuroblastoma cells, a 
cellular model of neuronal differentiation that is reciprocally regulated by FKBP51 and 
FKBP52.[63] In this system, overexpression of the point-mutated proteins recapitulated the 
effect of their wildtype counterparts on neurite differentiation. FKBP51WT and FKBP51F67V 
inhibited neurite outgrowth while FKBP52WT and FKBP52F67V enhanced it. With ligand 1 it 
was now possible to selectively block the effects of the mutated FKBP51 or of FKBP52, 
while sparing the wildtype FKBPs. Using this system, it was possible to unambiguously show 
that inhibition of FKBP51 is neuritotrophic while inhibition of FKBP52 is anti-neuritotrophic. 
Strikingly, inhibition of both FKBPs at the same time showed no effect, emphasizing the 
necessity for selective ligands.  
Induced fit – The key to FKBP51 selectivity 
The results in the N2a cell model made the need for selective FKBP51 ligands even more 
pressing. The turning point in the development of selective FKBP51 ligands was eventually a 
serendipitous discovery. During development of the artificial FKBP51/52F67V ligand series, 
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the ligand iFit1 (Fig. 8) showed weak binding affinity to FKBP51WT. This was not expected 
since the Cα substituent was supposed to clash with the protein according to the canonical 
binding mode. Even more surprising was the absence of binding to FKBP52WT.  
The crystal structure of the FKBP51-iFit1 complex uncovered that iFit1 induces a 
conformational change in the protein, whereby the Cα substituent points into a newly formed 
cavity. In the apo-form of the protein, this cavity is occupied by the phenyl side chain of 
Phe67. An overlay of this crystal structure with FKBP51 co-crystal structures of unselective 
ligands reveals a flip of Phe67. In the new binding conformation Phe67 formed a close 
contact with Lys58 and Lys60 of FKBP51. Lys58 and Lys60 themselves were stabilized by 
Phe129. Notably, in FKBP52 these amino acids are replaced by the sterically hindered 
residues Thr58, Trp60, Val129, which likely make a conformational rearrangement of Phe67 
energetically less favored for FKBP52.  Interestingly, apart from the Cα substituent the rest of 
iFit1 adopted a similar binding mode in the FKBP51 binding pocket as the unselective ligands 
described in the chapter before.  
There are already many proteins known, beside FKBP51, that show ligand-induced 
conformational rearrangement, e.g. COX-2, the estrogen receptor or the enzyme 
neuraminidase. Although crystal structures of their different binding conformations exist, a 
priori theoretical predictions are difficult to make due to the highly flexible binding sites.[64] 
To explore the newly formed subpocket of FKBP51WT a series of ligands was synthesized that 
contained different substituents in the Cα position, which represent the first series of 
FKBP51WT selective ligands (Fig. 2).  
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Fig. 8: Discovery of the iFit series of FKBP51-selective ligands and their binding affinities to FKBP51WT 
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The binding data showed that an increasing size of the Cα substituent did not affect the 
selectivity, since still no binding to FKBP52WT could be detected. In contrast the enlarged 
substituents had a significant effect on the binding affinity for FKBP51. A clear correlation 
between size of the substituent and Ki was observed, whereby increasing size of the 
substituent resulted in higher binding affinities. Crucial for all ligands, regarding affinity and 
selectivity, was the stereochemistry of the Cα substituent.  
  
Fig. 9: Co-crystal structure of 1a/ FKBP51WT (left, pdb code: 4DRK) and iFit4/FKBP51WT (right, pdb code: 
4TW7). The key residue F67, which is displaced by iFit ligands, is highlighted in cyan 
The introduction of a six-membered ring as Cα substituent led to a strong increase of binding 
affinity suggesting an optimal match between the substituent and the subpocket. The co-
crystal structure of FKBP51-iFit4 (Fig. 9) confirmed this by revealing that the cyclohexenyl 
ring is sitting tightly in the new protein cavity. A reduction of the double bond of the 
cyclohexenly moiety further increased the affinity for FKBP51, leading to SAFit1 and 
SAFit2, the best FKBP51 ligands published so far. SAFit1 and SAFit2 (selective antagonists 
of the FK506-binding protein 51 by induced fit) had Ki values of 4 nM and 6 nM respectively. 
Both show > 10,000 fold selectivity over FKBP52WT. SAFit1 did not show any 
immunosuppressive effects, which is expected since it lacks the effector domain necessary to 
form ternary complexes with calcineurin or mTOR (Fig. 1). While SAFit1 was the ligand of 
choice for cellular assays, SAFit2 had better in vivo stability and improved brain permeability 
and was therefore chosen for animal studies. Upon sub-chronic dosing in mice, SAFit2 
reduced the corticosterone levels during the peak time of the circadian rhythm of 
glucocorticoid secretion. A similar effect was observed in FKBP51-/- mice, supporting the 
idea that the effect of SAFit2 was due to FKBP51 inhibition. SAFit2 also sensitized mice to 
low doses of the glucocorticoid dexamethasone in a combined dexamethasone-CRF test. This 
test measures the suppressability of the hypothalamus-pituitary-adrenal axis, one of the major 
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endocrine stress-coping systems in mammals. Notably, a blunted regulation of the 
hypothalamus-pituitary-adrenal axis is a recurrent finding in subpopulation of depressive 
patients. Finally, SAFit2 promoted a more active stress-coping behavior in the forced swim 
test, the classical test to characterize clinically used antidepressants.[61]  
The discovery of the iFit class of FKBP51 ligands can be considered a landmark in FKBP 
research. It provided extremely powerful tools to study the role FKBP51. In addition, the 
understanding of the underlying structural basis for selectivity offers the possible to develop 
more drug-like FKBP51-selective ligands by rational design. In the absence of the 
serendipitously discovered FKBP51-specific conformation it would have been very difficult if 
not impossible to achieve selectivities like the ones displayed by SAFit1 or SAFit2. 
Open issues in FKBP51 drug development 
The in vivo results of SAFit2 provided the proof-of-concept that compounds directed to the 
FK506-binding site of FKBP51 might have beneficial therapeutic effects. However, several 
important questions remain to be addressed during the further development. For example, it is 
unknown by which molecular mechanism SAFit2-like compounds work. The binding of 
FKBP51 to at least some interactions partners (Akt, PHLPP or calcineurin) are not mediated 
by the PPIase active site and thus unaffected by FK506 analogs.[40,42] Clarifying the drug 
sensitivity of FKBP51-regulated signaling pathways is important to predict the efficacy 
profile or potential target-based side effects.  
When considering depression as a potential indication, two distinguishing aspects of FKBP51, 
compared to other targets, are its established human genetic association and the strong 
mechanistic link to stress endocrinology. This offers possibilities for patient stratification. For 
example, patients with an early life trauma and FKBP51 high-inducing (epi)genetic variants 
might benefit preferentially from FKBP51 inhibitors. Likewise, patients with a hypo-sensitive 
feedback regulation of the hypothalamus-pituitary adrenal axis (clinically measurable by a 
dexamethasone suppression test) might be a preferred population for FKBP51 inhibitors. 
Normalization of the HPA axis regulation by FKBP51 inhibitors should be fast and this could 
be used as a functional biomarker.   
The current FKBP51-selective ligands such as SAFit1 and SAFit2 should be regarded 
primarily as tool compounds for research. The molecular weight is prohibitively high and 
their usefulness as chemical starting points for the development of FKBP51-directed drugs 
remains to be seen. Like for the bicyclic pan-selective FKBP ligand series, we expect 
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innovative chemistry bolstered by structure-based rational design to be instrumental for the 
development of FKBP51-selective drug candidates. 
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6. Publication/Manuscript II-IV: Pharmacological effects of SAFit1 and SAFit2 
SAFit1 and SAFit2 currently represent the most advanced selective FKBP51 ligands. With 
these compounds, for the first time, pharmacological selective FKBP51 inhibition is possible. 
In preliminary in vitro and in vivo studies both ligands have already proven their usefulness as 
research tools. In order to further verify FKBP51 as drug target in FKBP51-related disease 
and to show that pharmacological FKBP51 inhibition could be a possible treatment, an 
optimization and scale up of the chemical synthesis of SAFit1 and SAFit2 was conducted. 
Both compounds were then synthesized in gram scales and used in collaborative FKBP51 
research projects, which are described in the following chapter. 
 
6.1. Publication II 
FKBP51 employs both scaffold and isomerase functions to promote NFκB activation in 
melanoma 
(Simona Romano, Yichuan Xiao, Mako Nakaya, Anna D’Angelillo, Mikyoung Chang, Jin 
Jin, Felix Hausch, Mariorosario Masullo, Xixi Feng, Maria Fiammetta Romano, Shao-Cong 
Sun, Nucleic Acids Research 2015, Vol. 43, No. 14, 6983-6993, doi: 10.1093/nar/gkv615) 
 
Summary 
FKBP51 is linked to the severity of skin cancer due to its role in NFκB activation, which 
influences tumor progression, metastasis and apoptosis resistance. The presented study aimed 
to explain the underlying molecular mechanisms. 
It was shown that FKBP51, as a scaffold, enhances IKK activity upon binding to the subunits 
and assisting the assembly of the kinase complex that activates NFκB. Hereby different 
FKBP51 domains interact with the different subunits. Both SAFit compounds, as well as 
FKBP51 knock out, reduced IKK activation, whereby the contact between both proteins was 
not abolished (indicating the importance of the PPIase activity for the effect). Additionally an 
interaction between FKBP51 and TRAF2 was observed which is supposed to facilitate IKK 
activation. Disturbing NFκB activation by FKBP51 inhibition could hence be a starting point 
for novel melanoma therapies.  
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6.2. Manuscript III 
The stress regulator FKBP51 drives chronic pain by modulating spinal glucocorticoid 
signaling – submitted manuscript 
(Maria Maiarù, Keri Tochiki, Marc B. Cox, Leonette V. Annan, Christopher G. Bell, Xixi 
Feng, Felix Hausch, Sandrine M. Géranton) 
 
Summary 
Several studies indicated that FKBP51, as a negative regulator of the glucocorticoid receptor 
(GR), is involved in the severity of muskoskeletal pain after traumata. The role and direct 
contribution of the protein was assessed in the presented study.  
An upregulation of FKBP51 as well as decreased methylation of the FKBP51 promoter 
sequence was observed after CFA injection. Supporting the assumption that the protein is 
important for long term pain states, it was shown that mice, exhibiting limited FKBP51 
function by knock out, antisense silencing on spinal level or pharmacological inhibition by 
SAFit2 (intrathecal administration), showed reduced hypersensitivity in several persistent 
pain models. KO mice also showed lower levels of the pro-inflammatory cytokine IL6. Since 
it is known that IL6 transcription is regulated by GR, this finding supports that changes in GR 
activity are involved in the maintenance of chronic pain. Therefore, FKBP51 is suggested as a 
promising new target and pharmacological FKBP51 inhibition as possible treatment of long 
term pain states. 
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  6.3. Manuscript IV 
Loss or inhibition of FKBP51 protects against diet-induced metabolic disorders by 
shaping insulin signaling – manuscript in preparation  
(Georgia Balsevich, Nils C Gassen, Alexander Häusl, Xixi Feng, Carola W Meyer, Stoyo 
Karamihalev, Carine Dournes, Andres Uribe, Sara Santarelli, Kathrin Hafner, Marily 
Theodoropoulou, Christian Namendorf, Manfred Uhr, Marcelo Paez-Pereda, Felix Hausch, 
Alon Chen, Matthias H Tschöp, Theo Rein, Mathias V Schmidt) 
 
Summary 
Genetic variants in FKBP5, the gene encoding FKBP51, have been recently associated with 
type 2 diabetes and markers of insulin resistance. Also a deregulation of the enzyme AKT, 
which is regulated by FKBP51, was linked to diabetes and glucose metabolism. The aim of 
the study was therefore to assess the role of FKBP51 in energy and glucose homeostasis.  
The study showed that FKBP51KO, as well as pharmacological inhibition of FKBP51 with 
SAFit2, protected mice from high-fat diet-induced weight gain. Also with normal chow a 
reduced body weight was observed. The phenotypic change is hereby caused by an increased 
resting metabolic rate and no decreased calorie intake was observed. A loss or inhibition of 
FKBP51 also resulted in improved glucose tolerance, especially in skeletal muscle by 
enhancing insulin signaling. Within the insulin signaling pathway it could be shown that, 
beside AKT and downstream effector protein, also upstream signaling is affected is 
influenced by FKBP51 in tissue-specific manner. These data confirm FKBP51 inhibition as a 
promising drug target for the treatment of obesity as well as type 2 diabetes and suggest 
FKBP51 inhibition as a possible pharmacological intervention.  
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6.4. Manuscript V 
The FKBP51 antagonist SAFit2 decreases basal ultradian corticosterone secretion in the 
rat– manuscript in preparation 
(Francesca Spiga, Zidong Zhao, Xixi Feng, Felix Hausch, Stafford Lightman) 
 
Summary 
The ultradian rhythmicity of corticosterone secretion in rodents is regulated by 
feedback/feedforward interactions between pituitary ACTH and the adrenal CORT 
(corticosterone in rodents; cortisol in human beings), which leads to glucocorticoid receptor 
(GR) activation. Within this system the regulating role of GR in rats was analyzed by 
inhibiting FKBP51, a negative regulator of GR, with the FKBP51 selective antagonist 
SAFit2. 
It was shown that SAFit2 treatment led to decreased basal and stress induced CORT secretion. 
Reduced ultradian CORT pulse amplitudes and inter-pulse intervals were observed after 
prolonged administration, suggesting that the ultradian rhythmicity is GR-mediated. Since 
diseases like depression and stress-related depressive disorders have been associated with 
elevated CORT levels, FKBP51 inhibition, by modulating basal CORT secretion, could be a 
therapeutic strategy for the treatment. 
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7. Publication/Manuscript VI-VIII: Own publication 
7.1. Publication VI   
Structure−Affinity Relationship Analysis of Selective FKBP51 Ligands 
(Xixi Feng, Claudia Sippel, Andreas Bracher, Felix Hausch, J. Med. Chem. 2015, 58, 
7796-7806, doi: 10.1021/acs.jmedchem.5b00785) 
 
Summary 
In order to improve the drug-like properties of SAFit1 and 2 we started with an analysis of the 
structural requirements for FKBP51 selective ligands. Gaali et. al. discovered a 
cyclohexylring in the C9 position (Fig.2, Original Publication) as the key feature for high 
selectivity. We therefore developed a new series of ligands that all contained this moiety and 
discovered an asymmetric methyl-cyclohexyl group as the smallest possible structural feature 
for FKBP51 selective binding.  
Using this finding as a starting point we introduced a hydroxyl group in the C10 position via 
an asymmetric aldol reaction and performed a structure affinity relationship analysis. In 
FK506 and a derived ligand series by Gopalakrishnan et. al. a hydroxyl group in a similar 
position was engaged in a hydrogen bond with Asp68, which we were trying to reproduce. 
Unfortunately, the crystal structure of the best ligand in this series didn’t confirm this. Instead, 
we were delighted to discover that we were able to reproduce the induced fit binding mode 
and that substitution in this position does not influence selective binding, which is a useful 
finding for further drug optimization. 
The publication represents the first structure-affinity relationship analysis on FKBP51 
selective ligands after discovery of the induced fit binding mechanism.   
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An asymmetric aldol reaction as key synthesis step  
The central step in the synthesis of all SAFit-type ligands is the coupling step between the 
pipecolic acid top group ester (s. abstract) and a carboxylic acid (“Bottom Group”). In order 
to obtain a carboxylic acid building block that contained the cyclohexyl as well as the 
hydroxy group in a specific stereochemistry the chiral auxiliary-mediated aldol addition 
seemed to be the perfect reaction. We chose an Evans type (S)-benzylthiazolidinethione 
auxiliary since high diastereoselectivities can be achieved and the cleavage can be conducted 
under milder conditions than the classic oxazolidinones auxiliaries.42 
 
Scheme 2: Proposed transition states of the chiral auxiliary-mediated syn and anti aldol reactions. Adapted from 
Crimmins et al.42 and Evans et al.43. 
Scheme 2 shows the versatility of this type of reaction. Starting from the same n-acyl 
thiazolidinethione and aldehyde it is theoretically possible to obtain three specific 
diastereomers, whereby we were only interested in the Evans syn aldol adduct and the anti 
aldol adduct, due to the stereochemistry of the cyclohexyl ring. We used different aldehydes 
and synthesized a series of Evans syn aldol adducts with a method developed by Crimmins et. 
al.42 In all reactions only one major diastereomer was isolated. By slightly changing the 
reaction conditions, in fact only the equivalents of the base, it would also be possible to obtain 
the non Evans aldol adduct. Although the reaction conditions a very similar, the proposed 
transition states differ significantly. Addition of 2 eq base seems to inhibit the chelation of the 
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thiocarbonyl, which happens during formation of the non Evans syn aldol adduct. It is 
supposed that this is caused by the amine coordinating to the titanium. Although direct 
conversions of thiazolidinethiones to amides are described with primary42 and secondary44 
amines we observed no reaction when we conducted this step with pipecolic ester 36 (Orig. 
Publ.). We assume that this is caused by the low nucleophilicity of the pipecole nitrogen and 
the sterically demanding cyclohexyl group. The latter one is also the reason why a very mild 
cleavage method45 with H2O and DMAP to obtain the carboxylic acid did not work. In the 
end, the auxiliary was cleaved with the classic LiOOH method46. 
Though starting with the same reactants, but different reagents, the anti aldol product is 
formed via a complete different transition state. It is assumed that the Mg center is not 
coordinating to the thiocarbonyl and a boat-metal transition structure is suggested. Only this 
would explain, why a (Z) metal enolate can lead to an anti aldol product. Interestingly, a Mg-
catalyzed anti aldol reaction with N-acyloxazolidinones leads to the complementary adducts.47 
In this publication Evans et al.47 also mention that a current limitation of the procedure is β-
branched substituents, which would include our cyclohexylacetyl residue. We hoped we could 
circumvent this problem by using the thiazolidinethione auxiliary, since it also worked in the 
syn-aldol series. Unfortunately, this was not the case. No product conversion was observed 
using the described reaction conditions. Attempts to obtain the desired anti product via a 
boron enolate, a method described by Walker et al.48, were also not successful. 
 
Scheme 3: Theoretically proposed synthetic strategies for the synthesis of the anti diastereomer of 41. 
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We then decided to use the best syn aldol product from our ligand series (41, Orig. Publ.) as 
starting point to obtain the corresponding anti-diastereomer (Scheme 2). The Mitsunobu 
reaction was performed with 41 and p-nitrobenzoic acid, since the resulting ester can be 
cleaved under mild conditions49. After the reaction several peaks with the same mass that 
either corresponded to the p-nitrobenzoic ester or the elimination product were obtained in the 
LCMS. We assume that the reaction conditions induced deprotonation and thus racemization 
and elimination of the hydroxyl stereocenter, leading to a mixture of different undesired 
products. The same problem occurred, when we tried to convert the respective intermediate 
(25, Org. Publ.) that was obtained after aldol reaction. 
In our next attempt 42 (Org. Publ.) was reduced under Luche conditions50 in order to obtain a 
mixture of the desired compound and 41. Chromatographic separation should then provide the 
desired anti-diastereomer. As already suspected the reaction did not lead to a 1:1 mixture of 
both diastereomers. HPLC analysis showed one major peak and one minor peak (~ 5 %), 
whereby we assign the syn-diastereomer with the major peak after comparing the retention 
time. Unfortunately, the defined position of the cyclohexylring seems to only favor the 
formation of the (R)-hydroxy group, leading to the syn-product that we already obtained from 
the aldol reaction. A formation of the (S)-hydroxy group is sterically more hindered since the 
hydrogen would have to attack from the side the cyclohexyl ring is pointing towards.   
In the end, the synthesis of the anti diasteromer of 41 could not be realized and the influence 
of this single hydroxyl group on the binding affinity still remains an open question.   
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ORIGINAL PUBLICATION - http://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.5b00785 
Reproduced with permission from Journal of Medicinal Chemistry. Copyright 2015 American 
Chemical Society. 
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I. Crystallography 
 
Dataset FKBP5141 
Space group P212121 
Cell dimensions  
  a, b, c (Å) 43.37, 50.22, 61.81 
  , ,  (°) 90, 90, 90 
Wavelength (Å) 0.97895 
Resolution (Å) 43.37- 2.25 (2.32 - 
2.25)* 
Rmerge 0.093 (0.599) 
I/σI 10.4 (2.4) 
Completeness (%)  99.4 (95.9) 
Redundancy  5.2 (5.3) 
Refinement  
Resolution (Å) 30 - 2.25 
No reflections 6454 
Rwork / Rfree 0.211 / 0.284 
Number of atoms  
  Protein 986 
  Ligand/ion 49 
  Water 55 
B-factors  
  Protein 39.71 
  Ligand/ion 42.14 
  Water 41.11 
R.m.s. deviations  
  Bond length (Å) 0.007 
  Bond angles (°) 1.437 
* Values in parenthesis for outer shell. 
Table 1| Data Collection and Refinement Statistics 
 
Crystallization 
The complexes were prepared by mixing FKBP51 (16-140)-A19T protein at 1.75 mM with 
29 mM 41 dissolved in DMSO in 9:1 ratio. Crystallization was performed at 20 °C using the 
hanging drop vapor-diffusion method, equilibrating mixtures of 1 µl protein complex and 1 µl 
reservoir against 500 µl reservoir solution. Crystals were obtained with reservoir solution 
containing 22 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5. 
 
Structure Solution and Refinement 
The diffraction data were collected at beamline ID29 of the European Synchrotron Radiation 
Facility (ESRF) in Grenoble, France.  Diffraction data were integrated with XDS1 and further 
processed with Aimless and Ctruncate2, as implemented in the CCP4i interface3, 4.  The 
crystal structures were solved by molecular replacement employing the program Molrep5.  
B. Research Articles – Publication/Manuscript VI 
 
74 
 
Iterative model improvement and refinement were performed with Coot6 and Refmac57. The 
dictionaries for the compounds were generated with the PRODRG server8.  Residues facing 
solvent channels without detectable side chain density were modeled as alanines.  
Molecular graphics figures were generated with the program Pymol9. 
 
II. Chemistry 
Chromatographic separations were performed either by manual flash chromatography or 
automated flash chromatography using an Interchim Puriflash 430 with an UV detector.  
Merck F-254 (thickness 0.25 mm) commercial plates were used for analytical TLC. 1H NMR 
spectra, 13C NMR spectra, 2D HSQC, HMBC, and COSY of all intermediates were obtained 
from the Department of Chemistry and Pharmacy, LMU, on a Bruker AC 300, a Bruker XL 
400, or a Bruker AMX 600 at room temperature. Chemical shifts for 1H or 13C are given in 
ppm (δ) downfield from tetramethylsilane using residual protio solvent as an internal 
standard.  
Mass spectra (m/z) were recorded on a Thermo Finnigan LCQ DECA XP Plus mass 
spectrometer at the Max Planck Institute of Psychiatry, while the high resolution mass 
spectrometry was carried out at MPI for Biochemistry (Microchemistry Core Facility) on 
Bruker Daltonics MicrOTOF. 
The purity of the compounds was verified by reversed phase HPLC. All gradients were started 
after 1 min of equilibration with starting percentage of solvent mixture. 
 
Analytical HPLC: 
Pump: Beckman System Gold 125S Solvent Module  
Detector: Beckman System Gold Diode Array Detector Module 168 
Column: Phenomenex Jupiter 4µ Proteo 90Å, 250 x 4.6 mm 4 micron 
 
Solvent A: 95% H2O, 5% MeCN, 0.1% TFA 
Solvent B: 95% MeCN, 5% H2O, 0.1% TFA 
 
Methods: Described for the specific compound 
 
Preparative HPLC:  
Pump:  Beckman System Gold Programmable Solvent Module 126 NMP 
Detector: Beckman Programmable Detector Module 166 
Column: Phenomenex Jupiter 10µ Proteo 90 Å, 250 x 21.2 mm 10 micron 
 
Methods: Described for the specific compound 
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(S)-3-(2-(3,5-dimethoxyphenyl)acetyl)-4-phenyloxazolidin-2-one 
 
 
 
3 
 
DIPEA (0.49 mL, 2.80 mmol) and pivaloyl chloride (0.35 mL, 2.80 mmol) were added to a 
solution of 2-(3,5-dimethoxyphenyl)acetic acid (620 mg, 3.16 mmol) in DCM (5.0 mL) at 
0 °C. The reaction mixture was stirred at that temperature for 30 min and at RT for 1 h. Then 
it was quenched by the addition of saturated NH4Cl and the product was extracted with DCM. 
The combined organics were dried over MgSO4, filtered and the solvent was removed to 
obtain the pivalic acid mixed anhydride as light yellow oil, which was used without further 
purification.  
In the meantime n-BuLi (1.22 mL, 3.06 mmoL, 2.5 M) was added to a solution of (S)-4-
phenyloxazolidin-2-one (457 mg, 2.80 mmo) in THF (8.0 mL) at -78 °C and stirred at that 
temperature for 1 h. The pivalic acid mixed anhydride, dissolved in DCM, was added and the 
reaction mixture was stirred for 16 h, whereby it was allowed to warm to RT. The reaction 
mixture was then quenched by the addition of saturated NH4Cl and the product was extracted 
with Et2O. The combined organics were dried over MgSO4, filtered and the solvent was 
removed. After purification by flash chromatography (gradient 0-20 % EtOAc in 
cyclohexane) the title compound was obtained as light yellow oil (588 mg, 1.72 mmol, 
67.7 %). 
 
TLC [EtOAc/cyclohexane, 4:6]: Rf = 0.38.  
 
Mass: (ESI+), calculated 342.13 [C19H19NO5+H]+, found 341.99 [M+H]+.  
 
1H NMR (300 MHz, CDCl3) δ 7.36 – 7.29 (m, 3H), 7.24 – 7.18 (m, 2H), 6.40 – 6.37 (m, 2H), 
6.37 – 6.34 (m, 1H), 5.42 (dd, J = 8.8, 3.9 Hz, 1H), 4.67 (t, J = 8.8 Hz, 1H), 4.28 – 4.23 (m, 
1H), 4.23 – 4.20 (m, 2H), 3.75 – 3.69 (m, 6H). 
 
13C NMR (75 MHz, CDCl3) δ 170.27, 160.72, 153.54, 138.72, 135.29, 129.07, 128.67, 
125.97, 107.57, 107.43, 99.59, 69.85, 57.75, 55.30, 55.25, 41.75. 
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(S)-3-(2-(3-methoxyphenyl)acetyl)-4-phenyloxazolidin-2-one 
 
 
4 
 
4 was synthesized according to 3 with DIPEA (0.58 mL, 3.31 mmol), pivaloyl chloride (407 
µl, 3.31 mmol), 2-(3-methoxyphenyl)acetic acid (500 mg, 3.01 mmol) in DCM (6.0 mL) and 
n-BuLi (1.44 mL, 3.61 mmol, 2.5 M), (S)-4-phenyloxazolidin-2-one (540 mg, 3.31 mmol) in 
THF (9.0 mL). After purification by flash chromatography (gradient 0-10 % EtOAc in 
cyclohexane) the title compound was obtained as light yellow oil (655 mg, 2.11 mmol, 
70.0 %). 
 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.18.  
 
Mass: (ESI+), calculated 312.12 [C18H17NO4+H]+, found 311.97 [M+H]+.  
 
1H NMR (400 MHz, CDCl3) δ 7.30 – 7.23 (m, 3H), 7.16 – 7.10 (m, 3H), 6.78 – 6.69 (m, 3H), 
5.36 (dd, J = 8.8, 3.9 Hz, 1H), 4.61 (t, J = 8.9 Hz, 1H), 4.20 (s, 3H), 3.68 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 170.54, 159.76, 153.72, 138.90, 134.81, 129.57, 129.24, 
128.82, 126.10, 122.19, 115.18, 113.12, 77.16, 70.01, 57.89, 55.28, 41.76. 
 
(S)-3-((S)-2-cyclohexyl-2-(3,5-dimethoxyphenyl)acetyl)-4-phenyloxazolidin-2-one 
 
 
 
5 
 
NaHMDS (2.58 mL, 2.58 mmol, 1.0 M) was added to a solution of 3 (588 mg, 1.72 mmol) in 
THF (20.0 mL) at - 78 °C. After stirring at -78 °C for 1h 3-bromocyclohex-1-ene (991 µl, 
8.61 mmol) was added drop wise. The reaction mixture was stirred at that temperature for 1 h 
and then at 4 °C for 16 h. Then it was quenched by the addition of saturated NH4Cl and the 
product was extracted with Et2O. The combined organics were dried over MgSO4, filtered and 
the solvent was removed. The crude product was purified and separated from the minor 
diastereomer by flash chromatography (gradient 0-5 % EtOAc in cyclohexane).  
The major alkylation product was dissolved in MeOH (10.0 mL) and the solution was 
degassed with argon. Then Pd-C (40.4 mg, 38 µmol, 10 % wt) was added. In the following 
step H2 was bubbled through the reaction mixture for 5 min. The reaction was then stirred 
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under H2 atmosphere for 16 h. After that time the dark suspension was filtered through celite 
and the solvent was removed under reduced pressure. After purification by flash 
chromatography (gradient 0-20 % EtOAc in cyclohexane) the title compound was obtained as 
colourless oil (144 mg, 0.34 mmol, 19.8 %). 
 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.32.  
 
Mass: (ESI+), calculated 424.21 [C25H29NO5+H]+, found 424.05 [M+H]+.  
 
1H NMR (800 MHz, CDCl3) δ 7.43 – 7.40 (m, 2H), 7.38 – 7.35 (m, 1H), 7.34 – 7.32 (m, 2H), 
6.61 (d, J = 2.3 Hz, 2H), 6.38 (t, J = 2.3 Hz, 1H), 5.37 (dd, J = 8.7, 3.4 Hz, 1H), 4.84 (d, J = 
10.7 Hz, 1H), 4.57 (t, J = 8.8 Hz, 1H), 4.22 (dd, J = 8.9, 3.5 Hz, 1H), 3.79 (s, 6H), 2.03 (qt, J 
= 11.0, 3.4 Hz, 1H), 1.62 – 1.54 (m, 2H), 1.46 – 1.40 (m, 3H), 1.15 – 1.05 (m, 3H), 1.00 – 
0.93 (m, 1H), 0.86 – 0.80 (m, 1H). 
 
13C NMR (201 MHz, CDCl3) δ 175.53, 162.55, 155.37, 141.68, 141.38, 131.09, 130.63, 
127.80, 126.27, 125.08, 109.15, 101.42, 71.33, 60.07, 57.27, 43.70, 33.40, 32.14, 28.86, 
28.20, 27.79, 27.73, 24.70, 19.73. 
 
(S)-3-((S)-2-cyclohexyl-2-(3-methoxyphenyl)acetyl)-4-phenyloxazolidin-2-one 
 
 
 
6 
 
6 was synthesized according to 5 with NaHMDS (1.88 mL, 1.88 mmol. 1.0 M), 4 (390mg, 
1.25 mmol), 3-bromocyclohex-1-ene (720 µl, 6.26 mmol) in THF (15.0 mL) and Pd-C 
(37.5 mg, 35 µmol, 10 % wt) in MeOH (10.0 mL) to obtain the title compound as colourless 
oil (130 mg, 0.33 mmol, 26.4 %). 
 
TLC [EtOAc/cyclohexane, 3:7]: Rf = 0.47.  
 
Mass: (ESI+), calculated 394.20 [C24H27NO4+H]+, found 394.01 [M+H]+.  
 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.22 (m, 5H), 7.17 – 7.10 (m, 1H), 6.95 – 6.89 (m, 2H), 
6.72 (ddd, J = 8.2, 2.6, 1.0 Hz, 1H), 5.27 (dd, J = 8.7, 3.5 Hz, 1H), 4.79 (d, J = 10.7 Hz, 1H), 
4.47 (t, J = 8.8 Hz, 1H), 4.12 (dd, J = 8.9, 3.5 Hz, 1H), 3.72 (s, 3H), 2.01 – 1.89 (m, 1H), 1.57 
– 1.43 (m, 1H), 1.29 (d, J = 12.5 Hz, 1H), 1.23 – 1.12 (m, 2H), 1.08 – 0.97 (m, 3H), 0.95 – 
0.84 (m, 1H), 0.80 – 0.68 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ 173.74, 159.62, 153.44, 139.44, 139.00, 129.27, 129.14, 
128.70, 125.89, 121.87, 114.63, 112.92, 69.40, 58.12, 55.21, 54.59, 41.82, 31.50, 30.23, 
26.93, 26.26, 25.85, 25.80. 
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(R)-4-benzyl-3-(2-cyclohexylacetyl)oxazolidin-2-one 
 
 
 
7 
 
To a solution of (R)-4-benzyloxazolidin-2-one (500 mg, 2.82 mmol) in THF (25.0 mL) was 
added n-BuLi (1.7 mL, 4.23 mmol, 2.5 M) at −78 °C and the resulting mixture was stirred at 
that temperature for 1.5 h, whereby it turned into an orange solution. To the resulting mixture 
was added 2-cyclohexylacetyl chloride (0.65 mL, 4.23 mmol) at −78 °C. The reaction was 
stirred at that temperature for 2.5 h and was then slowly warmed to RT. 
After stirring at 16 h, the colorless reaction mixture was quenched with sat. NH4Cl solution. 
The aqueous layer was extracted with Et2O. The combined organic layers were washed with 
brine, dried over MgSO4, filtrated, and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (gradient 0-10 % EtOAc in cyclohexane) to 
yield the title compound (850 mg, 2.82 mmol, quant.) as a colorless solid.  
 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.30.  
 
Mass: (ESI+), calculated 302.18 [C18H23NO3+H]+, found 302.14 [M+H]+. 
 
1H NMR (599 MHz, CDCl3) δ 7.35 – 7.31 (m, 2H), 7.29 – 7.26 (m, 1H), 7.23 – 7.20 (m, 2H), 
4.70 – 4.65 (m, 1H), 4.21 – 4.14 (m, 2H), 3.31 (dd, J = 13.4, 3.4 Hz, 1H), 2.90 – 2.86 (m, 1H), 
2.81 – 2.73 (m, 2H), 1.94 – 1.87 (m, 1H), 1.81 – 1.64 (m, 5H), 1.35 – 1.24 (m, 2H), 1.17 (qt, J 
= 12.7, 3.5 Hz, 1H), 1.09 – 0.99 (m, 2H). 
 
13C NMR (151 MHz, CDCl3) δ 172.59, 153.40, 135.33, 129.39, 128.92, 128.90, 127.30, 
66.05, 55.19, 42.65, 37.99, 34.29, 33.11, 33.06, 26.19, 26.12, 26.10. 
 
(R)-4-benzyl-3-((R)-2-cyclohexylpent-4-enoyl)oxazolidin-2-one 
 
 
 
8 
 
NaHMDS (1.5 mL, 1.5 mmol, 1.0 M in THF) was added to a solution of 7 (300 mg, 1.0 
mmol) in THF (2.0 mL) at -78 °C and stirred for 1 h, whereby it turned into a light yellow 
solution. Allyl bromide (129 µL, 1.5mmol) was then added dropwise. The reaction was stirred 
for 1 h at - 78 °C and then for 16 h at 4 °C.  
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The reaction mixture was quenched with saturated NH4Cl solution and the aqueous layer was 
extracted with Et2O. The combined organic layers were washed with brine, dried over 
MgSO4, filtrated, and concentrated under reduced pressure. The crude product was purified by 
flash chromatography (gradient 0-5 % EtOAc in cyclohexane) to yield the title compound 
(249 mg, 0.72 mmol, 73.2 %) as a colorless solid.  
 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.43.  
 
Mass: (ESI+), calculated 342.21 [C21H27NO3+H]+, found 342.27 [M+H]+. 
 
1H NMR (599 MHz, CDCl3) δ 7.47 – 6.99 (m, 5H), 5.90 – 5.71 (m, 1H), 5.07 (dq, J = 17.0, 
1.5 Hz, 1H), 5.02 – 4.98 (m, 1H), 4.67 (ddt, J = 10.3, 6.7, 3.2 Hz, 1H), 4.17 – 4.05 (m, 2H), 
3.90 (ddd, J = 9.6, 7.6, 4.4 Hz, 1H), 3.30 (dd, J = 13.4, 3.3 Hz, 1H), 2.62 (dd, J = 13.4, 10.1 
Hz, 1H), 2.51 – 2.32 (m, 2H), 1.87 – 1.79 (m, 1H), 1.77 – 1.58 (m, 4H), 1.30 – 1.15 (m, 3H), 
1.17 – 1.04 (m, 2H), 1.00 (qd, J = 12.4, 3.6 Hz, 1H). 
 
13C NMR (151 MHz, CDCl3) δ 175.83, 153.22, 135.64, 135.55, 129.38, 128.88, 127.22, 
116.88, 65.69, 55.64, 47.40, 40.05, 38.06, 33.78, 31.17, 29.66, 26.28. 
 
(R)-4-benzyl-3-((R)-2-cyclohexylpropanoyl)oxazolidin-2-one 
 
 
 
9 
 
NaHMDS (1.0 mL, 1.0 mmol, 1.0 M in THF) was added to a solution of 7 (200 mg, 0.66 
mmol) in THF (2.0 mL) at -78 °C and stirred for 1 h, whereby it turned into a light yellow 
solution. Iodomethane (415 µL, 6.64 mmol) was then added dropwise. The reaction was 
stirred for 2.5 h at - 78 °C and then for 16 h at 4 °C.  
The reaction mixture was quenched with saturated NH4Cl solution and the aqueous layer was 
extracted with Et2O. The combined organic layers were washed with brine, dried over 
MgSO4, filtrated, and concentrated under reduced pressure. The crude product was purified by 
flash chromatography (gradient 0-5 % EtOAc in cyclohexane) to yield the title compound 
(163 mg, 0.52 mmol, 78.0 %) as a colorless solid.  
 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.43. 
 
Mass: (ESI+), calculated 316.19 [C19H25NO3+H]+, found 316.03 [M+H]+. 
 
1H NMR (300 MHz, CDCl3) δ 7.48 – 7.10 (m, 5H), 4.66 (ddt, J = 10.0, 6.6, 3.3 Hz, 1H), 4.22 
– 4.11 (m, 2H), 3.64 (p, J = 7.0 Hz, 1H), 3.28 (dd, J = 13.2, 3.2 Hz, 1H), 2.75 (dd, J = 13.3, 
9.6 Hz, 1H), 1.79 – 1.53 (m, 6H), 1.29 – 0.89 (m, 8H). 
 
13C NMR (75 MHz, CDCl3) δ 177.16, 153.12, 135.38, 129.40, 128.89, 127.27, 65.88, 55.44, 
42.62, 40.47, 37.89, 31.47, 29.03, 26.30, 26.25, 14.16. 
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(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-oxopropoxy)phenyl)propyl piperidine-2-
carboxylate 
 
10 
 
Synthesized as previously described 10.  
 
(S)-2-cyclohexyl-2-(3,5-dimethoxyphenyl)acetic acid 
 
 
 
11 
 
LiOH (34.4 mg, 1.43 mmol) and H2O2 (163 µL, 1.59 mmol, 30 % wt) were added to a 
solution of 5 (135 mg, 0.32 mmol) in THF/H2O (6.5 mL, 8:5) at 0 °C. The reaction mixture 
was stirred at RT for 16 h and then it was quenched with saturated Na2SO3 solution. The 
aqueous layer was extracted with DCM and, in the following step, acidified with concentrated 
HCl. Then the aqueous layer was again extracted with DCM. These layers were combined, 
dried over MgSO4 and filtered. The solvent was then removed to obtain the title compound 
without any further purification as colorless oil (36.1 mg, 0.13 mmol, 40.7 %).  
 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.46.  
 
Mass: (ESI+), calculated 279.16 [C16H22O4+H]+, found 279.02 [M+H]+.  
 
1H NMR (800 MHz, CDCl3) δ 6.51 (d, J = 2.3 Hz, 2H), 6.38 (t, J = 2.2 Hz, 1H), 3.80 (s, 6H), 
3.16 (d, J = 10.7 Hz, 1H), 1.98 (qt, J = 11.1, 3.4 Hz, 1H), 1.92 – 1.89 (m, 1H), 1.79 – 1.72 (m, 
1H), 1.68 – 1.60 (m, 2H), 1.43 – 1.37 (m, 1H), 1.35 – 1.30 (m, 1H), 1.19 – 1.13 (m, 2H), 1.11 
– 1.03 (m, 1H), 0.81 – 0.72 (m, 1H). 
 
13C NMR (201 MHz, CDCl3) δ 178.74, 160.73, 139.54, 106.80, 99.19, 58.85, 55.32, 40.63, 
31.93, 30.27, 26.26, 25.95, 25.93. 
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(S)-2-cyclohexyl-2-(3-methoxyphenyl)acetic acid 
 
 
 
12 
 
12 was synthesized according to 11 with LiOH (32.9 mg, 1.37 mmol), H2O2 (156 µl, 1.53 
mmol, 30 % wt) and 6 (120mg, 0.31 mmol) in THF/H2O (6.5 mL, 8:5) to obtain the title 
compound as colorless oil (54.5 mg, 0.22 mmol, 71.7 %). 
 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.48.  
 
Mass: (ESI+), calculated 249.15 [C15H20O3+H]+, found 248.94 [M+H]+.  
 
1H NMR (599 MHz, CDCl3) δ 7.22 (t, J = 7.8 Hz, 1H), 6.92 – 6.88 (m, 2H), 6.82 – 6.79 (m, 
1H), 3.80 (s, 3H), 3.68 – 3.61 (m, 1H), 3.11 – 3.04 (m, 1H), 1.99 (qt, J = 11.0, 3.4 Hz, 1H), 
1.93 – 1.87 (m, 1H), 1.77 – 1.71 (m, 1H), 1.67 – 1.58 (m, 2H), 1.40 – 1.23 (m, 2H), 1.18 – 
1.12 (m, 1H), 1.10 – 1.02 (m, 1H), 0.75 (qd, J = 12.0, 3.9 Hz, 1H). 
 
13C NMR (151 MHz, CDCl3) δ 178.34, 159.93, 139.22, 129.96, 121.48, 114.70, 113.01, 
77.16, 58.91, 55.52, 54.07, 42.62, 40.99, 32.26, 30.63, 26.57, 26.39, 19.00, 17.73. 
 
(R)-2-cyclohexylpent-4-enoic acid 
 
 
 
14 
 
LiOH (72.6 mg, 3.03 mmol) and H2O2 (344 µl, 2.38 mmol, 30 % wt) were added to a solution 
of 8 (230 mg, 0.67 mmol) in THF/H2O (13.0 mL, 8:5). The resulting turbid solution was 
stirred at RT for 4.5 h. Then the reaction mixture was quenched with saturated Na2SO3 
solution and it was extracted with DCM. The organic layers were discarded. Then the aqueous 
layer was acidified with concentrated HCl to pH = 1 and extracted with DCM. The organic 
layers were combined, dried over MgSO4 and the solvent was removed. The title compound 
(80.0 mg, 0.44 mmol, 65.7 %) was obtained without further purification as a colorless oil. 
 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.56. 
 
Mass: (ESI+), calculated 183.14 [C11H18O2+H]+, found 183.14 [M+H]+. 
 
1H NMR (400 MHz, CDCl3) δ 4.81 – 4.52 (m, 2H), 4.07 – 3.94 (m, 1H), 3.37 (s, 3H), 2.49 
(dd, J = 7.8, 6.9 Hz, 1H), 1.83 – 1.58 (m, 6H), 1.25 (d, J = 6.3 Hz, 3H), 1.24 – 0.98 (m, 5H). 
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13C NMR (75 MHz, CDCl3) δ 181.42, 135.64, 116.59, 51.59, 39.57, 33.30, 30.76, 30.38, 
26.26, 26.25, 26.21. 
 
(R)-2-cyclohexylpropanoic acid 
 
 
 
15 
 
LiOH (51.3 mg, 2.14 mmol) and H2O2 (243 µl, 2.38 mmol, 30 % wt) were added to a solution 
of 9 (150 mg, 0.48 mmol) in THF/H2O (6.5 mL, 8:5) at 0 °C. The resulting turbid solution 
was stirred at that temperature for 1.5 h and at RT for 1.5 h.  
Then the reaction mixture was quenched with saturated Na2SO3 solution at 0°C and it was 
extracted with DCM. The aqueous layer was acidified with concentrated HCl to pH = 1 and 
extracted with DCM. These layers were combined, dried over MgSO4 and the solvent was 
removed. The title compound (74.3 mg, 0.48 mmol, quant.) was obtained without further 
purification as a colorless oil. 
 
TLC [EtOAc/cyclohexane, 4:6]: Rf = 0.44. 
 
Mass: (ESI+), calculated 157.12 [C9H16O2+H]+, found 157.08 [M+H]+. 
 
1H NMR (300 MHz, CDCl3) δ 2.27 (p, J = 7.1 Hz, 1H), 1.84 – 1.42 (m, 6H), 1.38 – 0.76 (m, 
8H). 
 
13C NMR (75 MHz, CDCl3) δ 182.63, 45.25, 40.44, 31.12, 29.37, 26.26, 26.25, 26.21, 13.64. 
 
(R)-4-benzyl-3-((S)-2-cyclohexyl-3-hydroxypropanoyl)oxazolidin-2-one 
 
 
 
23 
 
7 (200 mg, 0.66 mmol) in DCM (3.0 mL) was cooled to 0 °C and TiCl4 (730 µl, 0.73 mmol, 
1.0 M in DCM) was added drop wise. It was stirred for 10 min then DIPEA (139 µl, 0.80 
mmol) was added. The dark red enolate was stirred for 45 min at 0 °C. Then 1,3,5-Trioxane 
(90.0 mg, 1.0 mmol), dissolved in DCM (0.5 mL) and precooled, and afterward an additional 
equivalent of TiCl4 (1.0 M in DCM) were added drop wise. It was stirred for 2.5 h at 0 °C. 
The brown reaction mixture was quenched with half-saturated NH4Cl solution. The layers 
were separated and the organic layer was dried over MgSO4, filtrated and concentrated under 
reduced pressure. The crude product was purified by flash chromatography (0 – 20 % EtOAc 
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in cyclohexane) to afford the title compound as a colorless solid (171 mg, 0.52 mmol, 
77.7 %).  
 
TLC [EtOAc/cyclohexane, 4:6]: Rf = 0.39. 
 
Mass: (ESI+), calculated 332.19 [C19H25NO4 + H]+, found = 331.94 [M+H]+. 
 
1H NMR (300 MHz, CDCl3) δ 7.47 – 7.06 (m, 5H), 4.70 (ddt, J = 9.9, 6.6, 3.4 Hz, 1H), 4.27 
– 4.07 (m, 2H), 4.04 – 3.78 (m, 3H), 3.30 (dd, J = 13.5, 3.4 Hz, 1H), 2.81 (dd, J = 13.5, 9.3 
Hz, 1H), 1.92 – 1.50 (m, 6H), 1.34 – 0.94 (m, 5H). 
 
13C NMR (75 MHz, CDCl3) δ 176.04, 153.55, 135.21, 129.45, 128.90, 127.32, 66.00, 62.04, 
55.54, 50.51, 37.84, 37.61, 31.29, 29.91, 26.22, 26.15. 
 
(S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)-2-cyclohexylethanone 
 
 
24 
 
To a solution of (S)-4-benzylthiazolidine-2-thione (1 g, 4.78 mmol) in THF (dry, 50 mL) was 
added n-BuLi (2.87 mL, 7.17 mmol, 2.5 M) at − 78 °C. The resulting mixture was stirred at 
that temperature for 1.5 h, then 2-cyclohexylacetyl chloride (1.10 ml, 7.17 mmol) was added. 
The temperature was maintained at – 78 °C for 2.5 h. Then the reaction mixture was allowed 
to warm to RT and stirred for 16 h. After an aqueous work up with saturated NH4Cl solution 
the crude product was purified by flash chromatography (cyclohexane) to afford the title 
compound as a yellow crystalline solid (1.48 g, 4.45 mmol, 93 %). 
 
TLC [cyclohexane/EtOAc, 8:2]: Rf = 0.60. 
 
Mass: (ESI+), calculated 333.12 [C18H23NOS2 + H]+, found = 334.04 [M+H]+ 
 
1H NMR (599 MHz, CDCl3) δ 7.35 – 7.30 (m, 2H), 7.30 – 7.24 (m, 3H), 5.39 – 5.30 (m, 1H), 
3.36 (ddd, J = 11.5, 7.2, 1.0 Hz, 1H), 3.23 – 3.09 (m, 3H), 3.03 (dd, J = 13.2, 10.6 Hz, 1H), 
2.88 – 2.84 (m, 1H), 1.97 – 1.88 (m, 1H), 1.78 – 1.62 (m, 5H), 1.30 – 1.22 (m, 3H), 1.15 (qt, J 
= 12.7, 3.3 Hz, 3H), 1.08 – 0.92 (m, 2H). 
 
13C NMR (151 MHz, CDCl3) δ 201.08, 173.27, 136.58, 129.42, 128.85, 127.15, 68.67, 45.41, 
36.79, 34.54, 33.16, 32.91, 31.87, 26.22, 26.13, 26.04. 
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(2S,3R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-cyclohexyl-3-hydroxybutan-1-one 
 
 
 
25 
 
24 (200 mg, 0.60 mmol) in DCM (dry, 2 mL) was cooled to 0 °C. Then TiCl4 (660 µl, 
0.66 mmol, 1 M) was added dropwise. After 5 min TMEDA (226 µl, 1.50 mmol) was added 
and the resulting dark red enolate was stirred for 20 min at 0 °C. Then acetaldehyde (0.10 mL, 
1.80 mmol) was then added dropwise and it was stirred for 4 h at 0 °C. 
After an aqueous work up with half-saturated NH4Cl solution the crude product was purified 
by flash chromatography (0 – 100 % DCM in cyclohexane) to afford the title compound as a 
yellow oil (116.6 mg, 0.31 mmol, 52 %).  
 
TLC [DCM]: Rf = 0.19. 
 
Mass: (ESI+), calculated 378.57 [C20H27NO2S2 + H]+, found = 377.88 [M+H]+ 
 
1H NMR (599 MHz, CDCl3) δ 7.34 – 7.26 (m, 5H), 5.51 – 5.38 (m, 1H), 5.27 (dd, J = 9.1, 5.8 
Hz, 1H), 4.25 (q, J = 6.2 Hz, 1H), 3.33 (ddd, J = 11.4, 7.2, 1.1 Hz, 1H), 3.21 (dd, J = 13.2, 3.9 
Hz, 1H), 3.04 (dd, J = 13.2, 10.6 Hz, 1H), 2.80 (dd, J = 11.4, 0.7 Hz, 1H), 1.87 (dddd, J = 
12.4, 11.2, 6.5, 3.3 Hz, 1H), 1.82 – 1.76 (m, 2H), 1.74 – 1.66 (m, 2H), 1.66 – 1.62 (m, 2H), 
1.30 – 1.24 (m, 2H), 1.20 (d, J = 6.3 Hz, 3H), 1.18 – 1.06 (m, 2H). 
 
13C NMR (151 MHz, CDCl3) δ 203.00, 175.26, 136.51, 129.41, 128.86, 127.17, 69.30, 68.17, 
53.61, 38.47, 37.00, 31.66, 31.58, 30.12, 26.34, 26.29, 26.18, 18.49. 
 
(2S,3R,E)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-cyclohexyl-3-hydroxyhex-4-en-1-
one 
 
 
26 
 
26 was synthesized according to 25 with (E)-but-2-enal (0.15 mL, 1.80 mmol) to afford the 
title compound as yellow solid (171 mg, 0.43 mmol, 71 %). 
 
TLC [DCM]: Rf = 0.39. 
 
Mass: (ESI+), calculated 404.17 [C22H29NO2S2 + H]+, found = 404.01 [M+H]+. 
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1H NMR (400 MHz, CDCl3) δ 7.39 – 7.22 (m, 5H), 5.78 – 5.58 (m, 2H), 5.43 – 5.29 (m, 1H), 
5.20 (dd, J = 8.5, 6.5 Hz, 1H), 4.43 (t, J = 6.8 Hz, 1H), 3.30 (ddd, J = 11.3, 7.1, 1.0 Hz, 1H), 
3.22 (dd, J = 13.2, 4.0 Hz, 1H), 3.05 (dd, J = 13.2, 10.6 Hz, 1H), 2.81 (d, J = 11.4 Hz, 1H), 
1.92 – 1.75 (m, 2H), 1.72 (d, 3H), 1.70 – 1.55 (m, 6H), 1.43 – 1.32 (m, 1H), 1.29 – 1.04 (m, 
3H). 
 
13C NMR (101 MHz, CDCl3) δ 202.39, 175.27, 136.59, 130.22, 129.45, 129.39, 128.85, 
127.14, 73.61, 69.29, 52.80, 38.49, 36.95, 31.81, 31.03, 30.07, 26.44, 26.38, 26.27, 17.86. 
 
(2S,3R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-cyclohexyl-3-hydroxy-4-
methylpentan-1-one 
 
 
 
27 
 
27 was synthesized according to 25 with TiCl4 (1.12 mL, 1.12 mmol, 1 M), TMEDA (385 µl, 
2.55 mmol) and isobutyraldehyde (279 µL, 3.06 mmol) in DCM (3.4 mL). The title 
compound (86.8 mg, 0.21 mmol, 21.0 %) was obtained as yellow oil.   
 
TLC [DCM]: Rf = 0.60. 
 
Mass: (ESI+), calculated 406.19 [C22H31NO2S2 + H]+, found = 406.17 [M+H]+. 
 
1H NMR (300 MHz, CDCl3) δ 7.38 – 7.28 (m, 5H), 5.45 – 5.35 (m, 1H), 5.05 (t, J = 6.2 Hz, 
1H), 3.72 (dd, J = 6.0, 4.9 Hz, 1H), 3.35 – 3.20 (m, 2H), 3.06 (dd, J = 13.2, 10.6 Hz, 1H), 
2.92 – 2.81 (m, 1H), 1.88 – 1.79 (m, 2H), 1.77 – 1.69 (m, 3H), 1.65 (d, J = 10.7 Hz, 2H), 1.35 
– 1.09 (m, 6H), 0.99 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.7 Hz, 3H). 
 
13C NMR (75 MHz, CDCl3) δ 202.40, 177.33, 136.40, 129.42, 128.90, 127.24, 76.47, 69.00, 
50.01, 39.96, 36.68, 31.81, 31.62, 31.30, 29.20, 26.90, 26.63, 26.57, 26.20, 20.13, 16.98. 
 
(2S,3R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-cyclohexyl-3-hydroxy-5-
methylhexan-1-one 
 
 
 
28 
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28 was synthesized according to 25 with 3-methylbutanal (0.19 mL, 1.80 mmol) to afford the 
title compound as yellow solid (172 mg, 0.41 mmol, 68.3 %). 
 
TLC [DCM]: Rf = 0.52. 
 
Mass: (ESI+), calculated 420.20 [C23H33NO2S2 + H]+, found = 420.04 [M+H]+. 
 
1H NMR (300 MHz, CDCl3) δ 7.47 – 7.22 (m, 5H), 5.56 – 5.39 (m, 1H), 5.36 – 5.21 (m, 1H), 
4.13 (ddd, J = 10.4, 5.7, 2.2 Hz, 1H), 3.34 (ddd, J = 11.5, 7.2, 1.0 Hz, 1H), 3.21 (dd, J = 13.2, 
3.9 Hz, 1H), 3.08 – 2.96 (m, 1H), 2.91 – 2.72 (m, 1H), 1.84 – 1.60 (m, 7H), 1.33 – 1.14 (m, 
6H), 0.96 – 0.93 (m, 4H), 0.90 (d, J = 6.6 Hz, 4H). 
 
13C NMR (75 MHz, CDCl3) δ 203.01, 175.63, 136.52, 129.43, 128.85, 127.17, 70.06, 69.25, 
53.27, 41.18, 38.19, 37.01, 31.67, 31.50, 30.14, 26.89, 26.36, 26.33, 26.22, 24.51, 23.93, 
21.35. 
 
(2S,3S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-cyclohexyl-3-hydroxy-3-
phenylpropan-1-one 
 
 
 
29 
 
29 was synthesized according to 25 with TiCl4 (0.63 mL, 0.63 mmol, 1 M), TMEDA (226 µL, 
1.50 mmol) and benzaldehyde (91.0 µL, 0.90 mmol) in DCM (4.0 mL). After flash 
chromatography (0-50 % DCM in cyclohexane) the title compound (74 mg, 0.17 mmol, 
28.0 %) was obtained as yellow oil. 
 
TLC [DCM/cyclohexane, 1:1]: Rf = 0.09. 
 
Mass:(ESI+), calculated 440.17 [C25H29NO2S2 + H]+, found = 439.82 [M+H]+. 
  
1H NMR (599 MHz, CDCl3) δ 7.39 – 7.35 (m, 2H), 7.32 – 7.28 (m, 4H), 7.26 – 7.22 (m, 2H), 
7.20 – 7.17 (m, 2H), 5.17 (dd, J = 8.9, 5.4 Hz, 1H), 4.92 (d, J = 8.9 Hz, 1H), 4.61 – 4.55 (m, 
1H), 3.05 (dd, J = 13.3, 4.2 Hz, 1H), 2.86 (dd, J = 13.3, 10.5 Hz, 1H), 2.46 (dd, J = 11.1, 0.7 
Hz, 1H), 2.31 (ddd, J = 11.1, 6.9, 1.0 Hz, 1H), 2.25 – 2.18 (m, 1H), 2.11 – 2.05 (m, 1H), 1.92 
– 1.64 (m, 5H), 1.34 – 1.15 (m, 5H). 
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(S)-2-cyclohexyl-3-(methoxymethoxy)propanoic acid 
 
 
 
30 
 
23 (160 mg, 0.48 mmol) was dissolved in DCM (1.0 mL) and DIPEA (253 µL, 1.45 mmol) 
was added. The solution was cooled to 0 °C and MOM-Cl (110 µl, 1.45 mmol) was added and 
it was stirred 2.5 h at 0°C. The reaction mixture was diluted with DCM and washed with half 
saturated NH4Cl solution and half saturated NaHCO3 solution. The organic layer was dried 
over MgSO4 and the solvent was removed under reduced pressure. After this the residue was 
dissolved in THF/H2O (6.5 mL, 8:5) followed by the addition of LiOH (52.0 mg, 2.17 mmol) 
and H2O2 (247 µl, 2.41 mmol, 30% wt) at 0 °C. The reaction mixture was stirred at that 
temperature for 1.5 h and at RT for 1.5h.  
Then the reaction mixture was quenched with sat. Na2SO3 solution at 0°C. It was extracted 
with DCM and the combined organic layers were discarded. Then the aqueous layer was 
acidified with conc. HCl to pH = 1 and extracted with DCM. At this step the organic layers 
were combined, dried over MgSO4 and the solvent was removed under reduced pressure to 
yield the title compound (104 mg, 0.48 mmol, quant) without further purification as a 
colorless oil. 
 
TLC [EtOAc/cyclohexane, 4:6]: Rf = 0.26. 
 
Mass: (ESI+), calculated 217.14 [C11H20O4 + H]+, found = 216.86 [M+H]+. 
 
1H NMR (300 MHz, CDCl3) δ 4.60 (s, 2H), 3.83 – 3.62 (m, 2H), 3.34 (s, 3H), 2.60 – 2.47 (m, 
1H), 1.86 – 1.51 (m, 6H), 1.35 – 0.89 (m, 5H). 
 
13C NMR (75 MHz, CDCl3) δ 179.20, 96.48, 66.67, 55.29, 51.87, 37.55, 30.87, 30.64, 26.16, 
26.13. 
 
(2S,3R)-2-cyclohexyl-3-(methoxymethoxy)butanoic acid 
 
 
 
31 
 
The title compound was synthesized according to 30 with 25 (360 mg, 0.95 mmol), DIPEA 
(0.50 mL, 2.86 mmol) and MOM-Cl (0.72 mL, 9.53 mmol) in DCM (1.0 mL). The auxiliary 
was cleaved with LiOH (103 mg, 4.29 mmol), H2O2 (0.24 mL, 2.38 mmol, 30 % wt) in 
THF/H2O (8:5, 13.0 mL) at RT.  
The product (150 mg, 0.65 mmol, 68.2 %) was obtained after flash chromatography (0 – 20 % 
EtOAc in cyclohexane) as colorless oil.  
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TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.34. 
 
Mass: (ESI+), calculated 231.16 [C12H22O4 + H]+, found = 230.78 [M+H]+. 
 
1H NMR (300 MHz, CDCl3) δ 4.60 (s, 2H), 3.83 – 3.62 (m, 2H), 3.34 (s, 3H), 2.60 – 2.47 (m, 
1H), 1.86 – 1.51 (m, 6H), 1.35 – 0.89 (m, 5H). 
 
13C NMR (101 MHz, CDCl3) δ 177.89, 94.92, 71.12, 56.46, 55.61, 36.60, 30.93, 30.43, 
26.28, 26.26, 26.12, 16.70. 
 
(2S,3R)-2-cyclohexyl-3-(methoxymethoxy)-5-methylhexanoic acid 
 
 
 
32 
 
26 (170 mg, 0.41 mmol) and DIPEA (213 µl, 1.22 mmol) were dissolved in DCM (dry, 
0.5 mL) and cooled to 0 °C. Then MOM-Cl (155 µl, 2.04 mmol) was added and it was stirred 
at RT for 2.5 h. The reaction mixture was diluted with DCM and washed with half-saturated 
NH4Cl solution and a half-saturated NaHCO3 solution. The organic layer was dried over 
MgSO4, filtrated and the solvent was removed under vacuum. Then the residue was dissolved 
in THF/H2O (8:5, 1.3 mL) followed by the addition of LiOH (43.9 mg, 1.83 mmol) and H2O2 
(104 µl, 1.02 mmol, 30 % wt). The reaction mixture was stirred at RT for 2 h and then 
quenched with Na2SO3 solution (1.5 M) and it was extracted with DCM, whereby the organic 
layer was discarded. The aqueous layer was acidified and the product was extracted several 
times with DCM. The combined organics were dried over anhydrous MgSO4 filtrated and 
concentrated to afford the title compound (46 mg, 0.17 mmol. 41 %) as colorless oil.  
 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.45. 
 
1H NMR (300 MHz, CDCl3) δ 4.77 (d, J = 7.0 Hz, 1H), 4.61 (d, J = 7.1 Hz, 1H), 3.94 (ddd, J 
= 10.7, 5.6, 2.1 Hz, 1H), 3.42 (s, 3H), 2.61 (dd, J = 9.5, 5.5 Hz, 1H), 1.87 – 1.81 (m, 1H), 1.75 
– 1.66 (m, 6H), 1.29 – 1.14 (m, 5H), 1.03 (d, J = 10.4 Hz, 2H), 0.96 – 0.90 (m, 6H). 
 
13C NMR (75 MHz, CDCl3) δ 178.16, 129.00, 95.86, 74.20, 56.03, 55.01, 39.29, 36.56, 
31.75, 30.20, 26.29, 26.02, 25.94, 24.22, 24.04, 21.14. 
 
(2S,3R,E)-3-((tert-butyldimethylsilyl)oxy)-2-cyclohexylhex-4-enoic acid 
 
 
 
33 
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LiOH (32.0 mg, 1.34 mmol) and H2O2 (76 μL, 0.74 mmol, 30 % wt) were added to a solution 
of 26 (120 mg, 0.297 mmol) in THF/H2O (6.5 mL, 8:5). The reaction mixture was stirred at 
RT for 2 h. Then the reaction was quenched with 1.5 M Na2SO3 solution and it was extracted 
with DCM. The combined organic layers were discarded. In the following step the aqueous 
layer was acidified with conc. HCl to pH = 1 and again extracted with DCM. At this step the 
organic layers were combined, dried over MgSO4 and the solvent was removed under reduced 
pressure to yield the free carboxylic acid.  
The protection group was introduced at – 78 °C via drop wise addition of TBSOTf (162 µl, 
0.71 mmol) to a solution of the carboxylic acid in 2,6-Lutidine (137 µL, 1.18 mmol) and 
DCM (2.0 mL).The reaction was stirred for 2 h and then quenched with sat. NaHCO3 
solution. The layers were separated and it was extracted with Et2O. Then the combined 
organic layers were washed with sat. NH4Cl and brine, dried over MgSO4 and filtered. After 
the solvent was removed under reduced pressure the residue was dissolved in MeOH/THF 
(2.0 mL, 1:1) and a solution of K2CO3 (71.6 mg, 0.52 mmol) in H2O (0.40 mL) was added. 
The reaction was stirred at RT for 1 h and then diluted with 1 N NaOH. It was extracted with 
DCM and the organic layers were discarded. Subsequently, the aqueous layer was acidified 
and the product was extracted with DCM. The combined organic layers were dried over 
MgSO4, filtered and the solvent was removed under reduced pressure to obtain the title 
compound without further purification as colorless oil (22.0 mg, 67.4 µmol, 29.0 %). 
 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.65. 
 
1H NMR (400 MHz, CDCl3) δ 5.63 – 5.49 (m, 2H), 4.30 (t, J = 7.4 Hz, 1H), 2.45 – 2.34 (m, 
1H), 2.26 – 2.17 (m, 1H), 1.74 – 1.68 (m, 5H), 1.67 – 1.65 (m, 3H), 1.26 – 1.13 (m, 5H), 0.85 
(s, 9H), 0.04 (s, 3H), -0.00 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 178.02, 131.19, 128.08, 72.24, 58.36, 41.78, 36.18, 34.61, 
32.93, 31.26, 29.71, 26.45, 26.36, 26.17, 26.06, 25.96, 25.75, 25.67, 18.04, 17.62, -3.98, -
5.03. 
 
(2S,3R)-3-((tert-butyldimethylsilyl)oxy)-2-cyclohexyl-4-methylpentanoic acid 
 
 
 
34 
 
34 was synthesized according to 33 with 27 (85 mg, 0.21 mmol). The Evans auxiliary was 
cleaved with LiOH (22.6 mg, 0.94 mmol), H2O2 (0.54 mL, 0.52 mmol, 30 % wt) in THF/H2O 
(8:5, 6.5 mL). The TBS protected alcohol was obtained by treatment with TBSOTf (142 µL, 
0.62 mmol), 2,6-Lutidine (120 µL, 1.03 mmol) in DCM (2.0 mL) and K2CO3 (62.4 mg, 0.45 
mmol) in MeOH/THF (2 mL, 1:1).  
In the following step the organic solvent was removed, it was extracted with DCM and the 
combined organic layers were discarded. Then the aqueous layer was acidified with conc. HCl 
to pH = 1 and again extracted with DCM. At this step the organic layers were combined, dried 
over MgSO4 and the solvent was removed under reduced pressure. After flash 
chromatography (0-20 % EtOAc in cyclohexane) the title compound (33.0 mg, 0.10 mmol, 
48.9 %) was obtained as colorless crystalline solid. 
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TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.72. 
 
Mass: (ESI+), calculated 329.25 [C12H22O4 + H]+, found = 329.09 [M+H]+. 
 
1H NMR (400 MHz, CDCl3) δ 3.87 (dd, J = 5.1, 1.6 Hz, 1H), 3.82 (d, J = 2.9 Hz, 1H), 2.22 
(dd, J = 9.5, 1.6 Hz, 1H), 1.93 – 1.86 (m, 1H), 1.83 – 1.63 (m, 5H), 1.25 – 1.09 (m, 5H), 0.94 
(s, 12H), 0.91 (d, J = 7.0 Hz, 3H), 0.17 (s, 3H), 0.16 (s, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 174.18, 75.96, 52.19, 36.69, 33.85, 31.63, 30.92, 26.10, 
26.08, 26.05, 25.81, 19.14, 18.13, 16.52, -4.01, -4.66. 
 
(2S,3S)-3-((tert-butyldimethylsilyl)oxy)-2-cyclohexyl-3-phenylpropanoic acid 
 
HO
O OTBS
 
 
35 
 
35 was synthesized according to 33 with 29 (197 mg, 0.45 mmol). The auxiliary was cleaved 
with LiOH (49.0 mg, 2.05 mmol), H2O2 (0.30 mL, 2.94 mmol, 30 % wt) in THF/H2O (8:5, 
19.5 mL). The TBS protected alcohol was obtained with TBSOTf (314 µL, 1.37 mmol), 2,6-
Lutidine (265 µL, 2.28 mmol) in DCM (4.5 mL) and K2CO3 (138 mg, 1.0 mmol) in 
MeOH/THF (3 mL, 1:1).  
In the following step the organic solvent was removed, it was extracted with DCM and the 
combined organic layers were discarded. Then the aqueous layer was acidified with conc. HCl 
to pH = 1 and again extracted with DCM. At this step the organic layers were combined, dried 
over MgSO4 and the solvent was removed under reduced pressure to yield the title compound 
(69.8 mg, 0.19 mmol, 42.3 %) without further purification as a colorless crystalline solid. 
 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.65. 
 
1H NMR δ 7.33 – 7.18 (m, 5H), 4.82 (d, J = 9.7 Hz, 1H), 2.66 (dd, J = 9.7, 4.1 Hz, 1H), 2.13 
– 1.97 (m, 1H), 1.91 – 1.61 (m, 5H), 1.43 – 1.02 (m, 5H), 0.83 (s, 9H), 0.02 (s, 3H), -0.35 (s, 
3H). 
 
13C NMR (101 MHz, CDCl3) δ 177.77, 143.45, 128.53, 128.24, 127.89, 73.66, 60.88, 37.19, 
33.01, 28.47, 27.59, 27.11, 26.99, 26.33, 18.66, -3.92, -4.61.  
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(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl piperidine-2-
carboxylate 
 
 
36 
 
Synthesized as previously described 10. 
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7.2. Manuscript VII   
A novel decalin-based bicyclic scaffold for FKBP51-selective ligands – manuscript in 
preparation 
(Xixi Feng, Claudia Sippel, Andreas Bracher, Felix Hausch) 
 
Summary 
In the second “Bottom Group” series a novel bicyclic scaffold was designed and its usability 
as lead structure for further FKBP51 ligand development was tested. The crystal structure-
based model indicated that this type of chemical structure, in fact a trans decalin, could pre-
shape the cyclohexyl ring to its binding conformation. One ring of the bicycle is supposed to 
serve as a bridge, leading to a more stabilized conformation, less entropy loss during binding 
and thus higher binding affinities.   
A synthesis with an asymmetric intramolecular Diels-Alder cyclization as key synthetic step 
was developed that also allowed ring substitutions to perform structure affinity relationship 
analysis. None of the ligands from the decalin series showed any binding towards FKBP52. 
The best ligand of this series exhibited a Ki of 0.23 µM and contained a carbonyl group in the 
4-position. A cocrystal structure was solved to analyze the binding mode. We were delighted 
to see that our model was confirmed and that one of the bicyclic rings promoted an induced fit 
in FKBP51, exactly like the cyclohexyl ring in the previous series. This series also indicates 
that the rigidification itself is beneficial for the binding affinity. These findings, together with 
the possibility to further modify the bicycles make the decalin-series a promising lead 
structure for future ligand optimization.   
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Prescreening of bycyclic aromating scaffolds 
The discovery of a bicyclic structure as promising new scaffold led us to the idea to perform a 
rapid prescreening with commercially available aromatic, bicyclic carboxylic acids 
(Scheme 4, exemplified on 1-naphoic acid). The compounds were synthesized based on a 
solid phase-assisted method developed by Gopalakrishnan et al.21 (Scheme 4) and tested in a 
fluorescence polarization assay (Orig. Publ).  
 
Scheme 4: Synthesis of the aromatic bicycle series exemplified on 1-naphtoic acid. Reagents and conditions: (a) 
DCC, DMAP. (b) TFA, DCM (c) DIPEA (d) 4-methyl-piperidine, DCM. (e) HATU, DIPEA, DCM (f) TFA, 
DCM. 
Unfortunately, none of the compounds showed any binding towards FKBP51 which we 
attribute to the partially planar structure of the aromatic bicycles. Thereupon, we focused on 
the synthesis of the trans-decalin scaffold we obtained from the computer model.  
An asymmetric intramolecular Diels-Alder (IMDA) reaction as key synthesis step  
The trans-decalin scaffold we aimed to include in our ligands is a motif occurring in several 
natural products like tetrodecamycin, (-)-Himgaline and (-)-GB13 (Fig.9).  
 
Fig. 9: Examples of natural products containing a trans-decalin motif (red).  
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Paintner et al.51 carried out an asymmetric intramolecular Diels-Alder reaction as core step for 
the synthesis of the bicyclic potion of tetrodecamycin.  Evans et al.52 conducted a similar step 
during the synthesis of ent-Himgaline and ent-GB 13. The stereochemical outcome of the 
cyclization is mediated, similarly to our asymmetric aldol-reaction (see 7.1.), by an Evans 
oxazolidinone auxiliary but also electronic factors of the precursor. As in the aldol series the 
oxazolidinone auxiliary can be directly converted to a carboxylic acid and immediately 
coupled with the pipecolic esters to obtain the final compounds. The cyclization of a triene 
with a benzyloxazolidinone auxiliary, promoted by DMAC, (dimethylaluminium chloride) 
exhibits high diastereoselectivity and high endo selectivity.53  It is supposed that the formation 
of the exo product is disfavored since interactions between the diene and the chain linking the 
diene and the dienophile destabilize the resulting transition state and the bonding geometries 
are more difficult attained. Therefore, the formation of trans-fused products is favored.54 The 
suggested transition state is shown in Fig. 10. Additionally, it is assumed that a “π-stacking 
interaction” or charge-transfer occurs between the benzyl group and the dienophile.53  
 
Fig. 10: Proposed transition state for the chiral auxiliary-mediated intramolecular Diels-Alder cyclization. 
Adapted from Evans et al.53 and Roush et al.54. 
Together with steric effects, one diastereoface is selectively shielded, which leads to a high 
diastereoselective conversion. The Lewis acid DMAC promotes the reaction by chelating the 
imide carbonyls.54 
Also during our synthesis of the bicyclic ligand series we observed only the formation of one 
major product after the intramolecular cyclization step. Although we partly synthesized 
structures that were already described by Evans et al.54 our synthesis differs slightly. The 
described synthetic procedures, e.g. those for the natural products shown in Fig. 9, are 
optimized and adapted to the respective chemical scaffolds. Since we planned to perform a 
structure-affinity-relationship analysis on the bicyclic scaffold we designed the new synthesis 
in a way that it is both shorter and more versatile than the previous published procedure. With 
our synthesis we are able to introduce substituents on the terminal double bond via a Wittig 
reaction (Scheme 1, manuscript). Also the double bond, that is a leftover of the cyclization, 
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gives possibilities to chemically modify the bicyclic scaffold. The modifications we 
performed are summarized by Table 1 (manuscript). The stereochemical outcome of the 
dihydroxylation step that was conducted for the synthesis of intermediate 9d (and compounds 
23 and 24) is deviated from the dihydroxylation reaction conducted by Evans et al.52during 
the synthesis of ent-Himgaline and ent-GB 13. 
With the aldol series (chapter 7.1.) we aimed to reproduce a hydrogen bond that was observed 
between FK506 and Asp68 and also in the ligand series developed by Gopalakrishnan et al.20. 
Unfortunately, the cocrystal structure of a representative ligand of the series didn’t show the 
expected hydrogen bond. Therefore we hoped we could be more successful with our new 
scaffold and tried to introduce a hydroxyl group in the position corresponding to the position 
of the hydroxyl group in the aldol series.  
 
Fig. 11: Transferring the hydroxyl group from the aldol series to the new bicyclic scaffold.  
First, we utilized our new versatile synthesis and introduced a methyl vinyl ether group (1) via 
a Wittig reaction with (Methoxymethyl)triphenylphosphonium chloride. Cyclization of the 
linear precursor should provide the bicycle with a methoxy substituent (2), which represents a 
direct precursor of our desired structure (Scheme 5a). As suspected the labile methyl vinyl 
ether function did not survive the cyclization reaction. Directly after addition of DMAC to the 
linear precursor the reaction solution turned brown (usually light yellow). TLC control 
indicated an inseparable and unclear mixture. The same thing happened with a trimethylsilyl 
enol ether as functional group that was obtained by enolization of an α,β-unsaturated aldehyde 
(3->4) with TMSBr after a method developed by Iqbal et al.55 (Scheme 5b). Attempts to 
replace the labile TMS ether by more stable silyl ethers failed since the enolization step did 
not work. Due to synthetic reasons this step was first conducted with a precursor leading to 
the 9-membered bicycle. 
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Scheme 5: Unsuccessful intramolecular Diels-Alder cylizations. (Aux = Evans auxiliary)  
We then tried to use a more straightforward step and tested conditions to obtain the hydroxyl-
decalin from 6, the direct cyclization product, by allylic oxidations (Scheme 6).            
 
Scheme 6: Theoretically proposed allylic oxidation of the IMDA cyclization product.  
First attempts to introduce the alcohol via oxidation of the allylic methylene group (7) with 
SeO256 did not work since no clear conversion could be observed. We then changed our focus 
and tried to introduce a keto group (8), since it is more versatile for further chemical 
modifications and the hydroxy group could theoretically be obtained by simple reduction of 
the carbonyl. We tried several tBuOOH-based methods: in combination with sodium chlorite 
(NaClO2)57, with diacetoxyiodobenzene58 or with dirhodium(II) caprolactamate59. But none of 
the promising conditions led to a successful conversion of the reactant both with the 9- and 
the 10-membered bicycles as reactants. 
Within the decalin-series this issue is still an ongoing project and it is aimed to work on 
conditions that could lead to the desired moiety (see C-Outlook). 
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Abstract 
Selective inhibition of FKBP51 has emerged as possible novel treatment for diseases like 
major depressive disorders or obesity. However, the physicochemical properties of the current 
FKBP51 inhibitors are outside the range of drug-like molecules and therefore have to be 
further optimized. Using a rigidification strategy we hereby report the structure-based design 
and synthesis of a novel promising bicyclic scaffold for FKBP51 ligands. With the cocrystal 
structure of the best ligand in this novel series we show, how the cyclization locks the ligand 
in a conformation typical for FKBP51-selective binding. 
 
Introduction 
The important role of the FK506-binding protein 51 (FKBP51) has been shown in several 
diseases and pathologic states. It has been reported that FKBP51 is involved in the 
development of obese conditions by activating adipocyte differentiation.1 FKBP51 knockout 
mice were protected from weight gain after a high fat diet and in general exhibited reduced 
weight.2,3 FKBP51 influences have also been genetically associated with the severity of pain 
symptoms experienced after trauma.4 FKBP51 is also involved in the development of stress-
related psychiatric disorders, which is supposed to be its most prominent function.5 It is 
assumed that overactive FKBP51 leads to an impaired feedback in the stress regulation 
system, most notably the hypothalamus-pituitary-adrenal axis. In accordance with this, a 
knockout of the gene FKBP5 in mice resulted in improved stress-coping behavior.2 In 
humans, polymorphisms in the FKBP51-encoding gene (FKBP5) were linked to an enhanced 
susceptibility for stress-related disorders.5 In all these diseases FKBP51 was therefore 
considered as promising drug target.6 
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Figure 1: Chemical structures of the FKBP51-selective ligands SAFit1 (1), SAFit2 (2) and their binding 
affinities towards FKBP51.  
 
A key problem in FKBP51 drug discovery is to achieve selectivity over its close homolog 
FKBP52. Due to the high structural analogy between these proteins, all ligands derived from 
FK506 exhibit similar binding affinities to both proteins.7 Concomitant binding, however, has 
to be avoided since both proteins have opposing effects, e.g. in neuronal cells.8 An inhibition 
of FKBP52 is even supposed to have toxic effects, since a knockout of this protein in mice led 
to severe impairment of the reproduction system.9-12 In contrast to that, an inhibition of 
FKBP51 is well tolerated since no adverse phenotypes were observed in FKBP51 knockout 
mice.9  
With the discovery of SAFit2, a highly selective, potent and blood-brain permeable FKBP51 
inhibitor, it was possible to perform first studies to test the effects of FKBP51 inhibition in 
vivo. It was shown that SAFit2 has clear antidepressant-like effects.8 Additionally, mice that 
were treated with SAFit2 for 30 days showed a reduced body weight under control and high 
fat diet conditions.15 These data confirmed FKBP51 as a promising drug target and selective 
FKBP51 ligands as a possible novel treatment for obesity or major depression.  
However, SAFit1 and SAFit2 are unsuitable as drug candidates. Especially their high 
molecular weight (748 g/mol and 802 g/mol respectively) is far outside the typical range of 
CNS-directed drugs and further optimization is needed. In our previous structure-affinity-
relationship studies it became clear that an improved scaffold would be necessary to achieve 
drug-like selective FKBP51 inhibitors. The aim of this study was to explore decalin-based 
SAFit analogs as improved selective FKBP51 inhibitors. A similar approach has already been 
very effective in substantially increasing the ligand efficiencies of pan-selective FKBP 
inhibitors.16-18 
 
Results and Discussion 
Rigidification for improving binding affinity 
During the discovery of SAFit2 the cyclohexyl ring was found to be the most critical 
structural feature for high selectivity against FKBP52. Replacing it with smaller substituents 
led to a significant loss of both selectivity and binding affinity.8 In contrast the 
trimethoxyphenyl ring was shown to be important for high binding affinity but not for 
selectivity. Replacing it by different aliphatic substituents and alcohols retained a FKBP51-
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preferring, induced fit-like binding mode.19 In order to improve the affinity of the FKBP51-
selective ligands, we set out to explore a preorganization strategy.  
A closer inspection of the cocrystal structures of the SAFit1-analog SG62320, revealed that the 
trimethoxyphenyl ring as well as the cyclohexyl ring are positioned in a way that suggested a 
possible cyclization by an ethylene linker (Fig.2).    
 
 
 
Figure 2: A rigidification strategy to increase binding affinity. (a) SG623 is shown as stick (magenta) in its 
active conformation bound to FKBP51 (pipecolic ester amide is not shown for clarity). The decalin-derived 
scaffold is superimposed (green sticks). The ethylene linker is highlighted in orange. (b) The chemical structures 
of the respective stick representations. 
We first started with a screening of synthetic ligands that contained a bicyclic aromatic 
moiety instead of the trimethoxyphenyl-cyclohexyl group of SAFit1 (Fig. 3). All compounds 
were synthesized by solid phase-assisted synthesis21. Unfortunately, no binding towards 
FKBP51 was observed in a fluorescence polarization assay22. We attributed this to the planar 
geometry of the aromatic bicycles, which may not fit to the shape of the FKBP51 binding 
pocket. We therefore set out to synthesize exactly the saturated bicyclic structure derived 
from our modelling studies. Although this decalin structure contains three stereocenters, we 
were happy to find out that they can be all generated in a single step by an intramolecular 
Diels-Alder cyclization.    
N
N N
N
O
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Figure 3: Chemical structures of synthetic ligands that contain an aromatic bicycle, instead of the 
trimethoxyphenyl-cyclohexyl group of SAFit1.  
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Synthesis of a novel bicyclic FKBP51 ligand series 
The key step of the decalin synthesis is a dimethylaluminium chloride-promoted (DMAC) 
cyclization of trienimides 7a-c, whereby the stereochemistry is directed by an Evans auxiliary 
(Scheme 1). To obtain the trienimides for cyclization we developed a synthesis that is 
significantly shorter than Evans23 synthetic procedure (3 steps instead of 6 to synthesize the 
methyltrienoates). Additionally, our synthesis is more adjustable for the introduction of 
substituents.  
 
Scheme 1: Reagents and conditions. (a) Grubbs 2nd gen., DCM (b) ethyltriphenylphosphonium bromide (for 
4a+b); methyltriphenylphosphonium iodide (for 4c), KOtBu, THF (c) 1. (COCl)2, DMSO, DIPEA, DCM; 2. 
Methyl(triphenylphosphoranylidene) acetate (d)  NaOH, THF/H2O (e) 1. (COCl)2, DMF, DCM; 2. nBuLi, THF, 
(R)-4-Benzyl-2-oxazolidinone (f) DCC, DMAP, (R)-4-Benzyl-2-oxazolidinone (g) dimethylaluminium chloride, 
DCM. Yields stated in parentheses.   
The synthesis of the triene-chain starts with a cross metathesis between an alkenol and trans-
crotonaldehyde24 to exclusively yield the (E)-products 3a and 3b. In the following step the 
α,β-unsaturated aldehydes are converted by a Wittig reaction to the dienols 4a-c. Due to the 
wide range of commercially available Wittig reagents it is possible to introduce different ring 
moieties in this step that will result in a substituent in 2-position of the cyclized decalins. To 
further extend the chain at the opposite end the alcohols 4a-c were first converted under 
Swern conditions to aldehydes and elonged by adding Methyl(triphenylphosphoranylidene) 
acetate directly to the reaction mixture. Also this step mainly provided the E-isomers 5a-c. 
The small amounts of the formed Z-isomers (~ 5 %) can easily be separated from the desired 
trienoate by flash chromatography. To obtain the free carboxylic acids 6a-c the methyl esters 
were cleaved in a mixture of 2 M NaOH and THF respectively. The Evans auxiliary was 
introduced to the trienoic acids by acetylation with the respective acid chlorides of 6a-c or 
directly with a coupling reagent. The following DMAC-promoted cyclization steps of the 
trienimides proceeds smoothly, yielding the desired trans–cycloadducts as single 
diastereomers 8a-c.    
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Scheme 2: (h) BuLi, EtSH, THF (i) Hg(CF3COO)2, THF/H2O (j) LiOH, H2O2, THF/H2O (k) H2, Pd(C), MeOH 
(l) 27: 1. COMU/HATU/PyBrop, DIPEA, DMF; 2. TFA/DCM; 28: COMU, DIPEA, DMF (m) p-benzoquinone, 
Pd(AcO)2, HBF4, MeCN/H2O (n) OsO4, NMO, acetone (o) 2,2-dimethoxypropane, pTsOH, acetone (p) HCl, 
MeOH (r) NaBH4, CeCl3, MeOH. Yields stated in parentheses. 
After cyclization, the chiral auxiliary (Scheme 2) of the unsubstituted bicycles 8a and 8b was 
cleaved with LiOOH to obtain the free carboxylic acids 9a and 9b respectively. Bicycle 8c 
that is substituted in the 2-position was first converted to the respective thioester and then 
hydrolyzed with mercury (II) trifluoroacetate25 (9c). Hydrogenation catalyzed by Pd/C 
provided the respective saturated bicycles 10a-c.     
The free carboxylic acids were coupled to 27 or 28 with HATU or COMU as coupling reagent 
to obtain the final compounds as SAFit1 (after tBu deprotection) or SAFit2 derivatives 
respectively. 12 and 13 were oxidized under Wacker conditions27 to obtain the 3-keto (18, 20) 
and the 4-keto (19, 21) compounds in a 1:2.5 ratio, which can be easily separated by flash 
chromatography. In contrast, oxidation of 15 only provided the respective 4-keto compound 
23. To obtain 24 (dr = 3.4:1) the carbonyl group of 22 was reduced via Luche reduction.26 
To obtain 9d a dihydroxylation step was conducted with OsO4 and 8a. After protection of the 
hydroxyl groups the minor diastereomer was removed by flash chromatography. Then the 
auxiliary was cleaved and the free carboxylic acid was coupled to 28 to obtain 24. The 
dihydroxy compound 26 was obtained after treatment of 25 under acidic conditions. 
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Structure-Affinity Relationship (SAR) of a new FKBP51-selective ligand series 
11-26 were tested in a competitive fluorescence polarization assay for binding to FKBP51 and 
FKBP52. All bicycles showed binding towards FKBP51 but almost no binding towards 
FKBP52 was observed. This is in agreement with our modelling studies that one of the 
bicyclic rings corresponds to the cyclohexyl substituent that was previously reported to be 
important for FKBP51 selective ligands.19,20 
In general we observed that the [4.3.0] bicycles, containing octahydro-indene and derivatives, 
show lower binding affinities towards FKBP51 than their corresponding decalin-compounds. 
Additionally, all decalin-like compounds showed no binding towards FKBP52, whereas one 
octahydro-indene derivative (20) showed low binding towards FKBP52. In all cases a 
saturation of the double bond, a leftover of the intramolecular Diels-Alder cyclization, 
resulted in a significant increase in binding affinity (compare 11/15, 12/17, 14/18). Also the 
addition of a methyl group in the 2-position of the saturated decalins (18), led to a 2-fold 
increase in affinity.  
 
Table 1. FKBP binding affinities bicyclic SAFit1 (1) and SAFit2 (2) analogs; Ki values were determined by a 
competitive fluorescence polarization assay22;  22 was tested as diastereomeric mixture (3.4:1). 
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The introduction of polar groups to the ring system had interesting effects on the binding 
affinity. Carbonyl groups in the in the 3-position either had no effect or a negative effect on 
the binding affinity (19 and 21). A hydroxyl group in the 4-position improved binding to Ki = 
0.65 µM (24). A carbonyl group in the 4-position even improved the Ki of 22 and 23 to 
0.23 µM and 0.33 µM, respectively. Also the dihydroxylated derivative 26 shows a similar 
binding affinity of Ki = 0.28 µM, whereby alkylation of the hydroxy groups (25) significantly 
decreases the binding affinity.  
Cocrystal structure of 22  
22 represents the best ligand in our bicyclic FKBP51-selective ligand series. We therefore 
solved a cocrystal structure of 22 with FKBP51 to elucidate its binding mechanism (Fig. 4). 
The X-ray structure revealed a binding conformation that is in agreement with previously 
described FKBP ligands. The pipeciolic ester is centered in a hydrophobic pocket. The 
prominent hydrogen bonds to Ile87 and Tyr113, which until now have been observed in all 
FKBP51 complexes with carbonyl pipecolate-based ligands19,20,28 are also present (Fig. 4a). 
We were happy to see that also in this series selective binding to FKBP51 was accompanied 
by an induced fit-like binding mode, which is indicated by the position of Phe67 (Fig. 3a). 
One of the bicyclic rings is deeply buried in the enlarged binding pocket, similar to the 
cyclohexyl substituent known FKBP51-selective ligands. No clear interactions between the 
protein and the keto group were observed.  
 
Figure 4: X-ray structures of 22 in complex with the FK506-binding domain of FKBP51; Lys121 is not shown 
for clarity (a) Surface representation of FKBP51 in complex with 22 (green) Hydrogen bonds to Tyr113 (yellow) 
and Ile87 (yellow) are indicated as black dotted lines. Phe67 is shown as purple sticks. (b) Surface representation 
of FKBP51 in complex with 22 (green). SG623 bound to FKBP51 is superimposed in magenta. 
When we superimposed 22 with SG623 (Fig. 4b), a close analog of SAFit1, we were excited 
to see that the decalin-derivative virtually showed exactly the same conformation as SG623. 
The distal cyclohexyl ring completely correlates to the cyclohexyl ring of SG623, whereas the 
other serves as additional bridge to stabilize the spatial conformation. This allows introducing 
substituents in positions that cannot be achieved with open-chained analogs, which is in the 
crystal structures exemplified by the location of the carbonyl group. 
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Conclusion 
In order to improve the properties of selective FKBP51 antagonists, we used a rigidification 
strategy to design a novel scaffold for new FKBP51 ligands. The binding affinities of the 
resulting bicyclic structure and derivatives, in comparison with the corresponding open-
chained structure, confirmed our aim to increase binding affinity. Additionally we could show 
that despite of the clearly different structure of the bicyclic ligand series, the compound still 
exhibit the induced fit binding mechanism as previously published for FKBP51-selective 
ligands. The bicyclic structure also enables novel substitution patterns that are not possible 
with open-chained analogs. The decalin scaffold therefore serves as useful lead structure and 
scaffold for future FKBP51 drug development.  
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I. Crystallography 
 
Dataset FKBP5122 
Space group P212121 
Cell dimensions  
  a, b, c (Å) 42.56, 50.33, 62.78 
  , ,  (°) 90, 90, 90 
Wavelength (Å) 0. 97857 
Resolution (Å) 50.33- 2.05 (2.16 - 
2.05)* 
Rmerge 0.065 (0. 597) 
I/σI 13.3 (2.5) 
Completeness (%)  99.7 (99.6) 
Redundancy  5.3 (5.4) 
Refinement  
Resolution (Å) 30 - 2.05 
No reflections 8432 
Rwork / Rfree 0. 2137 / 0. 2870 
Number of atoms  
  Protein 975 
  Ligand/ion 50 
  Water 74 
B-factors  
  Protein 47.80 
  Ligand/ion 53.08 
  Water 59.08 
R.m.s. deviations  
  Bond length (Å) 0.011 
  Bond angles (°) 1.625 
* Values in parenthesis for outer shell. 
Table 1| Data Collection and Refinement Statistics 
 
Crystallization 
The complexes were prepared by mixing FKBP51 (16-140)-A19T protein at 1.75 mM with 
50 mM 22 dissolved in DMSO in 16:1 ratio. Crystallization was performed at 20 °C using the 
hanging drop vapor-diffusion method, equilibrating mixtures of 1 µl protein complex and 1 µl 
reservoir against 500 µl reservoir solution. Crystals were obtained with reservoir solution 
containing 28 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5. 
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Structure Solution and Refinement 
The diffraction data were collected at beamline ID29 of the European Synchrotron Radiation 
Facility (ESRF) in Grenoble, France.  Diffraction data were integrated with XDS1 and further 
processed with Scala and Ctruncate2, as implemented in the CCP4i interface3,4.  The crystal 
structures were solved by molecular replacement employing the program Molrep5. Iterative 
model improvement and refinement were performed with Coot6 and Refmac57. The 
dictionaries for the compounds were generated with the PRODRG server8. Residues facing 
solvent channels without detectable side chain density were modeled as alanines.  
Molecular graphics figures were generated with the program Pymol9. 
II. Chemistry 
All dry reactions were performed under argon atmosphere and with commercially available 
dry solvents  
Chromatographic separations were performed either by manual flash chromatography or 
automated flash chromatography using an Interchim Puriflash 430 with an UV detector.  
Merck F-254 (thickness 0.25 mm) commercial plates were used for analytical TLC. 1H NMR 
spectra, 13C NMR spectra, 2D HSQC, HMBC, and COSY of all intermediates were obtained 
from the Department of Chemistry and Pharmacy, LMU, on a Bruker Avance III HD 400/800 
or a Varian NMR system 300/400/600 at room temperature. Chemical shifts for 1H or 13C are 
given in ppm (δ) downfield from tetramethylsilane using residual protio solvent as an internal 
standard.  
Mass spectra (m/z) were recorded on a Thermo Finnigan LCQ DECA XP Plus mass 
spectrometer at the Max Planck Institute of Psychiatry, while the high resolution mass 
spectrometry was carried out at MPI for Biochemistry (Microchemistry Core Facility) on 
Bruker Daltonics MicrOTOF. 
The purity of the compounds was verified by reversed phase HPLC. All gradients were started 
after 1 min of equilibration with starting percentage of solvent mixture. All of the final 
compounds synthesized and tested have a purity of more than 95%.  
 
Analytical HPLC: 
Pump: Beckman System Gold 125S Solvent Module  
Detector: Beckman System Gold Diode Array Detector Module 168 
Column: Phenomenex Jupiter 4µ Proteo 90Å, 250 x 4.6 mm 4 micron 
 
Solvent A: 95% H2O, 5% MeCN, 0.1% TFA 
Solvent B: 95% MeCN, 5% H2O, 0.1% TFA 
 
Methods:  Described for the specific compound 
 
Preparative HPLC:  
Pump:  Beckman System Gold Programmable Solvent Module 126 NMP 
Detector:  Beckman Programmable Detector Module 166 
Column:  Phenomenex Jupiter 10µ Proteo 90 Å, 250 x 21.2 mm 10 micron 
Solvent A: 95% H2O, 5% MeOH, 0.1% TFA 
Solvent B: 95% MeOH, 5% H2O, 0.1% TFA 
 
Methods:  Described for the specific compound 
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General procedure A – Wittig olefination 
To a suspension of the Wittig salt (2.4 eq) in THF (0.2 M) was added dropwise KOtBu (2.6 
eq, 1 M in THF) at 0 °C. The solution was stirred at RT for 1 h and then again cooled to 0 °C. 
The aldehyde (1 eq) dissolved in some THF (1 M) was then added dropwise and the mixture 
was stirred at 4 °C for 16 h. After warming to RT the reaction was quenched by the addition 
of a saturated NH4Cl solution and the product was extracted several times with Et2O. The 
combined organics were dried over MgSO4, filtered and the solvent was removed under 
reduced pressure. The crude product was purified by flash chromatography to obtain the title 
compounds as light yellow oils. 
General procedure B– Swern Oxidation and subsequent Wittig olefination 
DMSO (3 eq) was added to a solution of oxalyl chloride (2 M in DCM, 1.5 eq) in DCM 
(0.1 M related to alcohol) at -78 °C and stirred at that temperature for 30 min. Then the 
alcohol (1 eq), dissolved in DCM (1 M) was added and the reaction mixture was stirred for 
further 60 min at -78 °C.  In the following step TEA (10 eq) was added and the slurry was 
allowed to warm to RT. methyl 2-(triphenylphosphoranylidene)acetate (1.1 eq) was added in 
one portion and the slurry was stirred at RT for 16 h. If necessary, the reaction mixture was 
diluted with some DCM to maintain adequate stirring. The reaction mixture was then washed 
with H2O and saturated NH4Cl solution. The organic layer was then dried over MgSO4, 
filtered and the solvent was removed under reduced pressure. The product was obtained after 
purification by flash chromatography. 
General procedure C – Methyl ester cleavage 
The methyl ester was dissolved in THF/1.5-2 M NaOH (1.5:1, 0.1 M) and stirred at 70 °C 
until the reaction was finished. After cooling to RT the reaction mixture was extracted with 
Et2O. The organic layer was removed and the aqueous layer acidified with concentrated HCl. 
Then free carboxylic acid was extracted several times with DCM. The combined organic 
solvents were dried over MgSO4, filtered and the solvent was removed under reduced 
pressure to obtain the product without further purification. 
General procedure D – N-Acylation of the Evans auxiliary 
The carboxylic acid (1 eq) was dissolved in DCM (1 M) and oxalyl chloride (2 M in DCM, 2 
eq) with a catalytic amount of DMF (a few drops) was added to convert the acid into an acid 
chloride. The reaction mixture was stirred at RT for 2. Then the solvent was removed and the 
carboxylic acid chloride was used without further purification. In the meantime n-BuLi (1.1 
eq, 2.5 M in hexane) was added to (R)-4-benzyloxazolidin-2-one (1.0 eq) in THF (0.2 M) at -
78 °C and the reaction mixture was stirred at that temperature for 1 h. Then the acid chloride, 
dissolved in some DCM, was added to the deprotonated auxiliary and the mixture was 
allowed to warm to RT. The reaction was quenched by the addition of saturated NH4Cl and 
the product was extracted with Et2O. The combined organics were then dried over MgSO4, 
filtered and the solvent was removed under reduced pressure. The product was obtained after 
purification by flash chromatography. 
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General procedure E – Intramolecular Diels Alder cyclization 
The acylated Evans auxiliary was dissolved in DCM (0.025 M) and cooled to -78 °C. DMAC 
(1.5 eq, 1 M in hexane) was added and the reaction mixture was stirred for 16 h, whereby it 
slowly warmed to RT. Then the mixture was quenched with 1 N HCl and the product 
extracted with DCM. The combined organics were then dried over MgSO4, filtered and the 
solvent was removed under reduced pressure. The product was obtained after purification by 
flash chromatography. 
General procedure F – Evans auxiliary cleavage 
To cleave the Evans auxiliary the reactant (1 eq) was dissolved in THF/H2O (0.075 M, 8:5) 
followed by the addition of LiOH (4.5 eq) and H2O2 (5 eq, 30 % wt). The reaction mixture 
was stirred at RT for 2.5 h and then quenched by adding a half-saturated Na2SO3 solution. It 
was extracted with DCM and the organic layers were removed.  Then the aqueous layer was 
acidified with concentrated HCl and the product was extracted with DCM. The combined 
organics were dried over MgSO4, filtered and the solvent was removed under reduced 
pressure to obtain the title compound without further purification. 
General procedure G – Double bond hydrogenation 
The reactant, containing the unsaturated double bond, was dissolved in MeOH (0.05 M) and 
the solution was degassed with argon. Then Pd/C (0.1 eq, 10 % wt) was added. In the 
following step H2 was bubbled through the reaction mixture for 5 min. The reaction was then 
stirred under H2 atmosphere for 16 h. After that time the dark suspension was filtered through 
celite and the solvent was removed under reduced pressure to obtain the title compound 
without further purification 
General procedure H – Coupling reaction with 34 
The carboxylic acid, 27 (1.0 eq), COMU (1.5 eq) and DIPEA (2.0 eq) were stirred in DMF 
(0.1 M) at RT for 16 h and the tBu-ester was isolated after flash chromatography (0-20 % 
EtOAc in cyclohexane). To obtain the free carboxylic acid the tBu-ester was cleaved in 
DCM/TFA (0.1 M) for 1 h at RT. The reaction mixture was quenched with saturated NaHCO3 
and the product was extracted with DCM. The combined organics were dried over MgSO4, 
filtered and the solvent was removed under reduced pressure to obtain the title compound, 
after purification. 
(E)-7-hydroxyhept-2-enal (3a) 
 
3a 
To a solution of Hoveyda-Grubbs 2nd generation catalyst (47.0 mg, 75.0 µmol) in DCM (35.0 
mL) was added hex-5-en-1-ol (0.75 g, 7.50 mmol) and crotonaldehyde (3.11 mL, 37.5mmol). 
The reaction mixture was heated to reflux for 2 h (oil bath was preheated to 50 °C). After 
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completion of the reaction the mixture was cooled to RT. Some silica gel was added to the 
flask and the resulting slurry was stirred open to air for 30 min. The solvent was removed and 
the crude product was purified by flash chromatography (0-40 % EtOAc in cyclohexane) to 
obtain the title compound as light brown oil (quantitative yield). 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.16 
Mass: (ESI+), calculated 129.09 [C7H12O2+H]+, found 129.87 [M+H]+. 
1H NMR (300 MHz, CDCl3) δ 9.49 (d, J = 7.8 Hz, 1H), 6.84 (dt, J = 15.6, 6.7 Hz, 1H), 6.12 
(ddt, J = 15.6, 7.9, 1.5 Hz, 1H), 3.70 – 3.59 (m, 2H), 2.47 – 2.24 (m, 2H), 1.70 – 1.53 (m, 
4H). 
13C NMR (75 MHz, CDCl3) δ 193.98, 158.21, 133.13, 62.34, 32.37, 32.00, 24.10. 
Analytical data in accordance with Biannic et al.10  
 
(E)-8-hydroxyoct-2-enal (3b) 
 
3b 
To a solution of Grubbs 2nd generation catalyst (85.0 mg, 100 µmol) in DCM (50.0 mL) was 
added hept-6-en-1-ol (1.35 mL, 10.0 mmol, d = 0.85 g/mL) and crotonaldehyde (4.14 mL, 
50.0 mmol, d = 0.85 g/mL). The reaction mixture was heated to reflux for 2 h (oil bath was 
preheated to 50 °C). After completion of the reaction the mixture was cooled to RT. Some 
silica gel was added to the flask and the resulting slurry was stirred open to air for 30 min. 
The solvent was removed and the crude product was purified by flash chromatography (0-40 
% EtOAc in cyclohexane) to obtain the title compound as light brown oil (quantitative yield) 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.32 
Mass: (ESI+), calculated 165.09 [C8H14O2+Na]+, found 164.08 [M+Na]+. 
1H NMR (599 MHz, CDCl3) δ 9.49 (d, J = 7.9 Hz, 1H), 6.83 (dt, J = 15.6, 6.8 Hz, 1H), 6.10 
(ddt, J = 15.6, 7.9, 1.5 Hz, 1H), 3.64 (t, J = 6.5 Hz, 2H), 2.38 – 2.30 (m, 2H), 1.61 – 1.56 (m, 
2H), 1.55 – 1.50 (m, 2H), 1.44 – 1.38 (m, 2H). 
13C NMR (151 MHz, CDCl3) δ 194.07, 158.54, 133.04, 62.63, 32.63, 32.36, 27.61, 25.32. 
 
 
(E)-octa-5,7-dien-1-ol (4a) 
 
4a 
General procedure A was used with 3a (963 mg, 7.51 mmol) and 
methyltriphenylphosphonium iodide to obtain the title compound after purification by flash 
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chromatography (0-40 % EtOAc in cyclohexane) as a light yellow oil (500 mg, 3.96 mmol, 
52.7 %). 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.43 
1H NMR (300 MHz, CDCl3) δ 6.30 (dt, J = 16.9, 10.2 Hz, 0H), 6.17 – 5.96 (m, 1H), 5.79 – 
5.59 (m, 1H), 5.18 – 4.87 (m, 2H), 3.64 (t, J = 6.4 Hz, 2H), 2.18 – 2.03 (m, 1H), 1.65 – 1.40 
(m, 4H), 1.30 – 1.19 (m, 1H). 
13C NMR (75 MHz, CDCl3) δ 137.16, 137.15, 134.82, 131.24, 114.86, 77.39, 77.18, 76.97, 
76.55, 62.78, 32.21, 32.17, 25.26. 
Analytical data in accordance with Craig et al.11 
 
 
(E)-nona-6,8-dien-1-ol (4b) 
 
4b 
General procedure A was used with 3b (1.07 g, 7.50 mmol) and methyltriphenylphosphonium 
iodide to obtain the title compound after purification by flash chromatography (0-40 % EtOAc 
in cyclohexane) as a yellow oil (1.0g, 7.14 mmol, 95.1 %). 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.51 
Mass: (ESI+), calculated 141.23 [C9H16O+H]+, found 140.90 [M+H]+. 
1H NMR (300 MHz, CDCl3) δ 6.31 (dt, J = 16.9, 10.2 Hz, 1H), 6.12 – 5.99 (m, 1H), 5.70 (dt, 
J = 14.6, 6.9 Hz, 1H), 5.14 – 5.04 (m, 1H), 4.99 – 4.92 (m, 1H), 3.64 (t, J = 6.6 Hz, 2H), 2.18 
– 2.00 (m, 2H), 1.68 – 1.49 (m, 2H), 1.47 – 1.32 (m, 5H). 
13C NMR (75 MHz, CDCl3) δ 137.23, 135.12, 131.07, 114.73, 62.92, 32.61, 32.44, 28.94, 
25.29. 
 
Analytical data in accordance with Craig et al.11 
 
 
(6E, 8Z)-deca-6,8-dien-1-ol (4c) 
 
4c 
 
General procedure A was used with 3c (711 mg, 5.0 mmol) and ethyltriphenylphosphonium 
bromide to obtain the title compound (containing ~20% 8E-isomer) after purification by flash 
chromatography (0-20 % EtOAc in cyclohexane) as a light yellow oil (680 mg, 4.41 mmol, 
88.2 %). 
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TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.46 
1H NMR (300 MHz, CDCl3) δ 6.44 – 6.24 (m, 1H), 6.09 – 5.88 (m, 1H), 5.71 – 5.59 (m, 1H), 
5.44 – 5.31 (m, 1H), 3.68 – 3.60 (m, 2H), 2.18 – 2.02 (m, 2H), 1.73 (dd, J = 7.1, 1.7 Hz, 3H), 
1.56 (dd, J = 15.7, 8.5 Hz, 3H), 1.48 – 1.30 (m, 4H). 
13C NMR (75 MHz, CDCl3) δ 134.12, 129.43, 125.52, 124.01, 62.94, 32.79, 32.62, 29.17, 
25.31, 13.25. 
 
Analytical data in accordance with Larson et al.12 
 
 
(2E, 7E)-methyl deca-2,7,9-trienoate (5a) 
 
5a 
General procedure B was used with 4a (490 mg, 3.88 mmol) and the title compound was 
obtained after purification by flash chromatography (0-5 % EtOAc in cyclohexane) as yellow 
oil (630 mg, 90.1 %, 3.50 mmol). 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.53 
Mass: (ESI+), calculated 181.12 [C11H16O2+H]+, found 181.00 [M+H]+. 
1H NMR (300 MHz, CDCl3) δ 6.95 (dt, J = 15.7, 7.0 Hz, 1H), 6.39 – 6.21 (m, 1H), 6.12 – 
5.98 (m, 1H), 5.82 (dt, J = 15.6, 1.6 Hz, 1H), 5.72 – 5.59 (m, 1H), 5.15 – 5.04 (m, 1H), 5.03 – 
4.91 (m, 1H), 3.72 (s, 3H), 2.28 – 2.16 (m, 2H), 2.11 (q, J = 7.0 Hz, 2H), 1.64 – 1.48 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 167.05, 149.09, 137.00, 134.05, 131.66, 121.14, 115.16, 51.36, 
31.80, 31.53, 27.42. 
Analytical data in accordance with Roush et al.13 
 
(2E,8E)-methyl undeca-2,8,10-trienoate (5b) 
 
5b 
General procedure B was used with 4b (700 mg, 4.99 mmol) and the title compound was 
obtained after purification by flash chromatography (0-5 % EtOAc in cyclohexane) as yellow 
oil (quantitative yield). 
TLC [EtOAc/cyclohexane, 1:9]: Rf = 0.48 
Mass: (ESI+), calculated 195.14 [C12H18O2+H]+, found 195.01 [M+H]+. 
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1H NMR (400 MHz, CDCl3) δ 6.95 (dt, J = 15.7, 7.0 Hz, 1H), 6.42 – 6.19 (m, 1H), 6.13 – 
5.97 (m, 1H), 5.81 (dt, J = 15.6, 1.6 Hz, 1H), 5.75 – 5.58 (m, 1H), 5.15 – 5.03 (m, 1H), 5.03 – 
4.86 (m, 1H), 3.72 (s, 3H), 2.20 (qd, J = 7.0, 1.6 Hz, 2H), 2.12 – 2.01 (m, 2H), 1.52 – 1.36 (m, 
4H). 
13C NMR (101 MHz, CDCl3) δ 167.11, 149.41, 137.13, 134.71, 131.25, 120.97, 114.92, 
51.37, 32.20, 32.00, 28.57, 27.48, 26.89. 
Analytical data in accordance with Roush et al.13 
 
(2E,8E,10Z)-methyl dodeca-2,8,10-trienoate (5c) 
 
5c 
General procedure B was used with 4c (680 mg, 4.41 mmol) and the title compound 
(containing ~20% 10E-isomer) was obtained, after purification by flash chromatography (0-
5 % EtOAc in cyclohexane) as colorless oil (904 mg, 4.34 mmol, 98.1 %). 
TLC [EtOAc/cyclohexane, 1:9]: Rf = 0.41 
Mass: (ESI+), calculated 209.30 [C13H20O2+H]+, found 208.99 [M+H]+. 
1H NMR (599 MHz, CDCl3)  δ 6.96 (dt, J = 15.6, 7.0 Hz, 1H), 6.32 (ddq, J = 15.1, 11.0, 1.4 
Hz, 1H), 5.99 – 5.93 (m, 1H), 5.85 – 5.78 (m, 1H), 5.66 – 5.59 (m, 1H), 5.44 – 5.32 (m, 1H), 
3.74 – 3.71 (m, 3H), 2.21 (qd, J = 7.1, 1.6 Hz, 2H), 2.15 – 2.08 (m, 2H), 1.75 – 1.71 (m, 3H), 
1.50 – 1.39 (m, 4H). 
13C NMR (151 MHz, CDCl3) δ 167.12, 149.47, 133.71, 129.33, 125.72, 124.20, 120.94, 
51.37, 32.56, 32.04, 28.83, 27.53, 13.27. 
Analytical data in accordance with Lygo et al.14 
 
(2E, 7E)- deca-2,7,9-trienoic acid (6a) 
 
6a 
General procedure C was used with 5a (620 mg, 3.44 mmol) to obtain the title compound as 
light brown oil (493 mg, 2.97 mmol, 86.2 %). 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.36 
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Mass: (ESI+), calculated 167.11 [C10H14O2+H]+, found 167.01 [M+H]+. 
1H NMR (300 MHz, CDCl3) δ 6.95 (dt, J = 15.7, 7.0 Hz, 1H), 6.39 – 6.21 (m, 1H), 6.12 – 
5.98 (m, 1H), 5.82 (dt, J = 15.6, 1.6 Hz, 1H), 5.72 – 5.59 (m, 1H), 5.15 – 5.04 (m, 1H), 5.03 – 
4.91 (m, 1H), 2.28 – 2.16 (m, 2H), 2.11 (q, J = 7.0 Hz, 2H), 1.64 – 1.48 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 167.05, 149.09, 137.00, 134.05, 131.66, 121.14, 115.16, 31.80, 
31.53, 27.42. 
 Analytical data in accordance with Evans et al.15 
 
(2E, 8E)- undeca-2,8,10-trienoic acid (6b) 
 
6b 
General procedure C was used with 5b (680 mg, 3.50 mmol) to obtain the title compound as 
light yellow oil (595 mg, 3.30 mmol, 94.3 %). 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.48 
Mass: (ESI+), calculated 181.12 [C11H16O2+H]+, found 181.00 [M+H]+. 
1H NMR (400 MHz, CDCl3) δ 7.07 (dt, J = 15.6, 7.0 Hz, 1H), 6.30 (dtd, J = 17.0, 10.2, 0.7 
Hz, 1H), 6.21 – 5.92 (m, 1H), 5.82 (dt, J = 15.6, 1.6 Hz, 1H), 5.78 – 5.55 (m, 1H), 5.15 – 5.05 
(m, 1H), 5.05 – 4.85 (m, 1H), 2.23 (qd, J = 6.9, 1.6 Hz, 2H), 2.18 – 2.03 (m, 2H), 1.62 – 1.30 
(m, 4H). 
13C NMR (101 MHz, CDCl3) δ 171.79, 152.04, 137.11, 134.63, 131.30, 120.71, 114.96, 
32.19, 32.11, 28.59, 27.34. 
Analytical data in accordance with Evans et al.15 
 
(2E,8E,10Z)-dodeca-2,8,10-trienoic acid (6c) 
 
6c 
General procedure C was used with 5c (890 mg, 4.27 mmol) to obtain the title compound 
(containing ~20% 10E-isomer) as light yellow oil (688 mg, 3.54 mmol, 82.9 %). 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.44 
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Mass: (ESI+), calculated 195.14 [C12H18O2+H]+, found 195.00 [M+H]+. 
1H NMR (599 MHz, CDCl3δ 7.08 (dt, J = 15.6, 7.0 Hz, 1H), 6.33 (ddq, J = 15.1, 10.9, 1.3 Hz, 
1H), 6.02 – 5.93 (m, 1H), 5.83 (dt, J = 15.6, 1.6 Hz, 1H), 5.67 – 5.59 (m, 1H), 5.44 – 5.33 (m, 
1H), 2.25 (qd, J = 7.1, 1.6 Hz, 2H), 2.15 – 2.10 (m, 2H), 1.76 – 1.72 (m, 3H), 1.53 – 1.47 (m, 
2H), 1.46 – 1.40 (m, 2H). 
13C NMR (151 MHz, CDCl3) δ 171.70, 152.14, 133.63, 129.32, 125.77, 124.25, 120.64, 
32.54, 32.15, 28.84, 27.39, 13.28. 
Analytical data in accordance with Lygo et al.14 
 
(R)-4-benzyl-3-((2E,8E)-undeca-2,8,10-trienoyl)oxazolidin-2-one (7b) 
 
7b 
General procedure D was used with 6b (900 mg, 4.99 mmol) and the title compound was 
obtained after purification by flash chromatography (0-10 % EtOAc in cyclohexane) as 
yellow oil (1.21 g, 3.55 mmol, 71.1 %). 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.40 
Mass: (ESI+), calculated 340.19 [C21H25NO3+H]+, found 340.28 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.34 – 7.30 (m, 2H), 7.26 – 7.16 (m, 5H), 6.30 (dtd, J = 17.1, 
10.3, 0.8 Hz, 1H), 6.15 – 5.98 (m, 1H), 5.68 (dtd, J = 15.0, 7.0, 0.8 Hz, 1H), 5.15 – 5.03 (m, 
1H), 5.02 – 4.88 (m, 1H), 4.82 – 4.64 (m, 1H), 4.26 – 4.11 (m, 2H), 3.33 (dd, J = 13.4, 3.3 
Hz, 1H), 2.78 (dd, J = 13.4, 9.6 Hz, 1H), 2.30 (qd, J = 6.9, 1.2 Hz, 2H), 2.10 (qd, J = 7.2, 1.4 
Hz, 2H), 1.55 – 1.49 (m, 2H), 1.48 – 1.43 (m, 2H). 
 
13C NMR (101 MHz, CDCl3) δ 165.06, 153.42, 151.64, 137.17, 135.37, 134.80, 131.24, 
129.44, 128.93, 127.29, 120.45, 114.92, 66.10, 55.32, 37.89, 32.53, 32.24, 28.67, 27.59, 
26.90. 
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(R)-4-benzyl-3-((2E,8E,10Z)-dodeca-2,8,10-trienoyl)oxazolidin-2-one (7c) 
 
7c 
General procedure D was used with 6c (611 mg, 3.45 mmol) and the title compound 
(containing ~20% 10E-isomer) was obtained, after purification by flash chromatography (0-5 
% EtOAc in cyclohexane) as yellow oil (800 mg, 2.26 mmol, 65.6 %). 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.42 
Mass: (ESI+), calculated 354.21 [C22H27NO3+H]+, found 354.08 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.36 – 7.31 (m, 2H), 7.29 – 7.26 (m, 2H), 7.25 – 7.20 (m, 3H), 
6.34 (ddq, J = 15.1, 11.0, 1.4 Hz, 1H), 6.02 – 5.90 (m, 1H), 5.71 – 5.59 (m, 1H), 5.43 – 5.35 
(m, 1H), 4.78 – 4.68 (m, 1H), 4.28 – 4.13 (m, 2H), 3.34 (dd, J = 13.4, 3.3 Hz, 1H), 2.80 (dd, J 
= 13.4, 9.6 Hz, 1H), 2.39 – 2.24 (m, 2H), 2.18 – 2.10 (m, 2H), 1.78 – 1.68 (m, 3H), 1.57 – 
1.51 (m, 2H), 1.50 – 1.40 (m, 2H). 
13C NMR (151 MHz, CDCl3) δ 165.07, 153.41, 151.67, 135.39, 133.77, 129.43, 129.37, 
128.93, 127.28, 125.72, 124.18, 120.45, 66.10, 55.32, 37.91, 32.57, 28.92, 27.64, 13.28. 
 
(R)-4-benzyl-3-((3aR,4R,7aS)-2,3,3a,4,5,7a-hexahydro-1H-indene-4-carbonyl)oxazolidin-
2-one (8a) 
 
 
8a 
To a suspension of (R)-4-benzyloxazolidin-2-one (665 mg, 3.75 mmol), DMAP (70.6 mg) and 
6a (480 mg, 2.89 mmol) in DCM (6.0 mL) was added DCC (596 mg, 2.89 mmol) at -78 °C. 
The reaction was stirred at that temperature for 1 h and then at 0 °C for 20 h. Purification by 
flash chromatography (0-10 % EtOAc in cyclohexane) provided the product as inseparable 
mixture of the title compound and the N-acylurea byproduct. To a solution of this mixture 
(490 mg) in DCM (50.0 mL) was added DMAC (2.26 mL, 2.26 mmol, 1 M in hexane) at -78 
°C. The solution was stirred for 16 h, whereby it was slowly warmed to RT. Then 1 N HCl 
was added and the product was extracted with DCM.  The combined organics were dried over 
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MgSO4, filtered and the solvent was removed under reduced pressure. Purification by flash 
chromatography provided the title compound as colorless oil (304 mg, 0.93 mmol, 24.9 % 
after 2 steps). 
TLC [EtOAc/cyclohexane, 1:9]: Rf = 0.26 
Mass: (ESI+), calculated 326.18 [C20H23NO3+H]+, found 326.14 [M+H]+. 
1H NMR (300 MHz, CDCl3) δ 7.44 – 7.02 (m, 5H), 5.85 (dq, J = 9.7, 2.0 Hz, 1H), 5.64 – 
5.53 (m, 1H), 4.79 – 4.57 (m, 1H), 4.29 – 4.02 (m, 2H), 3.86 (td, J = 10.7, 6.2 Hz, 1H), 3.25 
(dd, J = 13.1, 3.2 Hz, 1H), 2.76 (dd, J = 13.4, 9.5 Hz, 1H), 2.67 – 2.45 (m, 1H), 2.36 – 2.11 
(m, 1H), 2.03 – 1.95 (m, 1H), 1.92 – 1.78 (m, 2H), 1.81 – 1.62 (m, 3H), 1.25 – 1.06 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 175.83, 153.13, 135.26, 129.86, 129.40, 128.90, 127.32, 
125.29, 66.07, 55.28, 45.45, 43.60, 43.40, 37.96, 30.27, 28.90, 27.67, 21.83. 
 
(R)-4-benzyl-3-((1R,4aS,8aR)-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-
carbonyl)oxazolidin-2-one (8b) 
 
 
8b 
 
General procedure E was used with 7b (140 mg, 0.41 mmol) and the title compound was 
obtained after purification by flash chromatography (0-10 % EtOAc in cyclohexane) as 
colorless oil (115 mg, 0.34 mmol, 82.1 %).  
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.43 
Mass: (ESI+), calculated 340.19 [C21H25NO3+H]+, found 340.11 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.35 – 7.30 (m, 2H), 7.28 – 7.25 (m, 1H), 7.22 – 7.18 (m, 2H), 
5.64 – 5.60 (m, 1H), 5.49 – 5.41 (m, 1H), 4.72 – 4.67 (m, 1H), 4.21 – 4.14 (m, 2H), 3.87 (td, J 
= 10.8, 5.7 Hz, 1H), 3.25 (dd, J = 13.4, 3.3 Hz, 1H), 2.77 (dd, J = 13.4, 9.5 Hz, 1H), 2.41 – 
2.35 (m, 1H), 2.32 – 2.24 (m, 1H), 1.88 – 1.81 (m, 1H), 1.79 – 1.68 (m, 3H), 1.69 – 1.62 (m, 
1H), 1.61 – 1.49 (m, 1H), 1.34 – 1.28 (m, 2H), 1.12 – 0.99 (m, 2H). 
13C NMR (151 MHz, CDCl3) δ 176.37, 153.12, 135.24, 132.09, 129.41, 128.90, 127.32, 
123.96, 65.96, 55.29, 43.13, 42.46, 41.09, 37.96, 32.99, 29.95, 29.83, 26.62, 26.44. 
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(R)-4-benzyl-3-((1R,2S,4aS,8aR)-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-
carbonyl)oxazolidin-2-one (8c) 
 
8c 
General procedure E was used with 7c (790 mg, 2.24 mmol) and the title compound was 
obtained after purification by flash chromatography (0-20 % DCM in cyclohexane) as a 
colorless oil (470 mg, 1.33 mmol, 59.5 %).  
TLC [DCM/cyclohexane, 1:1]: Rf = 0.23 
Mass: (ESI+), calculated 354.21 [C22H27NO3+H]+, found 354.02 [M+H]+. 
1H NMR (800 MHz, CDCl3) δ 7.38 – 7.33 (m, 2H), 7.30 – 7.26 (m, 3H), 5.60 (ddd, J = 9.8, 
4.6, 2.5 Hz, 1H), 5.43 (dt, J = 9.9, 1.7 Hz, 1H), 4.76 – 4.71 (m, 1H), 4.21 – 4.11 (m, 2H), 3.84 
(dd, J = 11.4, 5.9 Hz, 1H), 3.44 (dd, J = 13.2, 3.4 Hz, 1H), 2.87 – 2.78 (m, 1H), 2.65 (dd, J = 
13.2, 10.5 Hz, 1H), 1.96 – 1.89 (m, 1H), 1.82 – 1.74 (m, 3H), 1.65 – 1.56 (m, 2H), 1.45 – 1.38 
(m, 1H), 1.34 (qt, J = 14.1, 3.9 Hz, 1H), 1.18 – 1.10 (m, 1H), 0.98 (d, J = 7.2 Hz, 3H), 0.93 – 
0.85 (m, 1H). 
13C NMR (201 MHz, CDCl3) δ 173.62, 153.06, 135.51, 130.83, 130.70, 129.34, 128.99, 
127.32, 66.03, 55.37, 47.67, 41.89, 38.29, 36.59, 33.17, 30.91, 30.09, 26.70, 26.59, 17.77. 
 
(3aR,4R,7aS)-2,3,3a,4,5,7a-hexahydro-1H-indene-4-carboxylic acid (9a) 
 
9a 
General procedure F was used with 8a (290 mg, 0.89 mmol) to obtain the title compound 
without further purification as a colorless solid (77 mg, 0.46 mmol, 52.1 %). 
TLC [EtOAc/cyclohexane, 1:9]: Rf = 0.26. 
1H NMR (599 MHz, CDCl3) δ 5.88 – 5.79 (m, 1H), 5.64 – 5.50 (m, 1H), 2.59 – 2.49 (m, 1H), 
2.48 – 2.28 (m, 2H), 1.98 – 1.80 (m, 3H), 1.79 – 1.64 (m, 2H), 1.56 (qd, J = 11.3, 6.4 Hz, 
1H), 1.32 – 1.23 (m, 1H), 1.23 – 1.14 (m, 1H). 
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13C NMR (151 MHz, CDCl3) δ 181.57, 129.77, 125.21, 45.54, 45.12, 44.11, 29.78, 28.97, 
28.08, 21.79. 
Analytical data in accordance with Clive et al.16 
 
(1R,4aS,8aR)-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxylic acid (9b) 
 
9b 
General procedure F was used with 8b (43 mg, 0.13 mmol) to obtain the title compound 
without further purification as a colorless solid (19 mg, 0.11 mmol, 83.2 %). 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.12 
1H NMR (300 MHz, CDCl 3) δ 5.65 – 5.57 (m, 1H), 5.45 (dq, J = 9.9, 1.9 Hz, 1H), 2.48 – 
2.39 (m, 1H), 2.38 – 2.29 (m, 2H), 1.87 – 1.71 (m, 4H), 1.68 – 1.21 (m, 4H), 1.19 – 0.99 (m, 
2H). 
13C NMR (75 MHz, CDCl 3) δ 181.95, 132.09, 123.79, 46.17, 42.12, 41.33, 32.94, 30.31, 
29.47, 26.58, 26.36. 
 
(1R,2S,4aS,8aR)-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carboxylic acid (9c) 
 
9c 
n-Buli (0.42 mL, 1.06 mmol, 2.5 M) was added to a solution of ethanethiol (94 µL, 1.27 
mmol, d = 0.84 g/mol) in THF (4.5 mL) at -78 °C and stirred for 10 min. The reaction mixture 
was transferred to an ice bath and 8c (150 mg, 0.42 mmol), dissolved in THF (0.5 mL), was 
added. The solution was stirred at 0 °C for 1 h, then quenched with saturated NH4Cl solution 
and extracted with Et2O. The organics were combined, dried over MgSO4, filtered and 
concentrated in vacuo.  
After purification (quantitative yield) by flash chromatography (0-5 % EtOAc in cyclohexane) 
the thioester (80.0 mg, 0.34 mmol) was dissolved in THF/H2O (1.8 mL, 5:1) followed by 
addition of mercury(II)trifluoroacetate (215 mg, 0.5 mmol). The reaction mixture was stirred 
at 60 °C for 2 h and the title compound was obtained after purification by flash 
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chromatography (0-20 % EtOAc in cyclohexane) as colorless solid (33.9 mg, 0.17 mmol, 52.0 
%). 
TLC [EtOAc/cyclohexane, 3:7]: Rf = 0.42. 
Mass: (ESI+), calculated 195.14 [C12H18O2+H]+, found 195.01 [M+H]+. 
1H NMR (599 MHz, CDCl 3) δ 5.55 (ddd, J = 9.9, 4.0, 2.7 Hz, 1H), 5.39 (dq, J = 9.8, 0.9 Hz, 
1H), 2.64 – 2.55 (m, 2H), 2.05 – 1.98 (m, 1H), 1.80 – 1.74 (m, 2H), 1.72 – 1.66 (m, 1H), 1.43 
– 1.38 (m, 1H), 1.38 – 1.34 (m, 1H), 1.35 – 1.32 (m, 1H), 1.32 – 1.27 (m, 1H), 1.12 – 1.05 (m, 
1H), 1.00 – 0.97 (m, 3H), 0.96 – 0.88 (m, 1H). 
13C NMR (151 MHz, CDCl 3) δ 179.77, 130.95, 130.52, 49.32, 42.01, 36.26, 33.01, 32.14, 
30.04, 26.63, 26.47, 17.61. 
 
(3aR,5R,5aR,9aR,9bS)-2,2-dimethyldecahydronaphtho[1,2-d][1,3]dioxole-5-carboxylic 
acid (9d) 
            
N O
O O
HO
OH
O
O
O
HO
N O
O O
O
O
N O
O O
8b 9d9d1 9d2  
8b (80 mg, 0.26 mmol) was dissolved in acetone (1.0 mL) and H2O (0.5 mL). Then 4-
methylmorpholine-4-oxide (55 mg, 0.47 mmol) and osmium tetroxide (118 µL, 9.4 µmol, 
2.5 % wt in tBuOH) were added and the mixture was stirred at RT for 16 h. The crude product 
was directly loaded on silica and purified by flash chromatography (0-50 % [EtOAc + 2 % 
MeOH] in cyclohexane) to obtain 9d1 as a diastereomeric mixture (dr = 4:1, quant. yield). 9d1 
was dissolved in acetone and 2,2-dimethoxypropane (1:1, 1.4 mL) and PTSA (0.02 eq) was 
added . The reaction was stirred for 24 h and then purified by flash chromatography (0-5 % 
EtOAc in cyclohexane), whereby the minor diasteroemer was separated, to obtain 9d2. Then 
general procedure F was used to obtain 9d without further purification as colorless oil (24 mg, 
9.4 µmol, 36.3 % from 8b). 
TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.20. 
Mass: (ESI+), calculated 255.16 [C14H22O4+H]+, found 255.02 [M+H]+. 
1H NMR (400 MHz, CDCl3) δ 4.28 – 4.20 (m, 1H), 3.60 (dd, J = 8.6, 4.9 Hz, 1H), 2.46 – 
2.36 (m, 1H), 2.32 (ddd, J = 14.9, 4.0, 2.6 Hz, 1H), 2.13 – 2.04 (m, 1H), 1.96 (ddd, J = 14.8, 
12.1, 4.0 Hz, 1H), 1.84 – 1.64 (m, 3H), 1.48 (s, 3H), 1.34 (s, 3H), 1.26 – 1.14 (m, 4H), 1.02 
(dt, J = 10.9, 6.1 Hz, 1H), 0.97 – 0.87 (m, 1H). 
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13C NMR (101 MHz, CDCl3) δ 181.15, 108.31, 79.53, 72.31, 44.28, 43.73, 40.16, 30.73, 
30.12, 29.67, 28.53, 26.38, 25.77, 25.59. 
 
(3aR,4R,7aS)-octahydro-1H-indene-4-carboxylic acid (10a) 
 
10a 
General procedure G was used with 9a (15 mg, 90 µmol) to obtain the title compound 
(quantitative yield) as colorless oil.   
TLC [EtOAc/cyclohexane, 1:9]: Rf = 0.45 
1H NMR (599 MHz, CDCl3) δ 2.14 – 2.03 (m, 1H), 1.95 (d, J = 12.9 Hz, 1H), 1.92 – 1.76 (m, 
3H), 1.79 – 1.71 (m, 1H), 1.69 – 1.47 (m, 2H), 1.40 (qd, J = 12.9, 12.4, 3.5 Hz, 1H), 1.31 – 
1.04 (m, 5H), 1.00 (qd, J = 12.2, 3.3 Hz, 1H). 
13C NMR (151 MHz, CDCl3) δ 182.17, 48.91, 47.60, 45.52, 30.96, 30.81, 29.67, 29.57, 
29.39, 25.74, 21.31. 
 
(1R,4aS,8aR)-decahydronaphthalene-1-carboxylic acid (10b) 
 
10b 
General procedure G was used with 9b (24 mg, 0.133 mmol) to obtain the title compound 
(quantitative yield) as colorless solid.   
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.24 
Mass: (ESI+), calculated 183.14 [C11H18O2+H]+, found 183.14 [M+H]+. 
1H NMR (400 MHz, CDCl3) δ 2.04 (ddd, J = 12.2, 10.7, 3.5 Hz, 1H), 1.94 (dqd, J = 12.7, 3.4, 
1.6 Hz, 1H), 1.78 (dq, J = 13.2, 3.1 Hz, 1H), 1.74 – 1.71 (m, 1H), 1.71 – 1.66 (m, 2H), 1.64 – 
1.56 (m, 2H), 1.55 – 1.44 (m, 2H), 1.39 – 1.26 (m, 2H), 1.26 – 1.17 (m, 2H), 1.09 – 0.90 (m, 
3H). 
13C NMR (75 MHz, CDCl3) δ 182.36, 50.11, 44.21, 41.80, 34.00, 33.39, 31.30, 30.22, 26.38, 
26.29, 25.29. 
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(1R,2S,4aS,8aR)-2-methyldecahydronaphthalene-1-carboxylic acid (10c) 
 
10c 
General procedure G was used with 9c (10 mg, 0.05 mmol) to obtain the title compound 
(quantitative yield) as colorless oil.  
 TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.27. 
1H NMR (400 MHz, CDCl3) δ 2.32 – 2.21 (m, 2H), 1.85 – 1.77 (m, 1H), 1.71 – 1.53 (m, 5H), 
1.46 – 1.18 (m, 5H), 1.08 – 1.00 (m, 1H), 0.97 (d, J = 6.9 Hz, 3H), 0.95 – 0.92 (m, 1H), 0.88 – 
0.78 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ 180.47, 52.59, 42.65, 37.54, 33.89, 32.68, 31.58, 31.07, 
27.38, 26.55, 26.42, 26.20, 14.36. 
 
2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((1R,4aS,8aR)-1,2,4a,5,6,7,8,8a-
octahydronaphthalene-1-carbonyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic 
acid (11) 
 
11 
9a (20.0 mg, 0.11 mmol), 27 (57.0 mg, 0.11 mmol), PyBrop (77.0 mg, 0.17 mmol) and 
DIPEA (58.0 µL, 0.33 mmol) were stirred in DCM (1.5 mL) at RT for 16 h. The tBu-ester 
was obtained after purification (0-20 % EtOAc in cyclohexane). To obtain the free carboxylic 
acid the tBu-ester was cleaved in DCM (3.0 mL) and TFA (300 µL) for 16 h at RT. The title 
compound was obtained after preparative HPLC (64-75 % B) as colorless solid (43.3 mg, 
69.9 µmol, 42.1 %).  
TLC [EtOAc/cyclohexane, 1:1 + 1 % HCOOH]: Rf = 0.18. 
HPLC [50-100% Solvent B, 20 min]: Rt = 15.8 min.  
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HRMS: calculated 620.3223 [C36H45NO8+H]+, found 620.3210 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.22 (t, J = 8.1 Hz, 1H), 6.89 – 6.74 (m, 4H), 6.70 – 6.61 (m, 
2H), 5.72 – 5.63 (m, 1H), 5.61 – 5.49 (m, 2H), 5.47 – 5.36 (m, 1H), 4.66 – 4.52 (m, 2H), 4.01 
– 3.93 (m, 1H), 3.87 – 3.75 (m, 6H), 3.34 (t, J = 10.7 Hz, 1H), 2.86 – 2.72 (m, 1H), 2.66 – 
2.51 (m, 2H), 2.39 – 2.23 (m, 1H), 2.22 – 2.15 (m, 1H), 2.12 – 2.01 (m, 2H), 1.93 – 1.85 (m, 
2H), 1.77 – 1.67 (m, 4H), 1.60 – 1.54 (m, 2H), 1.36 – 1.23 (m, 4H), 1.18 – 1.10 (m, 2H), 1.11 
– 1.00 (m, 1H), 0.91 – 0.80 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ 175.89, 171.85, 170.28, 158.02, 148.84, 147.30, 142.02, 
133.41, 131.99, 129.65, 124.55, 120.16, 119.97, 115.21, 114.78, 112.03, 111.64, 110.87, 
76.34, 65.40, 55.89, 52.31, 49.72, 43.60, 42.25, 41.77, 38.06, 33.39, 32.96, 31.38, 30.46, 
29.55, 27.13, 26.42, 25.51, 24.74, 21.09. 
 
2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((3aR,4R,7aS)-2,3,3a,4,5,7a-hexahydro-1H-
indene-4-carbonyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (12) 
 
12 
General procedure H was used with 9a (20.0 mg, 0.12 mmol) and the title compound was 
obtained after flash chromatography (0-30 % [EtOAc + 1 % HCOOH] in hexane) as colorless 
solid (53.2 mg, 87.8 µmol, 73.0 %).  
TLC [EtOAc/cyclohexane, 1:1 + 1 % HCOOH]: Rf = 0.22. 
HPLC [50-100% Solvent B, 20 min]: Rt = 13.9 min.  
HRMS: calculated 606.3067 [C35H43NO8+H]+, found 606.3107 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.24 – 7.19 (m, 1H), 6.89 – 6.83 (m, 2H), 6.81 – 6.75 (m, 2H), 
6.70 – 6.62 (m, 2H), 5.83 – 5.77 (m, 1H), 5.65 (dd, J = 8.8, 5.0 Hz, 1H), 5.55 – 5.50 (m, 1H), 
5.50 – 5.44 (m, 1H), 4.60 (q, J = 16.5 Hz, 2H), 3.94 (d, J = 13.2 Hz, 1H), 3.88 – 3.79 (m, 6H), 
3.28 (td, J = 13.1, 2.7 Hz, 1H), 3.06 (q, J = 7.6 Hz, 1H), 2.86 – 2.79 (m, 1H), 2.69 – 2.58 (m, 
1H), 2.59 – 2.47 (m, 1H), 2.41 – 2.32 (m, 1H), 2.27 – 2.14 (m, 3H), 2.08 – 2.03 (m, 1H), 1.90 
– 1.80 (m, 2H), 1.76 – 1.62 (m, 5H), 1.53 – 1.39 (m, 1H), 1.39 – 1.30 (m, 1H), 1.23 – 1.13 (m, 
2H), 1.04 (p, J = 10.7 Hz, 1H). 
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13C NMR (151 MHz, CDCl3) δ 175.73, 171.69, 170.30, 158.12, 148.88, 147.35, 141.97, 
133.42, 129.69, 129.62, 125.68, 120.15, 119.28, 115.40, 111.66, 111.32, 110.48, 76.38, 65.67, 
55.91, 55.84, 52.31, 45.66, 45.43, 43.85, 43.44, 41.88, 38.07, 31.43, 29.97, 28.95, 28.22, 
27.07, 25.47, 21.75, 21.11, 14.17, 8.39. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((1S,4aS,8aR)-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl)piperidine-2-
carboxylate (13) 
 
 
13 
9b (40.0 mg, 0.22 mmol), 28 (125 mg, 0.24 mmol), HATU (127 mg, 0.33 mmol) and DIPEA 
(86.0 mg, 0.67 mmol) were stirred in DMF (4.0 mL) at RT for 16 h. The reaction mixture was 
loaded on silica and purified by flash chromatography (0-100 % [EtOAc + 2 % MeOH + 
0.1 % TEA] in cyclohexane) to obtain the title compound as light yellow oil (quantitative 
yield). 
TLC [EtOAc + 2 % MeOH + 1 % TEA]: Rf = 0.32. 
HPLC [30-100% Solvent B, 20 min]: Rt = 14.5 min.  
HRMS: calculated 675.4009 [C40H54N2O7+H]+, found 675.3999 [M+H]+. 
1H NMR (599 MHz, DMSO-d6) δ 7.26 – 7.21 (m, 1H), 6.88 – 6.80 (m, 4H), 6.75 – 6.70 (m, 
1H), 6.67 – 6.62 (m, 1H), 5.59 (dd, J = 8.8, 4.7 Hz, 1H), 5.56 – 5.50 (m, 2H), 5.41 – 5.33 (m, 
2H), 5.27 – 5.23 (m, 1H), 3.71 – 3.66 (m, 6H), 3.59 – 3.52 (m, 4H), 2.53 – 2.48 (m, 2H), 2.44 
– 2.38 (m, 3H), 2.20 – 2.14 (m, 2H), 2.11 – 2.05 (m, 3H), 1.83 – 1.76 (m, 1H), 1.72 – 1.56 (m, 
7H), 1.54 – 1.48 (m, 3H), 1.36 – 1.20 (m, 5H), 1.06 – 1.01 (m, 2H), 0.98 – 0.93 (m, 2H), 0.91 
– 0.85 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ 179.56, 177.17, 175.45, 167.31, 163.49, 153.81, 152.20, 
147.22, 138.31, 136.98, 134.77, 129.69, 125.10, 123.27, 118.96, 117.35, 116.96, 80.59, 71.20, 
70.25, 64.78, 62.12, 60.68, 60.40, 58.75, 56.65, 48.13, 47.26, 45.54, 42.66, 40.94, 37.71, 
35.78, 34.45, 31.29, 30.14, 26.21, 19.23. 
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2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((1R,2S,4aS,8aR)-2-methyl-1,2,4a,5,6,7,8,8a-
octahydronaphthalene-1-carbonyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic 
acid (14) 
 
14 
General procedure H was used with 9c (10.0 mg, 0.05 mmol) and the title compound was 
obtained after purification by flash chromatography (0-30 % [EtOAc + 0.1 % HCOOH] in 
hexane) as colorless oil (13.8 mg, 20.0 µmol, 42.3 %). 
TLC [EtOAc/cyclohexane, 1:1 + 1 % HCOOH]: Rf = 0.29. 
HPLC [50-100% Solvent B, 20 min]: Rt = 15.5 min.  
HRMS: 634.3380 [C37H47NO8+H]+, found 634.3383 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.24 – 7.19 (m, 1H), 6.89 – 6.84 (m, 2H), 6.81 – 6.76 (m, 2H), 
6.72 – 6.62 (m, 2H), 5.68 (dd, J = 8.8, 4.8 Hz, 1H), 5.51 – 5.46 (m, 2H), 5.35 (dt, J = 9.9, 1.5 
Hz, 1H), 4.65 – 4.59 (m, 1H), 3.91 (d, J = 14.8 Hz, 1H), 3.89 – 3.83 (m, 6H), 3.34 – 3.26 (m, 
1H), 2.79 (dd, J = 10.9, 6.0 Hz, 1H), 2.72 – 2.64 (m, 1H), 2.63 – 2.53 (m, 2H), 2.45 – 2.33 
(m, 2H), 2.27 – 2.18 (m, 2H), 2.10 – 2.05 (m, 1H), 2.00 – 1.93 (m, 1H), 1.79 – 1.66 (m, 6H), 
1.53 – 1.47 (m, 1H), 1.46 – 1.33 (m, 3H), 1.31 – 1.28 (m, 1H), 1.09 (qd, J = 12.1, 3.2 Hz, 
1H), 0.80 – 0.69 (m, 4H). 
13C NMR (151 MHz, CDCl3) δ 173.56, 171.19, 170.49, 163.04, 158.00, 148.90, 147.38, 
142.04, 133.42, 130.88, 130.82, 129.59, 120.16, 119.44, 115.71, 111.65, 111.33, 109.68, 
76.36, 65.57, 60.42, 55.92, 55.86, 52.05, 45.92, 43.21, 42.34, 38.09, 36.87, 33.11, 31.52, 
31.00, 30.37, 27.29, 26.81, 26.46, 25.58, 21.19, 17.51, 14.18. 
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(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((1R,2S,4aS,8aR)-2-methyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-
carbonyl)piperidine-2-carboxylate (15) 
 
15 
9c (45.0 mg, 0.23 mmol), 28 (119 mg, 0.23 mmol), COMU (149 mg, 0.35 mmol) and DIPEA 
(81.0 µL, 0.46 mmol, d = 0.74 g/mL) were stirred in DMF (3.0 mL) at RT for 16 h. The 
resulting orange solution was diluted with Et2O and washed with brine. Then the organic layer 
was dried over MgSO4, filtered and the solvent was removed under vacuo. After purification 
by flash chromatography (0-60 % [EtOAc + 2 % MeOH + 0.1 % TEA] in cyclohexane) the 
title compound was obtained as light yellow oil (118 mg, 0.17 mmol, 74.0 %).  
TLC [EtOAc + 2 % MeOH + 0.1 % TEA]: Rf = 0.28. 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.2 min.  
Mass: (ESI+), calculated 689.42 [C41H56N2O7+H]+, found 689.21 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.24 – 7.19 (m, 1H), 6.92 – 6.87 (m, 1H), 6.84 – 6.74 (m, 3H), 
6.67 – 6.61 (m, 2H), 5.75 (dd, J = 8.2, 5.5 Hz, 1H), 5.51 – 5.48 (m, 1H), 5.41 – 5.35 (m, 1H), 
4.19 – 4.14 (m, 2H), 3.90 – 3.85 (m, 1H), 3.85 – 3.81 (m, 6H), 3.82 – 3.76 (m, 4H), 3.18 – 
3.09 (m, 1H), 3.00 – 2.96 (m, 2H), 2.80 – 2.75 (m, 4H), 2.64 – 2.55 (m, 2H), 2.54 – 2.48 (m, 
1H), 2.44 – 2.37 (m, 1H), 2.35 – 2.28 (m, 1H), 2.24 – 2.18 (m, 1H), 2.06 – 1.98 (m, 2H), 1.94 
(dd, J = 12.4, 3.2 Hz, 1H), 1.74 – 1.59 (m, 6H), 1.54 – 1.49 (m, 1H), 1.43 – 1.32 (m, 4H), 
1.14 – 1.04 (m, 2H), 0.91 – 0.85 (m, 3H), 0.78 – 0.69 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ 172.38, 171.01, 162.60, 158.36, 148.84, 147.30, 141.81, 
133.52, 131.01, 130.92, 129.62, 120.11, 119.20, 113.90, 112.75, 111.66, 111.27, 76.03, 66.02, 
64.73, 57.34, 55.90, 55.82, 53.76, 53.71, 51.46, 45.61, 43.19, 42.37, 38.06, 37.03, 36.50, 
33.18, 31.44, 31.35, 31.01, 30.43, 26.96, 26.83, 26.52, 25.73, 21.20, 17.88. 
 
  
B. Research Articles – Publication/Manuscript VII 
 
129 
 
2-(3-((R)-1-(((S)-1-((1R,4aS,8aR)-decahydronaphthalene-1-carbonyl)piperidine-2-
carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid (16) 
 
16 
10b (20.0 mg, 0.11 mmol), 27 (67.6 mg, 0.13 mmol), HATU (62.6 mg, 0.17 mmol) and 
DIPEA (57.5 µL, 0.33 mmol) were stirred in DMF (2.0 mL) at 40 °C for 16 h. The tBu-ester 
was purified by flash chromatography (0-10 % EtOAc in cyclohexane). ). To obtain the free 
carboxylic acid the tBu-ester was cleaved in DCM (3.0 mL) and TFA (300 µL) for 16 h at 
RT. The title compound was obtained after flash chromatography (0-20 % [EtOAc + 2 % 
MeOH + 0.1 % TFA] in hexane) as colorless solid (30.3 mg, 48.7 µmol, 44.3 %).  
TLC [EtOAc/cyclohexane, 1:1 + 1 % HCOOH]: Rf = 0.11 
HRMS: calculated 622.3380 [C36H47NO8+H]+, found 622.3360 [M+H]+. 
HPLC [50-100% Solvent B, 20 min]: Rt = 15.4 min.  
1H NMR (599 MHz, CDCl3) δ 7.21 (t, J = 7.8 Hz, 1H), 6.92 – 6.80 (m, 3H), 6.79 – 6.73 (m, 
1H), 6.70 – 6.58 (m, 2H), 5.67 – 5.62 (m, 1H), 5.50 – 5.45 (m, 1H), 4.64 – 4.57 (m, 2H), 3.92 
(d, J = 13.8 Hz, 1H), 3.88 – 3.76 (m, 6H), 3.24 – 3.17 (m, 1H), 2.64 – 2.58 (m, 1H), 2.55 – 
2.49 (m, 1H), 2.39 – 2.28 (m, 2H), 2.21 – 2.13 (m, 1H), 2.06 – 1.96 (m, 2H), 1.75 – 1.70 (m, 
2H), 1.67 – 1.60 (m, 5H), 1.58 – 1.47 (m, 3H), 1.43 – 1.34 (m, 4H), 1.24 – 1.16 (m, 3H), 1.03 
– 0.94 (m, 2H), 0.81 – 0.71 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ 170.50, 158.10, 148.84, 147.29, 141.97, 133.46, 129.59, 
120.15, 119.37, 114.82, 111.66, 111.39, 111.29, 76.17, 65.45, 55.89, 55.82, 44.33, 43.37, 
42.20, 38.10, 34.04, 33.40, 31.42, 31.32, 29.80, 27.08, 26.53, 26.35, 25.56, 25.52, 21.18. 
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2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((3aR,4R,7aS)-octahydro-1H-indene-4-
carbonyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (17) 
 
17 
General procedure H was used with 10a (15.0 mg, 89.0 µmol) and the title compound was 
obtained after flash chromatography (0-20 % [EtOAc + 1 % HCOOH] in hexane) as colorless 
oil (35.9 mg, 59.1 µmol, 66.2 %).  
TLC [EtOAc/cyclohexane, 1:1 + 1 % HCOOH]: Rf = 0.20. 
HPLC [50-100% Solvent B, 20 min]: Rt = 15.0 min.   
HRMS: calculated 608.3223 [C35H45NO8+H]+, found 608.3257 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.24 – 7.19 (m, 1H), 6.88 – 6.81 (m, 2H), 6.79 – 6.75 (m, 2H), 
6.71 – 6.66 (m, 2H), 5.63 (dd, J = 8.9, 4.8 Hz, 1H), 5.48 (d, J = 5.8 Hz, 1H), 4.69 – 4.58 (m, 
2H), 3.91 (d, J = 13.6 Hz, 1H), 3.89 – 3.80 (m, 6H), 3.30 (t, J = 12.7 Hz, 1H), 2.71 – 2.61 (m, 
1H), 2.60 – 2.52 (m, 1H), 2.47 – 2.32 (m, 2H), 2.24 – 2.17 (m, 1H), 2.08 – 2.04 (m, 2H), 1.88 
– 1.80 (m, 2H), 1.79 – 1.69 (m, 4H), 1.61 – 1.51 (m, 2H), 1.45 – 1.31 (m, 4H), 1.28 – 1.23 (m, 
2H), 1.16 – 1.05 (m, 2H), 1.04 – 0.93 (m, 2H). 
13C NMR (151 MHz, CDCl3) δ 176.06, 171.17, 170.30, 158.05, 148.89, 147.36, 142.11, 
133.41, 129.61, 120.17, 119.31, 115.75, 111.66, 111.32, 109.83, 76.34, 65.53, 60.39, 55.91, 
55.85, 52.24, 47.64, 45.47, 43.35, 38.06, 31.47, 30.97, 30.77, 29.53, 29.21, 27.17, 25.97, 
25.48, 21.31, 21.13, 14.17. 
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2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((1R,2S,4aS,8aR)-2- 
methyldecahydronaphthalene-1-carbonyl)piperidine-2- 
carbonyl)oxy)propyl)phenoxy)acetic acid (18) 
 
 
18 
General procedure H was used with 10c (20.0 mg, 0.10 mmol) and the title compound was 
obtained after purification by flash chromatography (0-30 % [EtOAc + 0.1 % HCOOH] in 
hexane) as colorless oil (12.7 mg, 20.0 µmol, 19.6 %). 
TLC [EtOAc/cyclohexane, 1:1 + 1 % HCOOH]: Rf = 0.28. 
HPLC [50-100% Solvent B, 20 min]: Rt = 16.8 min.  
HRMS: calculated 636.3536 [C37H49NO8+H]+, found 636.3545 [M+H]+. 
1H NMR (599 MHz, CDCl3) δ 7.24 – 7.19 (m, 1H), 6.90 – 6.84 (m, 2H), 6.80 – 6.76 (m, 2H), 
6.71 – 6.65 (m, 2H), 5.66 (dd, J = 8.8, 4.8 Hz, 1H), 5.52 – 5.46 (m, 1H), 3.89 – 3.83 (m, 7H), 
3.32 – 3.24 (m, 1H), 2.71 – 2.65 (m, 1H), 2.63 – 2.55 (m, 1H), 2.44 (dd, J = 10.7, 4.2 Hz, 1H), 
2.39 – 2.33 (m, 1H), 2.25 – 2.19 (m, 1H), 2.10 – 2.05 (m, 2H), 1.79 (dt, J = 12.8, 3.3 Hz, 1H), 
1.74 – 1.61 (m, 5H), 1.58 – 1.50 (m, 5H), 1.45 – 1.35 (m, 2H), 1.31 – 1.26 (m, 2H), 1.24 – 
1.17 (m, 2H), 1.09 – 1.01 (m, 1H), 0.95 – 0.91 (m, 2H), 0.74 (d, J = 7.1 Hz, 3H), 0.65 (tdd, J 
= 12.4, 10.9, 3.4 Hz, 1H). 
13C NMR (151 MHz, CDCl3) δ 173.56, 171.19, 170.49, 163.04, 158.00, 148.90, 147.38, 
142.04, 133.42, 130.88, 130.82, 129.59, 120.16, 119.44, 115.71, 111.65, 111.33, 109.68, 
76.36, 65.57, 60.42, 55.92, 55.86, 52.05, 45.92, 43.21, 42.34, 38.09, 36.87, 33.11, 31.52, 
31.00, 30.37, 27.29, 26.81, 26.46, 25.58, 21.19, 17.51, 14.18. 
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2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((3aR,4R,7aS)-6-oxooctahydro-1H-indene-4-
carbonyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (19) 
2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((3aR,4R,7aR)-7-oxooctahydro-1H-indene-
4-carbonyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (20) 
 
 
    19     20 
A solution of tetrafluoroboric acid (17 µL, 0.11 mmol, 48 % wt in H2O) was added to a 
solution of palladium(II) acetate (0.89 mg, 3.96 µmol) and p-benzoquinone (8.57 mg, 79 
µmol) in MeCN (0.45 mL) and H2O (0.60 mL). This mixture was added to 12 (48.0 mg, 79 
µmol) and it was stirred at RT for 16 h. The reaction mixture was directly loaded on silica and 
purified by flash chromatography, whereby both products can easily be separated, to obtain 
title compounds 19 (13.0 mg, 20.9 µmol, 26.4 %) and 20 (31.8 mg, 51.1 µmol, 64.5 %) as 
colorless oils. 
TLC [EtOAc + 1 % HCOOH]: Rf = 0.39 (19), Rf = 0.31 (20) 
HPLC [30-100% Solvent B, 20 min]: Rt = 15.5 min (19), Rt = 15.0 min (20).  
HRMS: calculated 622.3016 [C35H44NO9+H]+, found 622.3036 [M(19)+H]+, 622.3050 
[M(20)+H]+. 
(19): 1H NMR (599 MHz, CDCl3) δ 7.24 – 7.15 (m, 1H), 6.97 – 6.80 (m, 2H), 6.85 – 6.70 
(m, 2H), 6.73 – 6.60 (m, 2H), 5.81 – 5.68 (m, 1H), 5.45 (d, J = 5.3 Hz, 1H), 4.69 – 4.63 (m, 
1H), 4.59 – 4.54 (m, 1H), 3.89 – 3.77 (m, 6H), 3.08 (q, J = 7.3 Hz, 1H), 2.98 – 2.87 (m, 2H), 
2.63 – 2.56 (m, 2H), 2.57 – 2.50 (m, 1H), 2.51 – 2.45 (m, 1H), 2.38 – 2.28 (m, 1H), 2.27 – 
2.12 (m, 2H), 2.08 – 1.97 (m, 2H), 1.97 – 1.90 (m, 1H), 1.90 – 1.82 (m, 1H), 1.82 – 1.67 (m, 
2H), 1.67 – 1.56 (m, 2H), 1.38 – 1.28 (m, 2H), 1.27 – 1.22 (m, 3H), 1.12 – 1.02 (m, 1H), 0.90 
– 0.78 (m, 1H). 
(19): 13C NMR (151 MHz, CDCl3) δ 212.73, 172.69, 171.32, 170.04, 158.45, 148.87, 147.36, 
141.33, 133.32, 129.66, 120.62, 120.17, 116.66, 111.70, 111.31, 109.99, 76.15, 65.78, 55.90, 
55.84, 52.37, 47.01, 46.87, 45.53, 45.36, 43.70, 43.07, 42.80, 37.35, 31.29, 31.04, 29.67, 
28.32, 26.70, 25.45, 22.63, 20.93, 8.43. 
 
(20): 1H NMR (599 MHz, CDCl3) δ 8.07 (s, 1H), 7.26 – 7.18 (m, 1H), 6.88 – 6.81 (m, 2H), 
6.81 – 6.73 (m, 2H), 6.70 – 6.58 (m, 2H), 5.70 – 5.62 (m, 1H), 5.46 (d, J = 6.0 Hz, 1H), 4.69 
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– 4.52 (m, 2H), 4.10 (qd, J = 7.2, 1.7 Hz, 1H), 3.96 (d, J = 12.6 Hz, 1H), 3.89 – 3.74 (m, 6H), 
3.36 – 3.25 (m, 1H), 2.93 – 2.83 (m, 1H), 2.62 – 2.49 (m, 2H), 2.42 – 2.33 (m, 2H), 2.28 (dd, 
J = 13.4, 4.6 Hz, 1H), 2.22 – 2.10 (m, 2H), 2.02 – 1.92 (m, 2H), 1.86 (ddd, J = 11.5, 7.8, 5.7 
Hz, 1H), 1.82 – 1.72 (m, 3H), 1.67 – 1.59 (m, 2H), 1.56 – 1.35 (m, 3H), 1.21 – 1.09 (m, 2H), 
0.93 – 0.82 (m, 1H). 
(20): 13C NMR (151 MHz, CDCl3) δ 209.86, 174.10, 171.69, 170.14, 163.87, 158.03, 148.89, 
147.37, 141.82, 133.32, 129.68, 120.15, 119.48, 115.19, 111.66, 111.34, 110.83, 65.46, 60.42, 
55.91, 55.85, 52.38, 49.90, 45.60, 44.21, 43.59, 40.38, 37.95, 31.37, 30.87, 30.28, 29.67, 
26.95, 25.48, 22.31, 21.11, 21.03, 14.16, 8.41. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((1R,4aS,8aR)-3-oxodecahydronaphthalene-1-carbonyl)piperidine-2-carboxylate (21) 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((1R,4aR,8aR)-4-oxodecahydronaphthalene-1-carbonyl)piperidine-2-carboxylate (22) 
 
    21     22 
A solution of tetrafluoroboric acid (16 µL, 0.10 mmol, 48 % wt in H2O) and 13 were added to 
a solution of palladium(II) acetate (0.83 mg, 3.70 µmol) and p-benzoquinone (8.01 mg, 74 
µmol) in MeCN (0.45 mL) and H2O (0.60 mL). The reaction mixture was stirred at RT for 16 
h and then directly loaded on silica for purificaion by flash chromatography (0-50 % [EtOAc 
+ 2 % MeOH + 0.1 % TEA] in hexane), whereby both products can easily be separated, to 
obtain title compounds 21 (11.4 mg, 20.9 µmol, 14.8 %) and 22 (19.0 mg, 51.1 µmol, 24.7 %) 
as colorless oils. 
TLC [EtOAc + 2 % MeOH + 2 % TEA]: Rf = 0.25. 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.9 min (21), Rt = 15.7 min (22).  
HRMS: calculated 691.3958 [C40H54N2O8+H]+, found 691.4118 [M(20)+H]+, 691.3991 
[M(21)+H]+. 
(21): 1H NMR (599 MHz, CDCl3)  δ 7.25 – 7.22 (m, 1H), 6.90 – 6.80 (m, 3H), 6.79 – 6.75 
(m, 1H), 6.69 – 6.60 (m, 2H), 5.76 – 5.67 (m, 1H), 5.46 (d, J = 4.8 Hz, 0H), 4.12 – 4.04 (m, 
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2H), 3.86 (sbr, 1H), 3.86 – 3.83 (m, 6H), 3.73 (t, J = 4.6 Hz, 3H), 3.11 (td, J = 13.2, 12.3, 2.2 
Hz, 1H), 2.86 – 2.76 (m, 3H), 2.64 – 2.53 (m, 5H), 2.52 – 2.44 (m, 1H), 2.42 – 2.27 (m, 3H), 
2.27 – 2.13 (m, 3H), 2.07 – 2.00 (m, 1H), 1.86 – 1.77 (m, 2H), 1.76 – 1.57 (m, 7H), 1.51 – 
1.35 (m, 2H), 1.36 – 1.27 (m, 2H), 1.27 – 1.22 (m, 1H), 1.22 – 1.07 (m, 2H), 0.91 – 0.79 (m, 
1H). 
(21): 13C NMR (151 MHz, CDCl3) δ 209.51, 172.74, 170.25, 158.80, 148.82, 147.29, 141.40, 
133.37, 129.66, 120.13, 118.91, 113.97, 113.13, 111.67, 111.26, 76.21, 66.90, 65.75, 57.62, 
55.89, 55.82, 54.08, 52.26, 48.38, 45.47, 44.14, 43.58, 43.48, 42.17, 37.83, 34.29, 31.17, 
30.52, 26.77, 25.84, 25.73, 25.49, 21.01. 
(22): 1H NMR (599 MHz, CDCl3) δ 7.24 – 7.21 (m, 1H), 6.95 – 6.74 (m, 4H), 6.68 – 6.62 
(m, 2H), 5.74 – 5.68 (m, 1H), 5.48 (d, J = 4.9 Hz, 1H), 4.15 – 4.04 (m, 2H), 3.97 (d, J = 13.5 
Hz, 1H), 3.89 – 3.79 (m, 6H), 3.79 – 3.67 (m, 4H), 3.21 (td, J = 13.1, 2.8 Hz, 1H), 2.85 (dt, J 
= 11.9, 5.3 Hz, 1H), 2.82 – 2.75 (m, 2H), 2.65 – 2.52 (m, 5H), 2.52 – 2.45 (m, 1H), 2.42 – 
2.33 (m, 3H), 2.24 – 2.16 (m, 1H), 2.13 – 1.59 (m, 11H), 1.51 – 1.42 (m, 1H), 1.41 – 1.32 (m, 
1H), 1.32 – 1.09 (m, 4H), 0.99 (qd, J = 12.3, 3.6 Hz, 1H). 
(22): 13C NMR (151 MHz, CDCl3) δ 210.44, 173.52, 170.47, 158.80, 148.84, 147.32, 141.40, 
133.40, 129.60, 120.10, 118.92, 113.84, 113.20, 111.66, 111.27, 76.24, 66.87, 57.64, 55.90, 
55.82, 54.08, 53.16, 52.06, 45.67, 44.50, 43.51, 40.36, 37.93, 32.29, 31.22, 29.40, 26.82, 
25.61, 25.42, 25.30, 25.14, 21.11. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((1R,2S,4aR,8aR)-2-methyl-4-oxodecahydronaphthalene-1-carbonyl)piperidine-2-
carboxylate (23) 
 
23 
 
Tetrafluoroboric acid (31.5 µL, 0.20 mmol, 48 % wt in H2O) was added to a solution of 
palladium(II) acetate (1.63 mg, 7.26 µmol) and p-benzoquinone (15.7 mg, 0.15 µmol) in 
MeCN (0.9 mL) and H2O (0.12 mL). This mixture was added to 15 (100 mg, 0.15 mmol) and 
it was stirred at RT for 16 h. The reaction mixture was directly loaded on silica and purified 
by flash chromatography to obtain title compounds as colorless solid (40.1 mg, 56.9 µmol, 
49.1 %) after lyophilization. 
TLC [DCM + 5 % MeOH]: Rf = 0.48. 
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HPLC [0-100% Solvent B, 20 min]: Rt = 16.1 min.  
HRMS: calculated 727.3934 [C41H56N2O8+H]+, found 727.3950 [M+H]+. 
1H NMR (800 MHz, CDCl3) δ 7.26 (t, J = 7.9 Hz, 1H), 6.91 – 6.82 (m, 3H), 6.82 – 6.77 (m, 
1H), 6.68 – 6.64 (m, 2H), 5.77 (dd, J = 7.9, 5.8 Hz, 1H), 5.56 – 5.52 (m, 1H), 4.17 – 4.10 (m, 
2H), 3.94 – 3.90 (m, 1H), 3.87 (s, 6H), 3.79 – 3.75 (m, 4H), 3.20 (td, J = 13.2, 2.9 Hz, 1H), 
2.98 (dd, J = 10.6, 4.1 Hz, 1H), 2.64 – 2.59 (m, 5H), 2.54 – 2.50 (m, 2H), 2.38 – 2.35 (m, 
1H), 2.29 – 2.27 (m, 1H), 2.25 – 2.20 (m, 1H), 2.14 – 2.06 (m, 2H), 2.00 – 1.91 (m, 2H), 1.84 
– 1.81 (m, 2H), 1.80 – 1.76 (m, 1H), 1.73 – 1.66 (m, 4H), 1.50 – 1.45 (m, 1H), 1.42 – 1.39 (m, 
1H), 1.30 – 1.26 (m, 2H), 1.22 – 1.18 (m, 1H), 0.98 – 0.94 (m, 1H), 0.88 (d, J = 7.1 Hz, 3H). 
 
13C NMR (201 MHz, CDCl3) δ 210.66, 171.69, 170.76, 148.87, 147.35, 141.48, 133.45, 
129.64, 120.11, 113.93, 111.66, 111.28, 76.26, 55.93, 55.84, 54.05, 53.76, 51.73, 48.06, 
48.03, 43.46, 40.76, 37.90, 32.63, 32.25, 31.33, 26.83, 25.78, 25.59, 25.52, 25.07, 21.17, 
15.40. 
 
 
(2S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((1R,4aR,8aR)-4-hydroxydecahydronaphthalene-1-carbonyl)piperidine-2-carboxylate 
(24) 
 
24 
Cerium(III) chloride heptahydrate (92 mg, 0.25 mmol) was added to a solution of 22 (17 mg, 
25 µmol) in THF/MeOH (2:1, 0.9 mL). It was stirred at RT for 15 min, then NaBH4 (4.7 mg, 
0.12 mmol) was added and it was stirred at RT for 30 min. The reaction mixture was 
quenched with H2O and alkalized with 1 N NaOH. The product was extracted with Et2O. 
Then the combined layers were dried over MgSO4, filtered and the solvent was removed 
under reduced pressure. Purification by flash chromatography (0-100 % [EtOAc + 2 % MeOH 
+ 0.1 % TEA] in cyclohexane) and following lyophilization provided the title compound as 
colorless solid (11.4 mg, 16.5 µmol, 66.9 %).  
TLC [EtOAc + 2 % MeOH + 2 % TEA]: Rf = 0.20. 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.2-16.4 min.  
HRMS: calculated 693.4115 [C40H56N2O8+H]+, found 693.4138 [M+H]+. 
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1H NMR (599 MHz, CDCl3) δ 7.24 – 7.20 (m, 1H), 6.89 – 6.85 (m, 1H), 6.85 – 6.80 (m, 2H), 
6.79 – 6.73 (m, 1H), 6.68 – 6.61 (m, 2H), 5.72 (ddd, J = 20.7, 8.0, 5.9 Hz, 1H), 5.51 – 5.46 
(m, 1H), 4.13 – 4.06 (m, 2H), 3.90 (d, J = 12.4 Hz, 1H), 3.85 – 3.83 (m, 6H), 3.74 – 3.71 (m, 
4H), 3.28 (ddd, J = 10.9, 9.4, 4.4 Hz, 1H), 3.14 (td, J = 13.2, 2.9 Hz, 1H), 2.82 – 2.75 (m, 2H), 
2.61 – 2.55 (m, 5H), 2.52 – 2.45 (m, 1H), 2.39 – 2.28 (m, 2H), 2.22 – 2.10 (m, 2H), 2.04 – 
1.97 (m, 2H), 1.81 – 1.74 (m, 2H), 1.71 – 1.63 (m, 6H), 1.57 – 1.51 (m, 2H), 1.44 – 1.40 (m, 
1H), 1.35 – 1.31 (m, 1H), 1.23 – 1.13 (m, 2H), 1.04 – 0.91 (m, 2H), 0.87 – 0.78 (m, 1H). 
13C NMR (151 MHz, CDCl3) δ 174.79, 170.67, 158.78, 148.83, 147.29, 141.57, 133.51, 
129.57, 120.12, 118.93, 113.86, 113.11, 111.72, 111.27, 76.04, 73.77, 66.88, 66.79, 65.70, 
57.65, 55.90, 55.83, 54.07, 51.92, 49.06, 44.96, 43.38, 42.33, 37.98, 34.57, 31.25, 31.20, 
28.86, 27.37, 26.83, 25.90, 25.60, 21.16. 
 
(2S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((5R,5aR,9aR)-2,2-dimethyldecahydronaphtho[1,2-d][1,3]dioxole-5-carbonyl)piperidine-
2-carboxylate (25) 
 
25 
9d (20.0 mg, 0.08 mmol), 28 (44.3 mg, 0.09 mmol), HATU (44.9 mg, 0.12 mmol) and 
DIPEA (30.5 mg, 0.236 mmol) were stirred in DMF (2.0 mL) at RT for 18 h. The orange 
reaction mixture was loaded on silica and purified by flash chromatography (0-100 % [EtOAc 
+ 2 % MeOH + 0.1 % TEA] in cyclohexane) to obtain the title compound as light yellow oil 
(45.5 mg, 0.06 mmol, 77.2 %). 
TLC [EtOAc + 2 % MeOH + 1 % TEA]: Rf = 0.19. 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.7 min.  
HRMS: calculated 749.4377 [C43H60N2O9+H]+, found  749.4380 [M+H]+. 
1H NMR (599 MHz, DMSO-d6) δ 7.28 – 7.20 (m, 1H), 6.88 – 6.79 (m, 4H), 6.75 – 6.71 (m, 
1H), 6.67 – 6.60 (m, 1H), 5.58 (dd, J = 8.8, 4.7 Hz, 1H), 5.21 (d, J = 6.0 Hz, 0H), 4.20 (d, J = 
6.7 Hz, 1H), 4.14 – 4.02 (m, 3H), 3.93 (d, J = 13.4 Hz, 1H), 3.72 – 3.64 (m, 6H), 3.60 – 3.52 
(m, 4H), 3.09 – 2.99 (m, 1H), 2.98 – 2.91 (m, 1H), 2.87 – 2.75 (m, 0H), 2.71 – 2.66 (m, 2H), 
2.43 (ddd, J = 13.7, 8.3, 4.6 Hz, 1H), 2.19 – 2.12 (m, 2H), 2.09 – 2.01 (m, 2H), 1.98 – 1.95 
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(m, 2H), 1.77 – 1.48 (m, 8H), 1.44 – 1.31 (m, 5H), 1.29 – 1.04 (m, 8H), 1.02 – 0.66 (m, 4H), 
0.30 – 0.20 (m, 1H). 
 
13C NMR (151 MHz, DMSO-d6) δ 174.96, 170.87, 158.85, 149.02, 147.46, 142.43, 133.64, 
130.04, 120.38, 120.33, 118.68, 114.34, 112.59, 112.32, 75.86, 74.86, 68.72, 66.47, 65.58, 
57.36, 55.93, 55.78, 53.98, 51.88 38.45, 38.06, 34.59, 31.05, 30.85, 29.45, 29.37, 26.90, 
26.77, 26.26, 26.13, 25.39, 22.53, 21.18. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl 1-
((1R,3R,4S,4aR,8aR)-3,4-dihydroxydecahydronaphthalene-1-carbonyl)piperidine-2-
carboxylate (26) 
O
O
MeO
MeO
O
N
N
O
O
HO
HO
 
26 
25 (40 mg, 53 µmol) was stirred in MeOH (1.86 mL) and concentrated HCl (0.14 mL) for 
1.5 h at RT. The title compound (11.5 mg, 16.2 µmol, 30.3 %) was obtained after purification 
by preparative HPLC (40-50 % solvent B).  
TLC [EtOAc + 5 % MeOH + 1 % TEA]: Rf = 0.15. 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.2 min.  
HRMS: calculated 709.4064 [C40H56N2O9+H]+, found  709.4089 [M+H]+. 
1H NMR (599 MHz, DMSO-d6) δ 7.26 – 7.22 (m, 1H), 6.88 – 6.83 (m, 3H), 6.82 – 6.79 (m, 
1H), 6.74 – 6.71 (m, 1H), 6.66 – 6.62 (m, 1H), 5.58 (dd, J = 8.8, 4.7 Hz, 1H), 5.23 (d, J = 6.1 
Hz, 1H), 4.11 – 4.00 (m, 3H), 3.95 (d, J = 13.2 Hz, 1H), 3.69 (d, J = 11.7 Hz, 6H), 3.57 – 3.52 
(m, 4H), 3.49 (td, J = 8.8, 4.8 Hz, 1H), 3.06 (td, J = 13.1, 2.9 Hz, 1H), 2.76 – 2.69 (m, 1H), 
2.65 (q, J = 7.6, 6.5 Hz, 2H), 2.43 (tt, J = 9.2, 4.3 Hz, 4H), 2.18 – 2.12 (m, 1H), 2.11 – 2.05 
(m, 1H), 2.02 – 1.93 (m, 2H), 1.92 – 1.86 (m, 1H), 1.76 – 1.69 (m, 1H), 1.68 – 1.60 (m, 3H), 
1.59 – 1.46 (m, 3H), 1.36 – 1.28 (m, 2H), 1.24 – 1.16 (m, 3H), 1.14 – 1.03 (m, 3H), 0.88 – 
0.76 (m, 2H). 
13C NMR (151 MHz, DMSO-d6) δ 174.49, 170.79, 158.87, 149.04, 147.49, 142.36, 133.60, 
130.00, 120.38, 118.76, 114.33, 112.57, 112.31, 107.78, 79.10, 75.90, 72.55, 66.60, 57.42, 
55.92, 55.78, 54.05, 52.01, 43.48, 43.35, 37.91, 31.03, 30.34, 30.19, 29.60, 29.05, 26.87, 
25.96, 25.85, 25.38, 21.06. 
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(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-oxopropoxy)phenyl)propyl piperidine-2-
carboxylate (27) 
 
27 
Synthesized as previously described. 17  
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl piperidine-2-
carboxylate (28) 
 
28 
 
Synthesized as previously described. 17 
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7.3. Manuscript VIII 
Rapid, structure-based exploration of pipecolic acid amides as novel selective 
antagonists of the FK506-binding protein 51 – submitted manuscript  
(Steffen Gaali, Xixi Feng, Claudia Sippel, Andreas Bracher, Felix Hausch, J. Med. 
Chem.) 
Summary 
With a molecular weight of ~350-400 g/mol the “Top Group” (TG) of SAFit1 and 2 
represents a large proportion of the total molecular weight. Additionally, the biological labile 
ester linkage is not ideal. In order to improve drug-likeness of FKBP51 ligands these two 
problems were adressed in the presented study.   
The pipecolic esters of the SAFit compounds were systematically replaced by various smaller 
pipecolic acid amides. An efficient, solid phase-assisted method was developed to screen a 
series of amino acids as TGs. It was shown that none of the 37 ligands showed binding 
towards FKBP52, suggesting that the TG does not affect the selective binding mode. The best 
ligand of the series, containing a geminally substituted cyclopentyl ring as key feature, did not 
only exhibit a high binding affinity of Ki = 100 nM, but even a significantly reduced 
molecular weight (34% lower than SAFit2). A cocrystal structure was solved to understand 
the binding mode. The study represents the first systematic TG screening of FKBP ligands. 
Together with the findings of the “Bottom Group” series this series provides important 
complementing information for the further development of FKBP51-selective ligands. 
Steffen Gaali and I contributed equally to the synthesis of the ligands as well as the 
preparation of the manuscript.  
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ORIGINAL MANUSCRIPT 
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Rapid, structure-based exploration of pipecolic acid amides as novel selective 
antagonists of the FK506-binding protein 51 
 
 
Steffen Gaali*, Xixi Feng*, Claudia Sippel*, Andreas Bracher#, Felix Hausch* 
 
* Max Planck Institute of Psychiatry, Dept. Translational Research in Psychiatry, 
Kraepelinstrasse 2, 80804 Munich, Germany 
 
# Max Planck Institute of Biochemistry, Am Klopferspitz 18, 82152 Martinsried, Germany 
 
Abstract 
The FK506-binding protein 51 (FKBP51) is a key regulator of stress hormone receptors and 
an established risk factor for stress-related disorders. Drug development for FKBP51 has been 
impaired by the structurally similar but functionally opposing homologue FKBP52. High 
selectivity between FKBP51 and FKBP52 can be achieved by ligands that stabilize a recently 
discovered FKBP51-favoring conformation. However, drug-like parameters for these ligands 
remained unfavourable. In the present study, we replaced the potentially labile pipecolic ester 
group of previous FKBP51 ligands by various low molecular weight amides. This resulted in 
the first series of pipecolic acid amides, which had much lower MWs without affecting 
FKBP51 selectivity. We discovered a geminally substituted cyclopentyl amide as a preferred 
FKBP51-binding motif and elucidated its binding mode to provide a new lead structure for 
future drug optimization. 
Introduction 
The FK506-binding protein 51 (FKBP51) plays an important role in the pathogenesis 
of depression and other stress-related diseases. It inhibits signaling of the 
glucocorticoid receptor, a key receptor for the stress hormone cortisol, and its 
upregulation in the brain causes depression-like behaviors.1-3 In animal models of 
anxiety and depression, depletion of FKBP51 led to improved stress hormone signaling 
and stress-coping behavior.4-6 Moreover, in humans FKBP51 has repeatedly been 
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associated genetically with psychiatric endophenotypes and diseases.7, 8 Taken 
together, FKBP51 has emerged as a compelling target for stress-related disorders.9, 10 
Ligands for FKBPs have been traditionally derived from the natural product FK506 
(Fig. 1a) through structure-based design.11-15 For FKBP51 drug discovery, the key 
challenge is to achieve selectivity over its closest homologue FKBP52, which is the 
functional counter-player of FKBP51 and has opposing effects on the endocrine system 
and on behaviour.1-3 The active site residues of FKBP51 and FKBP52 are strictly 
conserved16-22 and almost all ligands tested so far did not discriminate between these 
two proteins.23-27 
 
(a)                         (b) 
 
Fig. 1: Chemical structures of (a) FK506 and (b) the FKBP51-selective ligands SAFit1 (1), SAFit2 (2) and their 
binding affinities towards FKBP51. 
Recently, we discovered the first FKBP51-selective ligands based on a novel, 
FKBP51-specific binding mode.28 The resulting tool compounds, SAFit1 (1) and 
SAFit2 (2) (Fig. 1b), for the first time allowed to pharmacologically probe the role of 
FKBP51. This enabled the proof-of-concept that inhibition of FKBP51 is 
neuritotrophic, enhances stress hormone regulation, has anxiolytic and antidepressant-
like effects, and suppresses NF-κB signalling, a key pathway in melanoma cancers.28-30  
Despite these encouraging findings, it is currently unclear if drug-like FKBP51-
selective inhibitors can be developed. SAFit1 and 2 deviate substantially from the 
physicochemical properties required for CNS-directed drugs.31 Clearly, the molecular 
weight (748 and 803 g/mol, compared to 426 g/mol for 90 % of CNS drugs), 
lipophilicity (clogD = 3.5 and 7.1, vs. <3.8 for CNS drugs), polar surface area (139 and 
114 Å2, vs. <86 for CNS drugs), and hydrogen bond acceptors (HA = 14 and 12) are 
B. Research Articles – Publication/Manuscript VIII 
 
143 
 
much too high, while the ligand efficiency is too low (LE = 0.21 and 0.19). 
Furthermore, there are biological stability issues that require attention. Therefore, we 
set out to identify improved lead structures that are better suited for further FKBP51 
drug development.  
Results and Discussion  
Cocrystal Structure of 3 
Replacing a labile ester linkage with a metabolically more stable amide group is a common 
strategy to enhance bioavailability. When we replaced the pipecolic ester moiety of SAFit1 by 
the analogous amide we were delighted to see that the SAFit1 amide analog 3 retained high-
affinity binding towards FKBP51 (Ki = 39 nM, Fig. 2a). No binding towards FKBP52 could 
be observed, in agreement with a SAFit-like FKBP51-selective binding mode. 
(a)                        (b)
N
O
R
O
MeO
OMe
OMe
NH
MeO
MeO
O
OH
O
H
N
R =
3
Ki = 0.039 µM
4
Ki = 37 µM      
Fig. 2: (a) Chemical structures of the SAFit1 amide analog 3 and ethyl amide analog 4 and their binding 
affinities towards FKBP51. (b) X-ray structure of 3 (cyan) in complex with the FK506-binding domain of 
FKBP51 (pdb: 5DIU). The hydrogen bonds to Tyr113 (blue), Ile 87 (red) and the intramolecular NH-Car 
interaction (magenta) are indicated as dotted lines. Phe67 (green) has been displaced by the cyclohexyl moiety 
upon binding of 3 and adopts two rotamers. 
We solved the co-crystal structure of 3 and FKBP51 to confirm this assumption (Fig. 2b). The 
binding mode of 3 is virtually identical to the previously determined iFit1 and iFit4-FKBP51 
complexes, including the key conformational rearrangement of Phe67 that is responsible for 
the strict selectivity over FKBP52.28 The important hydrogen bonds to Tyr113 (red) and Ile 87 
B. Research Articles – Publication/Manuscript VIII 
 
144 
 
(blue) are preserved. Moreover, the conformation of the cyclohexyl ring conformation is 
similar to the cylcohexenyl moiety of iFit4. It is buried in the subpocket that is generated by 
the displacement of Phe67. The pipecolate amide of 3 points to the face of the trimethoxy 
phenyl ring but does not change its conformation. 
Encouraged by this finding we started a systematic exploration of pipecolic acid amide 
substituents, starting with the small ethyl amide analog 4. As expected, the replacement of the 
large amide substituent of 3 by the simple ethyl group in 4 caused a substantial loss of binding 
affinity, resulting in a Ki value of 37 µM. Nevertheless 4 represented a suitable starting point 
for further derivatization.  
An efficient synthetic strategy for pipecolic acid amide screening 
During the investigation on selective FKBP51 ligands, the carboxylic acid 5 proved to be the 
best building block, regarding binding affinity and selectivity.28 We therefore developed an 
efficient, solid phase-assisted method (Fig. 3) to couple 5 with a variety of pipecolic acid 
dipeptides. The synthesis started with the coupling of an Fmoc protected amino acid to the 
Sieber amide resin.32 Then Fmoc-pipecolic acid and subsequently the carboxylic acid 5 were 
coupled to the free amines after Fmoc deprotection, respectively. Cleavage from the resin 
provided a variety of pipecolic acid amides in 20-90 % overall yield and excellent purities 
(> 90 % for crude products).  
 
Fig. 3: Solid phase synthesis for the pipecolic acid amide series; Reagents and conditions: (a) 20 % 4-
Methylpiperidine/DCM, (b) 4.8 eq. HBTU, 4.8 eq. HOBt, 10 eq. DIEA, 5 eq. Fmoc-amino acid (X,Y = different 
substituents). (c) 3.8 eq. HBTU, 3.8eq HOBt, 8 eq. DIEA, Fmoc-pipecolic acid. (d) 2 eq. HATU, 4 eq. DIEA, 2 
eq.  5. (e) 1% TFA/1% TIS/98% DCM.  
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This approach allowed rapid incorporation and testing of a large variety of commercially 
available amino acid building blocks. Altogether, an FKBP51-focussed library of 37 
compounds was synthesized by this method (Table 1-5). None of the ligands from this novel 
pipecolic acid amide series showed any binding to FKBP52. 
Structure-Affinity Relationship (SAR) of the Amide Substituent 
To perform a systematic investigation on the different amide substituents, we started our 
screening with simple unbranched side chains (Table 1). Entry 6, which derives from the 
simplest amino acid glycine, bound to FKBP51 in the same affinity range as the ethyl amide 
analog 5 (35 and 37 µM respectively). A significant affinity increase to 5.6 µM (7) was 
observed when an additional methylene group was added to the chain. Further prolongation of 
the chain, however, only resulted in a slight increase of the binding affinity (compounds 8 and 
9).  
O
NH2
NH2
O
NH2
O
NH2
O
Entry R Ki [µM]
35
5.6
4.7
3.3
6
7
8
9  
Table 1: FKBP51 affinities of amide analogs with unbranched amide substituents; Ki values were determined by 
competitive fluorescence polarization assay.33 
In the next series we assessed, whether branching with additional aliphatic groups would 
improve the binding affinity (Table 2). The addition of a methyl group (10a & b) increased 
the binding affinity irrespective of the configuration, compared to the linear analog 6. Further 
enlargement of the branched side chains resulted only in a slight increase of the binding 
affinity (11a & b, 14a & b, 15, 16a & b). Interestingly, compounds with branched side chains 
with (R)-configuration showed higher binding affinities than their corresponding 
diastereomers with (S)-configuration (14b > 14a, 16b > 16a). A clear improvement of the Ki 
value was observed when a geminally di-substituted amide was introduced (12, 13). 
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Table 2: FKBP51 binding affinities of amide analogs with branched aliphatic side chain; Ki values were 
determined by competitive fluorescence polarization assay.33 
We hypothesized that additional hydrophobic interactions might be beneficial for the binding 
to FKBP51 and therefore analyzed the effects of phenyl- and cyclohexyl rings branching off 
the linear precursor (Table 3). In general, compounds containing an aromatic ring showed 
better binding affinities than their aliphatic analog (e.g. 19a vs. 20). Also shorter linkers 
tended to result in better affinities towards the protein. As observed in the previous series, 
ligands with the side chain in (R)-configuration were better than their corresponding 
diastereomers in (S)-configuration (18b > 18a and 19b > 19a). 
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Table 3: FKBP51 binding affinities of amide analogs with branched side chains containing aromatic and non-
aromatic 6-membered rings; Ki values were determined by competitive fluorescence polarization assay.33 
FKBP51 has two hydrogen bond acceptors, the carbonyls of Gly84 and of Gln85, that are 
close to the pipecolate ester substituents of FKBP51-bound ligands. The high-affinity ligands 
FK506 and rapamycin gain part of their binding energy by donating direct or water-mediated 
hydrogen bonds to these residues.17, 19 We thus analyzed the effect of substituents containing 
polar groups in the side chain. As shown in Tab. 4, this did not result in any affinity 
enhancement over the aliphatic counterparts. As for the branched aliphatic derivatives, we 
observed a preference for substituents with the (R)-configuration (24b > 24a, 25b > 25a). The 
exception was the histamine derivatives, where this trend was reversed (26a > 26b).  
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Table 4: FKBP51 binding affinities of amide analogs with side chains containing heteroatoms; Ki values were 
determined by competitive fluorescence polarization assay.33 
Intrigued by the promising ligand efficiency of the geminally disubstituted analog 12, we 
extended our studies to amide substituents containing geminally substituted carbocycles of 
different ring sizes (Table 5). While constraining the two geminal substituents by a 
cyclopropyl ring in 27 reduced affinity, the cyclobutyl (28) and 6-membered ring analogs (30, 
31) had affinities comparable to 12. A surprising discovery was the high affinity of the 
cyclopentyl compound 29, which showed exceptionally strong inhibition (Ki = 0.1 µM). The 
beneficial effect of the cyclopentyl ring was confirmed by the close analog 32 that also 
showed a significant higher binding affinity, compared to the other carbocycles. 
 
B. Research Articles – Publication/Manuscript VIII 
 
149 
 
O
NH2
O
NH2
O
NH2
O
NH2
O
NH2
O
O
H
N
O
NH2
17
4.7
0.1
1.6
2.3
0.7
27
28
29
30
31
32
Entry R Ki [µM] Entry R Ki [µM]
 
Table 5: FKBP51 binding affinities of amide analogs containing geminally substituted carbocycles or 
tetrahydropyran; Ki values were determined by competitive fluorescence polarization assay.33 
 Cocrystal Structure of 29 
To better understand the basis for the surprisingly high affinity of 29 we solved the cocrystal 
structure of 29 in complex with FKBP51 (Fig.4).  
              (a)                                                              (b) 
                              
Fig. 4: X-ray structure of 29 (yellow) in complex with the FK506-binding domain of FKBP51 (pdb: 5DIV); 
Lys121 is not shown for clarity; (a) The hydrogen bonds to Tyr113 (blue) are indicated by dotted lines; 
Compound 3 in complex with FKBP51 is superimposed and shown as cyan lines. (b) 29 in complex with 
FKBP51 is shown as spheres. The cyclopentane ring and residues Phe77, Gln85, and Val86 have been 
highlighted in salmon and orange, respectively. 
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The cocrystal structure revealed that the pipecolic acid core and the 2-trimethoxyphenyl-2-
cylcohexyl acetic acid moiety (derived from 5) adopt the same conformation and engage in 
the same interactions as observed for 3 (Fig. 2b). The pipecolic acid core sits tightly in the 
binding pocket in a chair conformation, positioning both carbonyl groups optimally for 
forming hydrogen bonds with Ile87 (blue) and Tyr113 (red), respectively. Similar to ligand 3, 
the cyclohexyl ring of 29 is deeply buried in a hydrophobic pocket formed by Gly59, Lys60, 
Leu61, Lys66, Asp68, and Ile122. The trimethoxyphenyl ring points towards the open space. 
In contrast to 3, the terminal amide of the pipecolate substituent of 29 donates a hydrogen 
bond to the hydroxyl group of Tyr113, which in turn donates a hydrogen bond to the carbonyl 
group of the 2-trimethoxyphenyl-2-cylcohexyl acetic acid moiety. The cyclopentane of 29 
neatly fills the space between the piperidine of 29, the trimethoxyphenyl of 29 and Phe77, 
Gln85 and Val86 of FKBP51 (Fig. 4b). This tight, sandwich-like, intramolecular packing 
explains, why even small deviations in the carbocycle size dramatically affect the interactions 
with FKBP51. 
Conclusion 
SAFit1 and SAFit2 were just recently reported as the best selective FKBP51 ligands so far, 
but they are too large for further drug optimization studies. In this study we have shown, that 
replacing the pipecolic ester moiety by a low molecular weight amide containing a geminally 
substituted cyclopentyl ring leads to ligands with high binding affinities (Ki = 0.1 µM) and 
low molecular weight, while retaining selectivity for FKBP51 over FKBP52. Especially with 
29 we were able to reduce the molecular weight by 34 % (MW = 529.7 g/mol compared to 
802 g/mol for SAFit2) and to improve key physicochemical parameters (clogD = 3.1, tPSA = 
120 Å2, 9 HA, LE = 0.25). Due to these enhanced properties as well as the well-understood 
molecular binding mode, 29 represents a substantially improved starting point for the further 
development of FKBP51-directed drug candidates. 
Experimental Section 
Chemistry  
Chromatographic separations were performed either by manual flash chromatography or 
automated flash chromatography using an Interchim Puriflash 430 with an UV detector. 
1H NMR spectra, 13C NMR spectra, 2D HSQC, HMBC, and COSY of all intermediates were 
obtained from the Department of Chemistry and Pharmacy, LMU, on a Bruker Avance III HD 
400/800 or a Varian NMR-System 300/400/600 at room temperature. Chemical shifts for 1H 
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or 13C are given in ppm (δ) downfield from tetramethylsilane using residual protio solvent as 
an internal standard.  
Mass spectra (m/z) were recorded on a Thermo Finnigan LCQ DECA XP Plus mass 
spectrometer at the Max Planck Institute of Psychiatry, while the high resolution mass 
spectrometry was carried out at MPI for Biochemistry (Microchemistry Core Facility) on 
Bruker Daltonics MicrOTOF. 
The purity of the compounds was verified by reversed phase HPLC (see supporting 
information for detailed conditions). All of the final compounds synthesized and tested had a 
purity of > 95 %. 
General Synthetic procedure for solid phase coupling reaction 
All steps were performed at RT. Sieber amide resin (108 mg, 80 µmol) was treated with 20 % 
4-methylpiperidine in DMF (2.0 mL) for 20 min for removing the Fmoc-group. The resin was 
filtered and washed with DMF (2.0 mL x 4). To the resin was added a solution of the Fmoc- 
protected amino acid (400 µmol, 5 eq.), HBTU (145 mg, 386 µmol, 4.8 eq.), HOBt (52 mg, 
386 µmol, 4.8 eq.) and DIPEA (140 µL, 800 µmol, 10 eq.) in DMF (2.0 mL). The mixture 
was then mixed on a shaker for 2 h. In the following step the resin was filtered and washed 
with DMF (2 mL x 4). Fmoc deprotection and washing was performed as before. In the 
following step (S)-N-Fmoc-piperidine-2-carboxylic acid (112 mg, 320 µmol, 4 eq.), HBTU 
(115mg, 304 µmol, 3.8 eq.), HOBt (41 mg, 304 µmol, 4.8 eq.) and DIPEA (120 µL, 640 
µmol, 8 eq.) in DMF (2.0 mL) was added to the resin and mixed for 2 h. Washing and 
deprotecting was repeated as before, followed by the addition of 5 (48 mg, 136 µmol, 1.7 eq.), 
HATU (61 mg, 144 µmol, 1.8 eq.) and DIPEA (60 µl, 320 µmol, 4 eq.). The suspension was 
mixed for 16 h. Then the resin was washed with DMF, MeOH, DCM and Et2O (2 mL x 4 
each) and dried in vacuo. The compounds were cleaved from the resin using DCM + 1 % 
TFA + 1 % TIS (2.0 mL) for 2 min. This was repeated 5 times and after every step the 
solution, containing the cleaved product, was neutralized using saturated NaHCO3 solution. 
The aqueous solution was then extracted three times with DCM. The combined organics were 
dried over MgSO4, filtered and the solvent was removed to obtain the compounds after 
removing the solvent under reduced pressure. If necessary the compounds were purified by 
flash chromatography. (Note: The synthesis of 14a+b, 19a+b and 20 were conducted starting 
with 160 µmol resin. The coupling step with 5 was performed with 5 (3 eq.), HATU (2.8 eq.) 
and DIPEA (6 eq.).) 
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The purity of the compounds was verified by reversed phase HPLC. All of the final 
compounds synthesized and tested have a purity of more than 95%.  
2-(3-((R)-1-((S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-
carboxamido)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid (3) 
5 (30 mg, 0.20 mmol), HATU (110 mg, 0.29 mmol) and DIPEA (0.13 mL, 0.78 mmol) were 
dissolved in DCM (2.0 mL) at RT and stirred for 30 min. Then 3-2 (50 mg, 0.20 mmol), 
dissolved in) DCM (300 µL) was added and the reaction mixture was stirred for 16 h at RT. 
The crude product was concentrated and purified by flash chromatography (0-20 % EtOAc in 
cyclohexane). Then the carboxylic acid was liberated using 10% TFA in DCM (2.0 mL) at RT 
for 5 h. The reaction mixture was concentrated and flash purified by preparative HPLC 
(Gradient: 65-75% B in 20min) to obtain the title compound (15 mg, 20 µmol, 24 %) as a 
colourless oil. 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.7 min. HRMS: calculated 747.3857 
[C42H55N2O10 +H]+, found 747.3854 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.13 – 7.08 
(m, 1H), 6.95 – 6.90 (m, 1H), 6.84 (t, J = 8.4 Hz, 1H), 6.75 (dq, J = 11.8, 2.0 Hz, 2H), 6.72 – 
6.67 (m, 1H), 6.66 – 6.60 (m, 1H), 6.59 – 6.54 (m, 2H), 5.15 – 5.07 (m, 1H), 4.82 – 4.69 (m, 
1H), 4.69 – 4.56 (m, 3H), 3.76 – 3.72 (m, 1H), 3.72 – 3.69 (m, 6H), 3.65 – 3.64 (m, 1H), 3.58 
– 3.54 (m, 9H), 2.96 – 2.84 (m, 2H), 2.82 – 2.70 (m, 2H), 2.43 – 2.30 (m, 2H), 2.19 – 2.05 (m, 
2H), 1.99 – 1.87 (m, 2H), 1.88 – 1.76 (m, 3H), 1.59 (d, J = 8.2 Hz, 2H), 1.34 (d, J = 9.6 Hz, 
1H), 1.16 – 1.10 (m, 2H), 0.95 – 0.86 (m, 2H).13C NMR (101 MHz, DMSO-d6) δ 171.99, 
170.28, 170.12, 157.65, 152.52, 148.61, 147.00, 145.30, 135.97, 133.59, 130.71, 127.70, 
120.01, 112.62, 112.31, 112.26, 111.74, 105.56, 64.33, 63.08, 59.70, 55.96, 55.52, 55.48, 
55.34, 52.42, 51.79, 51.45, 42.79, 39.52, 38.52, 38.17, 31.59, 27.34, 27.03, 26.09, 24.87, 
20.68, 19.97. 
(S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)-N-ethylpiperidine-2-
carboxamide (4) 
(S)-N-ethylpiperidine-2-carboxamide (40.0 mg, 0.26 mmol) and 5 (60 mg, 0.39 mmol) were 
dissolved in DCM (1.0 mL). HATU (0.38 g, 0.26 mmol) and DIPEA (0.17 mL, 1.02 mmol) 
were added and the reaction was stirred at RT for 16 h. Then the organic solvent was removed 
and the title compound (68.0 mg, 0.15 mmol, 59.5 %) was obtained after purification by flash 
chromatography (EtOAc/cyclohexane 1:2). 
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HPLC [0-100% Solvent B, 20 min]: Rt = 18.8 min. HRMS: calculated 447.2859 
[C25H38N2O5 +H]+, found 447.2863 [M+H]+. 1H NMR (300 MHz, CDCl3,) δ 6.52 (s, 2H), 
5.50 (t, 1H), 5.23 (d, J = 5.3 Hz, 1H), 4.00 (d, J = 14.1 Hz, 1H), 3.84 – 3.83 (m, 6H), 3.82 – 
3.80 (m, 3H), 3.42 – 3.29 (m, 2H), 3.08 – 2.97 (m, 2H), 2.78 – 2.71 (m, 1H), 2.38 – 2.31 (m, 
1H), 2.22 – 2.08 (m, 2H), 1.91 (d, J = 12.6 Hz, 2H), 1.66 – 1.60 (m, 4H), 1.52 – 1.44 (m, 2H), 
1.34 – 1.26 (m, 2H), 1.20 – 1.15 (m, 2H), 0.92 – 0.86 (m, 1H), 0.81 (t, J = 7.2, 0.7 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 172.77, 170.10, 153.41, 137.08, 133.71, 105.14, 60.75, 56.24, 
55.23, 52.16, 43.71, 40.83, 34.03, 32.77, 30.49, 26.50, 26.10, 26.01, 25.84, 25.00, 20.61, 
14.48. 
(S)-N-(2-amino-2-oxoethyl)-1-((S)-2-cyclohexyl-2-(3,4,5- 
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (6) 
The general procedure was used with Fmoc-Gly-OH and 6 was obtained after purification by 
flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (22 mg, 46 µmol, 57.5 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 19.2 min. HRMS: calculated 476.2761 
[C25H38N3O6 +H]+, found 476.2772 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.57 (d, J = 
1.1 Hz, 1H), 6.52 (d, J = 1.1 Hz, 2H), 4.94 – 4.90 (m, 1H), 4.75 (d, J = 5.1 Hz, 1H), 4.31 (d, J 
= 13.0 Hz, 1H), 3.67 – 3.62 (m, 9H), 3.10 (d, J = 3.8 Hz, 1H), 2.68 (td, J = 12.9, 2.7 Hz, 1H), 
2.45 – 2.40 (m, 4H), 1.88 – 1.76 (m, 2H), 1.68 – 1.44 (m, 8H), 1.34 – 1.27 (m, 2H), 1.05 – 
0.89 (m, 4H). 13C NMR (101 MHz, DMSO-d6) δ 172.90, 172.28, 170.97, 170.55, 153.08, 
152.88, 136.32, 134.97, 134.22, 106.02, 105.82, 60.26, 56.32, 56.12, 53.56, 52.63, 48.98, 
32.37, 32.19, 30.23, 27.17, 26.51, 26.05, 25.50, 21.14, 20.37. 
(S)-N-(3-amino-3-oxopropyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (7) 
The general procedure was used with Fmoc-β-Ala-OH and 7 was obtained after purification 
by flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (19 mg, 39 µmol, 48.6 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.9 min. HRMS: calculated 490.2917 
[C26H39N3O6 + H]+, found 490.2945 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 6.52 (s, 2H), 
5.94 – 5.81 (m, 2H), 5.35 (s, 1H), 5.22 – 5.17 (m, 1H), 4.65 – 4.60 (m, 1H), 4.01 – 3.96 (m, 
1H), 3.88 – 3.80 (m, 9H), 3.44 – 3.37 (m, 2H), 3.17 – 3.11 (m, 1H), 2.83 – 2.76 (m, 1H), 2.30 
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(d, J = 13.6, 3.3, 1.8 Hz, 1H), 2.19 – 2.13 (m, 1H), 2.12 – 2.04 (m, 2H), 1.90 – 1.85 (m, 1H), 
1.73 – 1.61 (m, 4H), 1.60 – 1.55 (m, 1H), 1.50 – 1.42 (m, 2H), 1.37 – 1.29 (m, 2H), 1.19 – 
1.10 (m, 2H), 0.93 – 0.85 (m, 1H), 0.76 (qd, J = 12.1, 3.6 Hz, 1H). 13C NMR (151 MHz, 
CDCl3) δ 173.00, 172.65, 170.80, 153.32, 136.90, 133.83, 105.41, 105.13, 60.87, 56.33, 
56.26, 55.15, 52.30, 43.75, 40.97, 40.88, 35.29, 35.03, 32.70, 30.52, 26.48, 26.10, 26.01, 
25.76, 25.25, 20.54, 14.18. 
(S)-N-(4-amino-4-oxobutyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (8) 
The general procedure was used with Fmoc-GABA-OH and 7 was obtained after purification 
by flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (15 mg, 29 µmol, 36.3 %). 
HPLC [0-100% Solvent B, 10 min]: Rt = 16.2 min. HRMS: calculated 504.3074 
[C27H41N3O6 + H]+, found 504.3093 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 6.52 (s, 2H), 
6.30 (sbr, 1H), 5.69 (t, J = 6.1 Hz, 1H), 5.32 (sbr, 1H), 5.23 (d, J = 5.3, 2.2 Hz, 1H), 4.00 (d, 
1H), 3.84 – 3.79 (m, 9H), 3.40 (d, J = 10.2 Hz, 1H), 3.23 (dq, J = 13.1, 6.5 Hz, 1H), 2.89 (h, 
1H), 2.76 – 2.68 (m, 1H), 2.36 – 2.30 (m, 1H), 2.19 – 2.11 (m, 1H), 1.96 – 1.83 (m, 4H), 1.74 
– 1.64 (m, 5H), 1.61 – 1.55 (m, 1H), 1.52 – 1.46 (m, 3H), 1.37 – 1.33 (m, 1H), 1.32 – 1.27 (m, 
1H), 1.20 – 1.11 (m, 2H), 0.94 – 0.85 (m, 1H), 0.77 (qd, J = 12.2, 3.7 Hz, 1H). 13C NMR 
(151 MHz, CDCl3) δ 174.56, 172.93, 170.93, 153.42, 136.88, 133.89, 105.21, 60.86, 56.31, 
55.20, 52.32, 43.85, 41.00, 40.87, 38.41, 32.73, 32.47, 30.49, 26.46, 26.09, 26.00, 25.74, 
25.11, 20.58. 
(S)-N-(5-amino-5-oxopentyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (9) 
The general procedure was used with Fmoc-Ava-OH and 9 was obtained after purification by 
flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (22 mg, 41.5 µmol, 51.9 %). 
HPLC [0-100% Solvent B, 10 min]: Rt = 16.9 min. HRMS: calculated 518.3230 
[C28H43N3O6 + H]+, found 518.3264 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.44 (s, 2H), 
6.01 (s, 1H), 5.47 – 5.37 (m, 1H), 5.32 (sbr, 1H), 5.15 (d, J = 4.6 Hz, 1H), 3.93 (d, J = 14.2 
Hz, 1H), 3.78 – 3.70 (m, 9H), 3.32 (d, J = 10.2 Hz, 1H), 3.14 – 3.04 (m, 1H), 2.80 – 2.70 (m, 
1H), 2.65 (td, J = 13.4, 2.7 Hz, 1H), 2.27 (d, J = 14.3 Hz, 1H), 2.12 – 2.03 (m, 1H), 2.02 – 
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1.91 (m, 4H), 1.82 (d, J = 12.5 Hz, 1H), 1.66 – 1.56 (m, 4H), 1.53 – 1.46 (m, 1H), 1.37 (m, 
2H), 1.30 – 1.17 (m, 4H), 1.13 – 0.94 (m, 3H), 0.87 – 0.75 (m, 1H), 0.74 – 0.62 (m, 1H). 13C 
NMR (101 MHz, CDCl3) δ 175.37, 172.80, 170.43, 153.38, 136.61, 134.04, 105.07, 60.87, 
56.22, 55.18, 52.26, 43.84, 40.97, 40.88, 38.61, 34.84, 32.72, 30.48, 28.73, 26.48, 26.09, 
25.99, 25.81, 25.04, 22.47, 20.63. 
(S)-N-((S)-1-amino-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (10a) 
The general procedure was used with Fmoc-Ala-OH and 10a was obtained as colourless oil 
(15 mg, 31 µmo, 19.4 %).  
HPLC [0-100% Solvent B, 20 min]: Rt = 16.4 min. HRMS: calculated 490.2917 
[C26H39N3O6 +H]-, found 490.2945 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.63 (s, 1H), 
6.59 (s, 2H), 5.04 – 4.98 (m, 1H), 4.82 (d, J = 5.2 Hz, 1H), 4.33 – 4.25 (m, 1H), 4.10 – 4.00 
(m, 2H), 3.70 (d, J = 3.7 Hz, 9H), 3.60 (s, 2H), 2.04 (d, J = 10.0 Hz, 1H), 1.96 – 1.90 (m, 2H), 
1.70 (d, J = 12.5 Hz, 2H), 1.60 – 1.46 (m, 5H), 1.42 – 1.35 (m, 2H), 1.24 – 1.17 (m, 2H), 1.11 
– 1.03 (m, 2H), 0.91 (d, J = 7.0 Hz, 3H), 0.82 – 0.70 (m, 1H). 13C NMR (75 MHz, DMSO-d6) 
δ 174.22, 172.67, 170.28, 153.14, 153.03, 136.48, 134.34, 106.02, 60.44, 60.28, 56.45, 
56.17,53.46, 51.74, 48.27, 47.95, 43.26, 41.23, 32.31, 32.17, 30.20, 26.59, 26.09, 25.82,19.29, 
18.84. 
(S)-N-((R)-1-amino-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (10b) 
The general procedure was used with Fmoc-D-Ala-OH and 10b was obtained as colourless oil 
(8 mg, 17 µmol. 21.3 %).  
HPLC [0-100% Solvent B, 20 min]: Rt = 17.1 min. HRMS: calculated 490.2917 
[C26H39N3O6+H]+, found 490.2923 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.65 (s, 1H), 
6.54 (s, 2H), 4.93 – 4.87 (m, 1H), 4.85 (d, J = 5.3 Hz, 1H), 4.31 – 4.24 (m, 1H), 4.10 – 3.99 
(m, 2H), 3.70 – 3.68 (m, 6H), 3.60 – 3.58 (m, 3H), 3.08 – 2.96 (m, 1H), 2.78 – 2.68 (m, 1H), 
1.98 (t, J = 12.2 Hz, 2H), 1.71 (d, J = 11.9 Hz, 2H), 1.64 – 1.46 (m, 6H), 1.06 (s, 2H), 1.04 (s, 
2H), 1.02 – 1.02 (m, 3H), 0.95 (d, J = 0.7 Hz, 3H). 13C NMR (101 MHz, DMSO-d6) δ 174.38, 
173.07, 170.90, 153.10, 152.98, 136.38, 135.02, 134.13, 105.98, 60.44, 60.27, 56.39, 56.18, 
52.75, 48.05, 41.13, 30.24, 26.96, 26.10, 25.43, 20.29, 19.67, 19.28, 18.53. 
B. Research Articles – Publication/Manuscript VIII 
 
156 
 
(S)-N-((S)-1-amino-1-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (11a) 
The general procedure was used with Fmoc-Abu-OH and 11a was obtained after purification 
by flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
pale yellow oil (29 mg, 58 µmol, 72.5 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.8 min. HRMS: calculated 504.3074 
[C27H41N3O6+H]+, found 504.3086 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.63 (s, 1H), 
6.52 (s, 2H), 4.97 – 4.89 (m, 1H), 4.31 (d, J = 13.3 Hz, 1H), 3.73 – 3.60 (m, 9H), 3.45 – 3.38 
(m, 1H), 3.02 (t, J = 12.5 Hz, 1H), 2.06 – 1.80 (m, 4H), 1.73 – 1.63 (m, 3H), 1.55 – 1.46 (m, 
6H), 1.31 – 1.20 (m, 3H), 1.06 – 0.98 (m, 3H), 0.94 – 0.82 (m, 3H), 0.69 – 0.60 (m, 3H). 13C 
NMR (101 MHz, DMSO-d6) δ 173.54, 172.98, 171.00, 152.91, 136.34, 134.97, 134.13, 
105.93, 60.37, 60.19, 56.35, 56.10, 53.44, 52.60, 43.18, 41.09, 32.29, 30.18, 27.22, 26.50, 
26.04, 25.93, 25.40, 20.32, 10.30. 
(S)-N-((R)-1-amino-1-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (11b) 
The general procedure was used with Fmoc-D-Abu-OH and 11b was obtained after 
purification by flash chromatography (0% - 90% [EtOAc + 2% MeOH + 0.1% TEA] in 
cyclohexane) as colourless oil (10 mg, 20 µmol, 24.8 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.3 min. HRMS: calculated 504.3074 
[C27H41N3O6+H]+, found 504.3100 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 6.51 (s, 2H), 6.03 
(d, J = 7.9 Hz, 1H), 5.85 (sbr, 1H), 5.34 (sbr, 1H), 5.22 – 5.18 (m, 1H), 4.16 – 4.13 (m, 1H), 
4.05 (dt, J = 13.7, 3.4 Hz, 1H), 3.84 – 3.78 (m, 11H), 3.41 (d, J = 10.2 Hz, 1H), 3.04 – 2.96 
(m, 1H), 2.32 – 2.27 (m, 1H), 2.17 – 2.11 (m, 1H), 1.86 (d, J = 12.5 Hz, 1H), 1.71 – 1.64 (m, 
8H), 1.39 – 1.31 (m, 3H), 1.18 – 1.09 (m, 3H), 0.94 – 0.86 (m, 2H), 0.77 – 0.69 (m, 1H). 13C 
NMR (151 MHz, CDCl3) δ 173.63, 173.50, 171.12, 153.36, 137.11, 133.46, 105.24, 60.77, 
60.37, 56.22, 55.03, 53.94, 52.60, 43.89, 41.06, 32.63, 30.47, 26.47, 26.07, 26.02, 25.61, 
25.30, 24.73, 20.42, 14.18, 9.79. 
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(S)-N-(1-amino-2-methyl-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (12) 
The general procedure was used with Fmoc-Aib-OH and 12 was obtained after purification by 
flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
pale white oil (29 mg, 58 µmol, 72.5 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.1 min. HRMS: calculated 504.3074 
[C27H41N3O6+H]+, found 504.3108 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.59 (s, 1H), 
6.51 (s, 2H), 4.86 – 4.76 (m, 1H), 3.95 (d, J = 13.5 Hz, 1H), 3.68 – 3.60 (m, 7H), 3.60 – 3.51 
(m, 4H), 2.86 (td, J = 14.3, 13.8, 2.9 Hz, 1H), 1.96 – 1.83 (m, 2H), 1.71 – 1.61 (m, 2H), 1.57 
– 1.46 (m, 4H), 1.35 – 1.25 (m, 2H), 1.13 (d, J = 3.7 Hz, 6H), 1.09 – 0.96 (m, 4H), 0.85 – 
0.70 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ 176.37, 172.96, 170.58, 152.91, 136.31, 
134.11, 105.97, 60.21, 56.13, 55.93, 53.68, 52.78, 43.13, 32.36, 30.18, 26.53, 26.03, 25.43, 
24.88, 24.51, 20.18. 
(S)-N-(4-amino-2-methyl-4-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (13) 
The general procedure was used with Fmoc-3-amino-3-methyl-butyric acid and 13 was 
obtained as colorless oil (34 mg, 66 µmol, 82.5 %). 
HPLC [0-100% Solvent B, 15 min]: Rt = 14.6 min. HRMS: calculated 518.3230 
[C28H43N3O6+H]+, found 518.3264 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 6.52 (s, 2H), 5.99 
(sbr, 1H), 5.70 (s, 2H), 5.14 (d, J = 4.1 Hz, 1H), 4.05 (d, J = 14.0 Hz, 1H), 3.90 – 3.73 (m, 
9H), 3.39 (d, J = 10.2 Hz, 1H), 2.97 – 2.86 (m, 1H), 2.66 – 2.48 (m, 2H), 2.30 – 2.10 (m, 2H), 
1.84 (d, J = 13.2 Hz, 1H), 1.70 – 1.57 (m, 4H), 1.51 – 1.41 (m, 3H), 1.31 – 1.22 (m, 2H), 1.17 
– 1.12 (m, 3H), 1.06 – 1.00 (m, 6H), 0.93 – 0.86 (m, 1H), 0.79 – 0.67 (m, 1H). 13C NMR (75 
MHz, CDCl3) δ 173.45, 173.23, 170.88, 153.35, 137.14, 133.68, 105.32, 60.73, 56.24, 54.92, 
52.75, 52.22, 44.74, 43.68, 40.97, 32.61, 30.44, 27.57, 27.52, 26.46, 26.04, 25.97, 25.72, 
25.11, 20.51, 17.67, 12.27. 
(S)-N-((S)-1-amino-3-methyl-1-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (14a) 
The general procedure was used with Fmoc-Val-OH and 14a was obtained after purification 
by flash chromatography (50% - 100% [EtOAc + 0.1% TEA] in cyclohexane) as white 
crystals (24 mg, 46 µmol, 28.8 %).  
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HPLC [0-100% Solvent B, 20 min]: Rt = 15.1 min. HRMS: calculated 518.3230 
[C28H43N3O6+H]+, found 518.3264 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 6.54 (s, 2H), 6.17 
(d, J = 8.9 Hz, 1H), 5.23 – 5.18 (m, 1H), 4.10 – 4.07 (m, 2H), 3.83 (s, 6H), 3.78 (s, 3H), 3.37 
(s, 1H), 2.87 – 2.79 (m, 1H), 2.34 – 2.27 (m, 1H), 2.14 (qt, J = 11.0, 3.4 Hz, 2H), 1.93 – 1.88 
(m, 1H), 1.85 – 1.81 (m, 1H), 1.73 – 1.67 (m, 3H), 1.66 – 1.59 (m, 2H), 1.55 – 1.47 (m, 2H), 
1.36 – 1.25 (m, 2H), 1.19 – 1.09 (m, 3H), 0.97 (dd, J = 29.5, 6.8 Hz, 1H), 0.91 – 0.84 (m, 
1H), 0.77 – 0.69 (m, 1H), 0.62 (d, J = 6.8 Hz, 3H), 0.35 (d, J = 6.8 Hz, 3H). 13C NMR (151 
MHz, CDCl3) δ 173.81, 172.93, 171.06, 153.46, 137.12, 133.32, 105.18, 60.67, 57.82, 56.18, 
55.18, 52.73, 43.84, 41.51, 32.54, 30.43, 29.26, 26.44, 26.01, 25.95, 25.63, 24.91, 20.46, 
19.16, 16.71. 
(S)-N-((R)-1-amino-3-methyl-1-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (14b) 
The general procedure was used with Fmoc-D-Val-OH and 14b was obtained after 
purification by flash chromatography (50% - 100% [EtOAc + 0.1% TEA] in cyclohexane) as 
colourless solid (31 mg, 63 µmol, 39.4 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.6 min. HRMS: calculated 518.3230 
[C28H43N3O6+H]+, found 518.3254 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.58 (s, 2H), 
5.07 – 5.02 (m, 1H), 4.95 (d, J = 5.1 Hz, 1H), 4.10 (d, J = 13.9 Hz, 1H), 4.02 – 3.98 (m, 1H), 
3.69 (s, 6H), 3.58 (s, 3H), 2.87 – 2.80 (m, 1H), 2.08 – 2.02 (m, 1H), 1.88 – 1.79 (m, 2H), 1.73 
– 1.61 (m, 3H), 1.58 – 1.48 (m, 6H), 1.07 – 1.00 (m, 3H), 0.90 – 0.86 (m, 3H), 0.83 (dd, J = 
6.7, 3.6 Hz, 3H), 0.72 (d, J = 6.8 Hz, 3H), 0.59 (d, J = 6.8 Hz, 3H). 13C NMR (101 MHz, 
DMSO-d6) δ 173.07, 172.83, 171.00, 152.98, 136.65, 136.44, 135.02, 134.27, 106.00, 60.41, 
60.23, 57.12, 56.42, 56.13, 53.39, 52.50, 46.55, 43.29, 41.23, 35.51, 32.29, 32.22, 31.33, 
30.43, 30.24, 27.46, 26.56, 26.50, 26.09, 26.03, 25.65, 20.50, 19.84, 19.69, 18.17, 17.51, 
14.51. 
(S)-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (15) 
The general procedure was used with Fmoc-Leu-OH and 15 was obtained after purification by 
flash chromatography (0% - 80% [EtOAc + 2 % MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (8 mg, 15 µmol, 18.8 %). 
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HPLC [0-100% Solvent B, 20 min]: Rt = 18.8 min. HRMS: calculated 532.3387 
[C29H45N3O6+H]+, found 532.3215 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 6.53 (s, 2H), 6.26 
(s, 1H), 5.84 (d, J = 8.4 Hz, 1H), 5.34 (s, 1H), 5.22 – 5.17 (m, 1H), 4.26 (ddd, J = 10.1, 8.4, 
4.9 Hz, 1H), 4.10 – 4.04 (m, 1H), 3.87 – 3.77 (m, 9H), 3.37 (d, J = 10.2 Hz, 1H), 2.83 – 2.71 
(m, 1H), 2.40 – 2.32 (m, 1H), 2.13 (qt, J = 10.9, 3.8 Hz, 1H), 1.76 – 1.61 (m, 6H), 1.60 – 1.48 
(m, 4H), 1.37 – 1.29 (m, 1H), 1.18 – 1.06 (m, 3H), 0.99 – 0.85 (m, 3H), 0.78 – 0.71 (m, 1H), 
0.70 (d, J = 6.6 Hz, 3H), 0.66 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 173.89, 
173.74, 170.91, 153.51, 137.21, 133.22, 104.98, 60.81, 56.20, 55.30, 52.85, 51.07, 43.83, 
41.43, 39.60, 32.66, 30.41, 26.45, 26.04, 25.97, 25.49, 24.93, 24.85, 22.73, 21.21, 20.49. 
(S)-N-((2S,3S)-1-amino-3-methyl-1-oxopentan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (16a) 
The general procedure was used with Fmoc-Ile-OH and 16a was obtained after purification by 
flash chromatography (0% - 80% [EtOAc + 2 % MeOH + 0.1% TEA] in cyclohexane) 
obtained as colourless oil (13 mg, 25 µmol, 31.3 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.3 min. HRMS: calculated 532.3387 
[C29H45N3O6+H]+, found 532.3417 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 6.55 (s, 2H), 6.17 
(d, J = 8.9 Hz, 1H), 6.08 (s, 1H), 5.51 (s, 1H), 5.21 (d, J = 5.1 Hz, 1H), 4.16 (dd, J = 8.9, 6.0 
Hz, 1H), 4.10 – 4.04 (m, 1H), 3.85 (s, 9H), 3.36 (d, J = 10.2 Hz, 1H), 2.90 – 2.77 (m, 1H), 
2.35 – 2.29 (m, 1H), 2.13 (qt, J = 11.0, 3.5 Hz, 1H), 1.86 – 1.79 (m, 1H), 1.76 – 1.59 (m, 6H), 
1.56 – 1.47 (m, 2H), 1.38 – 1.30 (m, 1H), 1.29 – 1.22 (m, 1H), 1.19 – 1.07 (m, 2H), 1.02 – 
0.95 (m, 1H), 0.95 – 0.85 (m, 2H), 0.78 – 0.70 (m, 1H), 0.68 – 0.56 (m, 6H), 0.48 – 0.41 (m, 
1H). 13C NMR (151 MHz, CDCl3) δ 173.86, 172.97, 170.94, 153.40, 153.31, 137.13, 133.32, 
105.12, 60.72, 57.07, 56.17, 55.14, 52.81, 43.86, 41.69, 35.64, 32.56, 30.47, 26.45, 26.02, 
25.97, 25.63, 24.99, 24.00, 20.51, 15.45, 10.86. 
(S)-N-((2R,3R)-1-amino-3-methyl-1-oxopentan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (16b) 
The general procedure was used with Fmoc-D-Ile-OH and 16b was obtained after purification 
by flash chromatography (0% - 80% [EtOAc + 2 % MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (26 mg, 49 µmol, 61.3 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.0 min. HRMS: calculated 532.3387 
[C29H45N3O6+H]+, found 532.3411 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.45 (s, 2H), 6.13 
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(d, J = 8.8 Hz, 1H), 5.70 (s, 1H), 5.39 (s, 1H), 5.14 – 5.08 (m, 1H), 4.24 (dd, J = 8.7, 4.4 Hz, 
1H), 3.99 (d, J = 13.2 Hz, 1H), 3.73 (d, J = 12.1 Hz, 9H), 3.34 (d, J = 10.2 Hz, 1H), 2.97 
(ddd, J = 13.8, 12.3, 2.7 Hz, 1H), 2.24 – 2.15 (m, 1H), 2.07 (qt, J = 11.0, 3.4 Hz, 1H), 1.80 – 
1.70 (m, 2H), 1.65 – 1.54 (m, 5H), 1.48 – 1.36 (m, 2H), 1.30 – 1.21 (m, 2H), 1.19 – 1.12 (m, 
2H), 1.10 – 0.97 (m, 3H), 0.90 – 0.82 (m, 1H), 0.78 (t, J = 7.4 Hz, 3H), 0.72 – 0.62 (m, 1H), 
0.54 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.97, 173.65, 171.20, 153.32, 
137.10, 133.48, 105.36, 60.78, 56.19, 55.84, 54.97, 52.81, 43.95, 41.32, 36.45, 32.58, 30.50, 
26.46, 26.40, 26.06, 26.03, 25.62, 25.35, 20.40, 14.00, 11.60. 
(S)-N-((S)-2-amino-1-cyclohexyl-2-oxoethyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (17) 
The general procedure was used with Fmoc-Chg-OH and 17 was obtained after purification 
by flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (22 mg, 39 µmol, 48.8 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.7 min. HRMS: calculated 558.3543 
[C31H47N3O6+H]+, found 558.3574 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 6.62 (s, 2H), 
6.57 (s, 1H), 5.04 (d, J = 4.1 Hz, 1H), 4.19 – 4.10 (m, 1H), 4.02 (dd, J = 8.8, 5.6 Hz, 1H), 3.69 
– 3.64 (m, 6H), 3.55 – 3.52 (m, 3H), 2.72 – 2.60 (m, 1H), 2.45 – 2.40 (m, 3H), 2.00 (d, J = 
12.6 Hz, 1H), 1.94 – 1.82 (m, 2H), 1.66 – 1.57 (m, 4H), 1.53 – 1.41 (m, 5H), 1.39 – 1.25 (m, 
5H), 1.13 – 0.90 (m, 8H), 0.79 – 0.60 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ 172.79, 
172.53, 170.15, 153.02, 136.33, 134.11, 105.56, 60.36, 60.04, 56.31, 56.08, 55.94, 53.33, 
51.74, 46.04, 43.45, 41.58, 32.23, 30.10, 29.78, 27.29, 26.50, 26.08, 25.93, 25.87, 25.60, 
20.74. 
(S)-N-((S)-2-amino-2-oxo-1-phenylethyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (18a) 
The general procedure was used with Fmoc-Phg-OH and 18a was obtained as pale yellow oil 
(38 mg, 69 µmol, 86.3 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.6 min. HRMS: calculated 552.3074 
[C31H41N3O6+H]+, found 552.3057 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.35 – 7.24 
(m, 5H), 6.60 (s, 2H), 5.83 (s, 1H), 5.62 (s, 2H), 5.24 (t, J = 3.3 Hz, 1H), 3.74 – 3.70 (m, 
10H), 3.45 – 3.41 (m, 1H), 2.97 (dt, J = 12.3, 5.3 Hz, 1H), 2.41 – 2.32 (m, 1H), 2.12 – 2.02 
(m, 1H), 1.92 – 1.65 (m, 5H), 1.62 – 1.39 (m, 7H), 1.32 – 1.22 (m, 2H). 13C NMR (101 MHz, 
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DMSO-d6) δ 176.49, 172.83, 172.02, 155.39, 138.52, 137.39, 130.48, 128.88, 128.38, 127.05, 
108.27, 60.70, 57.77, 57.51, 57.41, 56.83, 43.29, 41.29, 32.44, 26.81, 26.27, 26.02, 25.47, 
22.24. 
(S)-N-((R)-2-amino-2-oxo-1-phenylethyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (18b) 
The general procedure was used with Fmoc-D-Phg-OH and 18b was obtained after 
purification by flash chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in 
cyclohexane) as pale yellow oil (24 mg, 43 µmol, 53.2%). 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.8 min. HRMS: calculated 552.3074 
[C31H41N3O6+H]+, found 552.3065 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.33 (m, 
2H), 7.34 – 7.29 (m, 2H), 7.16 – 7.06 (m, 2H), 6.83 – 6.76 (m, 1H), 6.62 (s, 1H), 6.54 (s, 1H), 
5.88 (sbr, 1H), 5.78 – 5.75 (m, 2H), 5.34 – 5.30 (m, 1H), 5.29 – 5.24 (m, 1H), 3.84 – 3.77 (m, 
9H), 3.39 (dd, J = 32.2, 10.1 Hz, 1H), 2.57 – 2.44 (m, 1H), 2.31 – 2.10 (m, 3H), 1.95 – 1.83 
(m, 1H), 1.75 – 1.56 (m, 7H), 1.22 – 1.10 (m, 3H), 0.98 – 0.86 (m, 1H), 0.83 – 0.69 (m, 1H). 
13C NMR (101 MHz, CDCl3) δ 173.32, 171.74, 170.38, 153.35, 153.23, 138.16, 137.12, 
133.73, 29.11, 128.89, 127.01, 126.61, 105.19, 60.81, 60.40, 56.91, 56.74, 55.36, 52.68, 
43.57, 41.56, 32.74, 26.53, 25.67, 25.38, 21.06, 20.35. 
(S)-N-((S)-1-amino-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (19a) 
The general procedure was used with Fmoc-Phe-OH and 19a was obtained after purification 
by flash chromatography (EtOAc + 0.1% TEA) as colourless solid (15 mg, 23 µmol, 28.8 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 19.1 min. HRMS: calculated 566.3230 
[C32H43N3O6 +H]+, found 566.3253 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 8.29 (s, 1H), 
7.21 – 7.16 (m, 1H), 7.15 – 7.12 (m, 4H), 6.60 (s, 2H), 6.45 (s, 2H), 5.08 (t, J = 7.3 Hz, 1H), 
5.01 (t, J = 3.2 Hz, 1H), 3.78 – 3.67 (m, 10H), 3.56 (dd, J = 12.4, 7.2 Hz, 1H), 3.39 (d, J = 1.8 
Hz, 1H), 3.02 (dd, J = 12.4, 7.3 Hz, 1H), 2.88 (dt, J = 12.5, 5.3 Hz, 1H), 2.61 – 2.50 (m, 1H), 
2.29 – 2.18 (m, 1H), 1.90 – 1.78 (m, 1H), 1.73 – 1.59 (m, 4H), 1.55 – 1.40 (m, 8H), 1.35 – 
1.20 (m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 173.39, 172.96, 170.95, 153.11, 152.90, 
138.43, 138.20, 136.67, 136.40, 134.95, 134.23, 129.67, 129.44, 128.38, 128.33, 126.54, 
106.14, 105.97, 60.44, 60.27, 56.43, 56.16, 53.75, 52.56, 41.23, 37.92, 30.27, 26.54, 26.11, 
20.03. 
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(S)-N-((R)-1-amino-1-oxo-3-phenylpropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (19b) 
The general procedure was used with Fmoc-D-Phe-OH and 19b was obtained after 
purification by flash chromatography (50% [EtOAc + 0.1% TEA] - 100% [EtOAc + 
1% TEA] in hexane) as white solid (19 mg, 34 µmol, 21.3 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 19.4 min. HRMS: calculated 566.3230 
[C32H43N3O6 +H]+, found 566.3248 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.29 (s, 1H), 
7.21 – 7.12 (m, 3H), 7.10 – 7.04 (m, 1H), 6.55 (s, 1H), 6.51 (s, 2H), 4.91 – 4.81 (m, 1H), 4.67 
(d, J = 4.8 Hz, 1H), 4.35 – 4.26 (m, 1H), 3.92 (d, J = 13.4 Hz, 1H), 3.72 – 3.62 (m, 7H), 3.61 
– 3.51 (m, 3H), 3.30 – 3.24 (m, 3H), 2.98 – 2.84 (m, 2H), 1.92 – 1.83 (m, 1H), 1.77 – 1.67 (m, 
2H), 1.62 – 1.52 (m, 3H), 1.45 (d, J = 12.9 Hz, 1H), 1.32 – 1.21 (m, 2H), 1.12 – 0.98 (m, 4H), 
0.92 – 0.83 (m, 2H), 0.78 – 0.60 (m, 1H). 13C NMR (101 MHz, DMSO-d6) δ 173.39, 172.96, 
170.95, 153.11, 152.90, 138.43, 138.20, 136.67, 136.40, 134.95, 134.23, 129.67, 129.44, 
128.38, 128.33, 126.54, 106.14, 105.97, 60.44, 60.27, 56.43, 56.16, 53.75, 52.56, 41.23, 
37.92, 30.27, 26.54, 26.11, 20.03. 
(S)-N-((S)-1-amino-3-cyclohexyl-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (20) 
The general procedure was used with Fmoc-Cha-OH and 20 was obtained after purification 
by flash chromatography (50% - 100% [EtOAc + 0.1% TEA] in cyclohexane) as white solid 
(19 mg, 34 µmol, 21.3 %). 
HPLC [30-100% Solvent B, 10 min]: Rt = 18.5 min. HRMS: calculated 572.3700 
[C32H49N3O6+H]+, found 572.3736 [M+H]+. 1H NMR (400 MHz, DMSO- d6) δ 7.00 (s, 1H), 
6.64 (s, 2H), 6.57 (s, 2H), 5.09 – 5.06 (m, 2H), 4.74 (d, J = 4.6 Hz, 1H), 4.39 – 4.29 (m, 2H), 
4.23 – 4.12 (m, 2H), 3.72 (s, 3H), 3.70 (s, 6H), 2.71 (t, J = 12.3 Hz, 2H), 2.08 (d, J = 10.3 Hz, 
1H), 1.99 – 1.90 (m, 2H), 1.65 – 1.51 (m, 9H), 1.44 – 1.34 (m, 4H), 1.22 – 1.15 (m, 4H), 0.85 
– 0.76 (m, 3H), 0.67 – 0.58 (m, 3H). 13C NMR (101 MHz, DMSO-d6) δ 174.17, 172.78, 
170.20, 153.10, 136.32, 134.23, 105.51, 60.14, 55.97, 55.48, 54.11, 53.48, 51.77, 50.48, 
49.67, 43.39, 41.46, 34.06, 33.52, 32.28, 32.22, 31.78, 30.15, 26.39, 26.29, 26.12, 26.05, 
20.79, 19.67, 18.28, 12.51, 10.09. 
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(S)-N-((S)-1-amino-1-oxo-4-phenylbutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (21) 
The general procedure was used with Fmoc-Homophe-OH and 21 was obtained after 
purification by flash chromatography (40% - 100% [EtOAc + 2 % MeOH + 0.1% TEA] in 
cyclohexane) as white solid (34 mg, 58 µmol, 72.5 %). 
HPLC [0-100% Solvent B, 10 min]: Rt = 19.2 min. HRMS: calculated 580.3387 
[C33H45N3O6+H]+, found 580.3434 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.23 – 7.12 
(m, 2H), 6.98 – 6.80 (m, 3H), 6.63 (s, 2H), 5.06 (s, 1H), 4.37 (s, 1H), 4.24 – 4.01 (m, 2H), 
3.64 – 3.48 (m, 3H), 3.06 – 2.93 (m, 9H), 2.93 – 2.82 (m, 1H), 2.42 – 2.16 (m, 2H), 2.05 – 
1.90 (m, 3H), 1.74 (d, J = 12.6 Hz, 2H), 1.58 – 1.44 (m, 5H), 1.23 – 1.04 (m, 5H), 0.90 – 0.71 
(m, 2H). 13C NMR (101 MHz, DMSO-d6) δ 173.39, 172.96, 170.95, 153.11, 152.90, 138.43, 
138.20, 136.67, 136.40, 134.95, 134.23, 129.67, 129.44, 128.38, 128.33, 126.54, 106.14, 
105.97, 60.44, 60.27, 56.43, 56.16, 53.75, 52.56, 41.23, 37.92, 30.27, 26.54, 26.11, 20.03. 
(S)-N-((S)-1-amino-4-cyclohexyl-1-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (22) 
The general procedure was used with Fmoc-L-HomoCha-OH and 22 was obtained after 
purification by flash chromatography (0% - 80% [EtOAc + 2% MeOH + 0.1% TEA] in 
cyclohexane) as pale white oil (37 mg, 63 µmol, 78.8 %). 
HPLC [0-100% Solvent B, 10 min]: Rt = 19.2 min. HRMS: calculated 586.3856 
[C33H51N3O6+H]+, found 586.3893 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.44 (s, 2H), 6.14 
(sbr, 1H), 5.90 (d, J = 8.3 Hz, 1H), 5.49 (sbr, 1H), 5.19 – 5.09 (m, 1H), 4.15 – 4.07 (m, 1H), 
3.94 (d, J = 6.5 Hz, 1H), 3.79 – 3.67 (m, 12H), 3.28 (d, J = 10.1 Hz, 1H), 2.77 – 2.65 (m, 1H), 
2.32 – 2.23 (m, 1H), 2.09 – 2.01 (m, 1H), 1.82 – 1.74 (m, 1H), 1.69 – 1.44 (m, 12H), 1.11 – 
0.98 (m, 6H), 0.94 – 0.81 (m, 3H), 0.74 – 0.66 (m, 3H), 0.63 – 0.52 (m, 2H). 13C NMR (101 
MHz, CDCl3) δ 173.68, 173.61, 170.92, 153.49, 137.18, 133.19, 104.93, 60.74, 60.38, 56.14, 
55.36, 52.78, 52.53, 43.79, 41.49, 36.36, 33.26, 32.94, 32.90, 32.74, 30.45, 28.40, 26.91, 
26.48, 26.47, 26.21, 26.15, 26.07, 26.01, 25.58, 24.96, 21.04, 20.53, 14.19. 
(S)-N-((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (23a) 
The general procedure was used with Fmoc-L-Ser(OTrt)-OH and 23a was obtained  as pale 
yellow oil (32 mg, 63 µmol, 78.8 %). 
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HPLC [0-100% Solvent B, 20 min]: Rt = 15.8 min. HRMS: calculated 506.2866 
[C26H39N3O7+H]+, found 506.2865 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 6.49 (s, 2H), 6.03 
(s, 1H), 5.18 – 5.10 (m, 2H), 4.35 – 4.25 (m, 2H), 3.99 (d, J = 13.6 Hz, 2H), 3.82 (s, 6H), 3.79 
(s, 3H), 3.70 (dd, J = 11.3, 3.9 Hz, 2H), 3.37 – 3.24 (m, 6H), 2.96 – 2.87 (m, 2H), 2.27 – 2.20 
(m, 1H), 2.14 – 2.08 (m, 1H), 1.61 – 1.50 (m, 3H), 1.17 – 1.09 (m, 3H), 0.95 – 0.86 (m, 2H), 
0.74 – 0.68 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 173.75, 173.27, 171.70, 153.28, 143.86, 
137.02, 133.32, 129.40, 128.25, 126.24, 105.49, 61.78, 60.79, 56.27, 55.32, 53.00, 45.65, 
43.75, 41.14, 32.64, 30.45, 26.45, 26.04, 25.35, 20.27, 17.67. 
(S)-N-((R)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (23b) 
The general procedure was used with Fmoc-D-Ser(OTrt)-OH and 23b was obtained obtained 
after purification by flash chromatography (0% - 100% [EtOAc + 5% MeOH] in 
cyclohexane) as colourless oil (7 mg, 14 µmol, 17.3 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.9 min. HRMS: calculated 506.2866 
[C26H39N3O7+H]+, found 506.2881 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 6.71 (d, J = 8.0 
Hz, 1H), 6.47 (s, 2H), 6.44 (sbr, 1H), 5.43 (sbr, 1H), 5.08 (t, J = 4.3 Hz, 1H), 4.38 – 4.30 (m, 
1H), 4.01 – 3.94 (m, 2H), 3.82 (d, J = 12.4 Hz, 9H), 3.53 (dd, J = 11.3, 4.8 Hz, 1H), 3.37 (d, J 
= 10.0 Hz, 1H), 3.02 (td, J = 13.7, 13.0, 2.9 Hz, 1H), 2.23 – 2.15 (m, 2H), 2.11 (ddt, J = 10.8, 
6.8, 3.3 Hz, 1H), 1.84 (d, J = 12.6 Hz, 1H), 1.72 – 1.61 (m, 5H), 1.33 – 1.27 (m, 3H), 1.18 – 
1.10 (m, 2H), 0.93 – 0.84 (m, 2H), 0.79 – 0.70 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 
173.92, 172.88, 171.73, 153.28, 137.11, 133.17, 105.52, 62.13, 60.82, 56.31, 55.37, 53.68, 
53.23, 43.88, 41.16, 32.76, 30.51, 29.67, 26.47, 26.09, 25.48, 25.33, 20.22. 
(S)-N-((S)-1-amino-4-hydroxy-1-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (24a) 
The general procedure was used with Fmoc-L-Homoser(Trt)-OH and 24a was obtained after 
purification by flash chromatography (40% - 100% [EtOAc + 2 % MeOH + 0.1% TEA] in 
cyclohexane) as colourless oil (25 mg, 39 µmol, 48.8 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.8 min. HRMS: calculated 503.2995 
[C27H40N3O6+H]+, found 503.2771 [M-O]+. 1H NMR (400 MHz, DMSO-d6) δ 6.64 (s, 1H), 
6.60 (s, 2H), 5.09 – 5.04 (m, 1H), 4.80 (d, J = 5.1 Hz, 1H), 4.31 – 4.27 (m, 1H), 4.23 – 4.13 
(m, 2H), 4.08 – 3.97 (m, 2H), 3.72 – 3.71 (m, 6H), 3.63 – 3.62 (m, 3H), 3.10 – 2.99 (m, 1H), 
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2.76 – 2.68 (m, 1H), 2.36 – 2.26 (m, 2H), 2.09 – 2.00 (m, 2H), 1.95 – 1.88 (m, 1H), 1.84 – 
1.67 (m, 2H), 1.62 – 1.54 (m, 4H), 1.51 – 1.43 (m, 2H), 1.42 – 1.32 (m, 3H), 1.14 – 1.01 (m, 
3H). 13C NMR (101 MHz, DMSO-d6) δ 175.63, 175.61, 172.62, 171.11, 152.89, 148.19, 
136.37, 134.45, 128.78, 128.19, 127.95, 106.18, 65.62, 60.33, 56.38, 56.17, 52.02, 48.17, 
43.30, 41.57, 32.38, 30.32, 28.51, 28.30, 27.93, 27.00, 26.56, 26.11, 25.72, 24.53, 20.54, 
18.29.  
(S)-N-((R)-1-amino-4-hydroxy-1-oxobutan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (24b) 
The general procedure was used with Fmoc-L-Homoser(Trt)-OH and 24b was obtained as 
colourless oil (4 mg, 8 µmol, 10.0 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.9 min. HRMS: calculated 503.2995 
[C27H40N3O6+H]+, found 503.2774 [M-O]+. 1H NMR (400 MHz, DMSO-d6) δ 6.64 (s, 1H), 
6.60 (s, 2H), 5.09 – 5.04 (m, 1H), 4.80 (d, J = 5.1 Hz, 1H), 4.31 – 4.27 (m, 1H), 4.23 – 4.13 
(m, 2H), 4.08 – 3.97 (m, 2H), 3.72 – 3.71 (m, 6H), 3.63 – 3.62 (m, 3H), 3.10 – 2.99 (m, 1H), 
2.76 – 2.68 (m, 1H), 2.36 – 2.26 (m, 2H), 2.09 – 2.00 (m, 2H), 1.95 – 1.88 (m, 1H), 1.84 – 
1.67 (m, 2H), 1.62 – 1.54 (m, 4H), 1.51 – 1.43 (m, 2H), 1.42 – 1.32 (m, 3H), 1.14 – 1.01 (m, 
3H). 13C NMR (101 MHz, DMSO-d6) δ 175.63, 175.61, 172.62, 171.11, 152.89, 148.19, 
136.37, 134.45, 128.78, 128.19, 127.95, 106.18, 65.62, 60.33, 56.38, 56.17, 52.02, 48.17, 
43.30, 41.57, 32.38, 30.32, 28.51, 28.30, 27.93, 27.00, 26.56, 26.11, 25.72, 24.53, 20.54, 
18.29.  
(S)-2-((S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-
carboxamido)pentanediamide (25a) 
The general procedure was used with Fmoc-Gln-OH and 25a was obtained as colorless oil (25 
mg, 46 µmol, 57.5 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.1 min. HRMS: calculated 547.3132 
[C28H42N4O7+H]+, found 547.3187 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 6.77 (sbr, 1H), 
6.70 (d, J = 7.7 Hz, 1H), 6.54 (sbr, 2H), 6.14 (sbr, 1H), 5.76 (sbr, 1H), 5.52 (sbr, 1H), 5.17 – 
5.07 (m, 1H), 4.42 – 4.30 (m, 1H), 4.00 (d, J = 14.2 Hz, 1H), 3.81 (dd, J = 14.3, 0.8 Hz, 9H), 
3.38 (d, J = 10.1 Hz, 1H), 2.94 (t, J = 12.9 Hz, 1H), 2.24 – 1.99 (m, 3H), 1.96 – 1.77 (m, 3H), 
1.73 – 1.52 (m, 6H), 1.38 – 1.22 (m, 3H), 1.18 – 1.08 (m, 2H), 1.00 – 0.85 (m, 2H), 0.78 – 
0.56 (m, 2H). 
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13C NMR (75 MHz, CDCl3) δ 174.79, 173.56, 173.10, 171.24, 153.23, 136.70, 133.79, 
105.45, 60.81, 56.24, 55.21, 52.92, 51.63, 43.72, 41.35, 32.59, 30.76, 30.51, 27.96, 26.46, 
26.07, 26.00, 25.38, 20.27. 
(R)-2-((S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-
carboxamido)pentanediamide (25b) 
The general procedure was used with Fmoc-D-Gln-OH and 25b was obtained as colorless oil 
(28 mg, 51 µmol, 64.4 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.8 min. HRMS: calculated 547.3132 
[C28H42N4O7+H]+, found 547.3196 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 6.79 (sbr, 1H), 
6.51 (s, 2H), 6.35 (sbr, 1H), 5.85 (sbr, 1H), 5.72 (sbr, 1H), 5.16 – 5.08 (m, 1H), 4.38 – 4.28 (m, 
1H), 4.02 (d, J = 13.7 Hz, 1H), 3.86 – 3.74 (m, 9H), 3.44 (d, J = 10.0 Hz, 1H), 3.20 – 3.06 (m, 
2H), 2.56 – 2.41 (m, 2H), 2.28 – 2.19 (m, 1H), 2.16 – 2.06 (m, 3H), 1.83 (d, J = 11.8 Hz, 1H), 
1.73 – 1.54 (m, 4H), 1.39 – 1.27 (m, 3H), 1.18 – 1.09 (m, 2H), 0.97 – 0.84 (m, 3H), 0.82 – 
0.69 (m, 2H). 13C NMR (75 MHz, CDCl3) δ 175.02, 173.79, 173.24, 171.24, 153.22, 136.92, 
133.60, 105.53, 60.78, 56.24, 54.98, 53.24, 40.97, 32.62, 30.54, 27.97, 26.89, 26.46, 26.07, 
25.44, 20.34, 17.68, 12.28. 
(S)-N-((S)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (26a) 
The general procedure was used with Fmoc-His(Trt)-OH. The trityl protection group was 
cleaved with 1% TFA and 1%TIS in DCM at RT for 5 h. The crude product was loaded on 
silica and purified by flash chromatography (50% [EtOAc + 2% MeOH + 0.1% TEA] -100% 
[EtOAc + 10% MeOH + 0.1% TEA] in cyclohexane) to obtain 26b as colourless oil (20 mg, 
36 µmol, 45.0 %).  
HPLC [0-100% Solvent B, 20 min]: Rt = 13.2 min. HRMS: calculated 556.3135 
[C29H41N5O6 +H]+, found 556.3229 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 7.30 (sbr, 1H), 
7.06 (d, J = 8.4 Hz, 1H), 6.57 (s, 2H), 6.33 (s, 1H), 6.18 (sbr, 1H), 5.10 – 5.04 (m, 1H), 4.71 – 
4.64 (m, 1H), 4.02 – 3.93 (m, 1H), 3.79 (d, J = 57.4 Hz, 9H), 3.41 (d, J = 10.0 Hz, 1H), 2.98 
(dd, J = 15.1, 4.9 Hz, 1H), 2.75 – 2.66 (m, 1H), 2.54 – 2.46 (m, 1H), 2.17 – 2.08 (m, 1H), 
2.03 (d, J = 12.8 Hz, 1H), 1.82 (d, J = 12.1 Hz, 1H), 1.74 – 1.59 (m, 4H), 1.59 – 1.52 (m, 2H), 
1.48 – 1.41 (m, 2H), 1.34 – 1.25 (m, 3H), 1.15 (q, J = 12.7 Hz, 2H), 0.95 – 0.86 (m, 1H), 0.82 
– 0.73 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 173.85, 172.04, 171.54, 153.30, 136.71, 
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133.81, 133.30, 129.38, 116.83, 105.45, 60.78, 56.21, 55.11, 52.62, 51.50, 43.74, 41.19, 
40.92, 32.50, 30.46, 28.08, 26.41, 26.03, 25.98, 25.12, 25.05, 19.94. 
(S)-N-((R)-1-amino-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (26b) 
The general procedure was used with Fmoc-D-His(Trt)-OH. The trityl protection group was 
cleaved with 1% TFA and 1%TIS in DCM at RT for 5 h. The crude product was loaded on 
silica and purified by flash chromatography (50% [EtOAc + 2% MeOH + 0.1% TEA] -100% 
[EtOAc + 10% MeOH + 0.1% TEA] in cyclohexane) to obtain 26a as colourless oil (13 mg, 
23 µmol, 28.8 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 13.7 min. HRMS: calculated 556.3135 
[C29H41N5O6 +H]+, found 556.3217 [M+H]+. 1H NMR (599 MHz, CDCl3) δ 7.61 (s, 1H), 
7.10 – 7.01 (m, 2H), 6.77 – 6.70 (m, 1H), 6.47 (s, 2H), 5.61 (s, 1H), 5.02 – 4.95 (m, 1H), 4.59 
– 4.52 (m, 1H), 3.99 – 3.92 (m, 0H), 3.84 – 3.72 (m, 9H), 3.66 – 3.60 (m, 1H), 3.43 (d, J = 
10.0 Hz, 1H), 3.23 – 3.12 (m, 1H), 2.94 – 2.81 (m, 2H), 2.18 – 2.03 (m, 2H), 1.80 (d, J = 12.4 
Hz, 1H), 1.70 – 1.58 (m, 5H), 1.48 (tdd, J = 13.0, 8.2, 4.6 Hz, 2H), 1.34 – 1.28 (m, 3H), 1.17 
– 1.07 (m, 2H), 0.98 – 0.86 (m, 1H), 0.79 – 0.70 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 
174.15, 173.14, 171.19, 153.17, 136.88, 134.53, 133.44, 105.60, 60.80, 56.28, 56.20, 55.14, 
53.82, 52.48, 44.01, 41.07, 40.96, 32.67, 30.57, 28.73, 26.44, 26.10, 25.84, 25.19, 20.11. 
(S)-N-(1-carbamoylcyclopropyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (27) 
The general procedure was used with Fmoc-1-amino-cyclopropane carboxylic acid and 27 
was obtained after purification by flash chromatography (0% - 100% [EtOAc + 2 % MeOH + 
0.1% TEA] in cyclohexane) as colourless oil (18 mg, 36 µmol, 45.0 %). HPLC [0-100% 
Solvent B, 20 min]: Rt = 16.8 min. HRMS: calculated 502.2917 [C27H39N3O6 +H]+, found 
502.2950 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.39 (s, 2H), 6.21 (s, 1H), 5.33 (s, 1H), 
4.94 – 4.83 (m, 1H), 3.89 (d, J = 13.8 Hz, 1H), 3.75 (d, J = 5.1 Hz, 9H), 3.30 (d, J = 10.1 Hz, 
1H), 2.70 (ddd, J = 14.5, 11.6, 3.2 Hz, 1H), 2.21 – 2.10 (m, 1H), 2.04 (qt, J = 11.0, 3.3 Hz, 
1H), 1.67 – 1.40 (m, 9H), 1.36 – 1.16 (m, 5H), 1.14 – 0.99 (m, 2H), 0.83 (qd, J = 12.3, 3.3 
Hz, 1H), 0.76 – 0.62 (m, 2H), 0.42 (ddd, J = 10.3, 7.6, 4.5 Hz, 1H). 13C NMR (101 MHz, 
CDCl3) δ 174.08, 173.91, 172.17, 153.63, 137.31, 132.96, 105.12, 60.85, 56.26, 55.62, 53.44, 
43.83, 40.95, 34.33, 32.77, 30.42, 26.46, 26.08, 26.03, 25.05, 24.79, 19.98, 17.37, 16.87. 
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(S)-N-(1-carbamoylcyclobutyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (28) 
The general procedure was used with Fmoc-1-amino-cyclobutane carboxylic acid and 28 was 
obtained after purification by flash chromatography (0% - 100% [EtOAc + 2 % MeOH + 
0.1% TEA] in cyclohexane) as colourless oil (17 mg, 33 µmol, 41.3 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.9 min. HRMS: calculated 516.3074 
[C28H41N3O6+H]+, found 516.3069 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.47 (s, 1H), 6.44 
(s, 2H), 6.11 (s, 1H), 5.13 – 5.03 (m, 2H), 4.02 – 3.96 (m, 1H), 3.76 – 3.67 (m, 9H), 3.33 (d, J 
= 10.2 Hz, 1H), 2.80 (ddd, J = 13.9, 12.3, 2.8 Hz, 1H), 2.54 – 2.42 (m, 2H), 2.21 (dd, J = 
13.5, 3.5 Hz, 1H), 2.13 – 2.03 (m, 1H), 1.83 – 1.70 (m, 2H), 1.69 – 1.52 (m, 8H), 1.52 – 1.39 
(m, 3H), 1.31 – 1.21 (m, 2H), 1.13 – 1.00 (m, 2H), 0.88 – 0.75 (m, 1H), 0.68 (qd, J = 12.0, 3.4 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.20, 173.73, 171.13, 153.55, 137.28, 133.33, 
105.14, 60.76, 59.06, 56.28, 55.27, 52.59, 43.87, 41.10, 32.66, 31.42, 31.02, 30.42, 26.91, 
26.47, 26.06, 26.00, 25.47, 24.84, 20.29, 15.53. 
(S)-N-(1-carbamoylcyclopentyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (29) 
The general procedure was used with Fmoc-1-amino-cyclopentane carboxylic acid and 29 
was obtained as colourless oil (32 mg, 60 µmol, 75.0 %). 
HPLC [0-100% Solvent B, 20 min]: Rt = 18.1 min. HRMS: calculated 530.3230 
[C29H43N3O6+H]+, found 530.3266 [M+H]+. 1H NMR (300 MHz, CDCl3) δ 6.52 (s, 2H), 5.94 
(s, 1H), 5.19 (sbr, 1H), 5.10 – 5.03 (m, 1H), 4.06 (dd, J = 13.2, 4.2 Hz, 1H), 3.88 – 3.73 (m, 
9H), 3.39 (d, J = 10.2 Hz, 1H), 2.95 – 2.82 (m, 1H), 2.26 (d, J = 13.4 Hz, 1H), 2.17 – 1.98 (m, 
3H), 1.88 – 1.75 (m, 2H), 1.74 – 1.44 (m, 10H), 1.41 – 1.24 (m, 4H), 1.23 – 1.06 (m, 3H), 
0.96 – 0.84 (m, 1H), 0.83 – 0.68 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 175.86, 173.91, 
171.21, 153.49, 137.33, 133.37, 105.24, 66.96, 60.73, 56.28, 55.10, 52.98, 43.82, 41.28, 
37.23, 36.25, 32.54, 30.40, 26.42, 26.01, 25.96, 25.44, 24.88, 23.87, 23.67, 20.23. 
(S)-N-(1-carbamoylcyclohexyl)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl) 
acetyl)piperidine-2-carboxamide (30) 
The general procedure was used with Fmoc-1-amino-cyclohexane carboxylic acid and 30 was 
obtained after purification by flash chromatography (0% - 100% [EtOAc + 2% MeOH + 
0.1% TEA] in cyclohexane) as colourless oil (21 mg, 38 µmol, 47.8 %).  
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HPLC [0-100 % Solvent B, 20 min]: Rt = 18.9 min. HRMS: calculated 544.3387 
[C30H45N3O6+H]+, found 544.3438 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.55 (s, 3H), 5.95 
(s, 1H), 5.28 (sbr, 1H), 5.20 – 5.12 (m, 1H), 4.19 – 4.14 (m, 1H), 3.88 – 3.77 (m, 9H), 3.63 
(ddt, J = 24.9, 12.1, 4.0 Hz, 2H), 3.45 (d, J = 10.3 Hz, 1H), 3.24 (td, J = 11.6, 2.6 Hz, 1H), 
3.14 – 2.95 (m, 2H), 2.37 – 2.25 (m, 1H), 2.22 – 2.12 (m, 1H), 2.10 – 2.06 (m, 1H), 2.05 – 
1.96 (m, 2H), 1.86 – 1.73 (m, 4H), 1.73 – 1.63 (m, 4H), 1.62 – 1.55 (m, 2H), 1.55 – 1.41 (m, 
2H), 1.39 – 1.29 (m, 2H), 1.17 (qd, J = 12.3, 2.9 Hz, 2H), 0.93 (qd, J = 12.3, 3.4 Hz, 1H), 0.77 
(qd, J = 12.0, 3.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.06, 174.24, 171.35, 153.51, 
137.37, 133.30, 105.29, 62.96, 62.70, 60.74, 57.22, 56.33, 54.99, 53.23, 44.04, 41.30, 32.79, 
32.51, 31.83, 30.43, 26.43, 26.01, 25.98, 25.45, 24.89, 20.27. 
(S)-N-(1-carbamoylcyclohexyl)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl) 
acetyl)piperidine-2-carboxamide (31) 
The general procedure was used with Fmoc-4-amino-tetrahydropyran-4-carboxylic acid and 
31 was obtained after purification by flash chromatography (0% - 100% [EtOAc + 2% MeOH 
+ 0.1% TEA] in cyclohexane) as colourless oil (19 mg, 35 µmol, 43.5 %).  
HPLC [0-100% Solvent B, 20 min]: Rt = 18.9 min. HRMS: calculated 546.3179 
[C29H44N3O7 +H]+, found 546.3201 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.55 (s, 3H), 
5.95 (s, 1H), 5.28 (s, 1H), 5.20 – 5.12 (m, 1H), 4.19 – 4.14 (m, 1H), 3.88 – 3.77 (m, 9H), 3.63 
(ddt, J = 24.9, 12.1, 4.0 Hz, 2H), 3.45 (d, J = 10.3 Hz, 1H), 3.24 (td, J = 11.6, 2.6 Hz, 1H), 
3.14 – 2.95 (m, 2H), 2.37 – 2.25 (m, 1H), 2.22 – 2.12 (m, 1H), 2.10 – 2.06 (m, 1H), 2.05 – 
1.96 (m, 2H), 1.86 – 1.73 (m, 4H), 1.73 – 1.63 (m, 4H), 1.62 – 1.55 (m, 2H), 1.55 – 1.41 (m, 
2H), 1.39 – 1.29 (m, 2H), 1.17 (qd, J = 12.3, 2.9 Hz, 2H), 0.93 (qd, J = 12.3, 3.4 Hz, 1H), 
0.77 (qd, J = 12.0, 3.5 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 175.06, 174.24, 171.35, 
153.51, 137.37, 133.30, 105.29, 62.96, 62.70, 60.74, 60.40, 57.22, 56.33, 54.99, 53.23, 44.04, 
41.30, 32.79, 32.51, 31.83, 30.43, 26.43, 26.01, 25.98, 25.45, 24.89, 20.27, 14.20. 
(S)-N-(1-((2-amino-2-oxoethyl)carbamoyl)cyclopentyl)-1-((S)-2-cyclohexyl-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxamide (32) 
The general procedure was used with Fmoc-Gly-OH and Fmoc-1-amino-cyclopentane 
carboxylic acid (first coupling step repeated). 32 was obtained after purification by flash 
chromatography (0% - 100% [EtOAc + 2% MeOH + 0.1% TEA] in cyclohexane) as 
colourless oil (14 mg, 24 µmol, 30.2 %).  
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HPLC [0-100% Solvent B, 20 min]: Rt = 19.1 min. HRMS: calculated 587.3445 
[C31H46N4O7 +H]+, found 587.3530 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 6.87 (s, 1H), 
6.81 (t, 1H), 6.47 (s, 2H), 6.11 (s, 1H), 5.34 (s, 1H), 4.97 (t, 1H), 4.00 (d, 1H), 3.86 (dd, 1H), 
3.76 (s, 6H), 3.72 (s, 3H), 3.62 (dd, 1H), 3.34 (d, 1H), 2.86 (m, 1H), 2.19 – 2.02 (m, 3H), 1.90 
– 1.84 (m, 3H), 1.74 (d, 2H), 1.65 – 1.52 (m, 8H), 1.32 – 1.16 (m, 5H), 1.11 – 1.01 (m, 2H), 
0.82 (qd, 1H), 0.75 – 0.57 (m, 1H). 13C NMR (101 MHz, CDCl3) δ 174.27, 173.39, 172.17, 
172.03, 153.56, 137.39, 133.37, 105.23, 66.78, 60.77, 56.32, 55.10, 53.26, 44.12, 43.10, 
41.30, 37.56, 36.40, 32.52, 30.39, 26.41, 26.00, 25.96, 25.38, 24.82, 23.88, 20.31. 
ASSOCIATED CONTENT  
Full characterization and synthetic procedures of all intermediates as well as crystallography 
information can be found in the supporting information. This material is available free of 
charge via the Internet at http://pubs.acs.org. 
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I. Crystallography 
 
Dataset FKBP513   FKBP5114 
Data collection   
Space group P212121 P63 
Cell dimensions   
  a, b, c (Å) 45.029, 48.414, 
56.852 
82.16, 82.16, 50.19 
  , ,  (°) 90, 90, 90 90, 90, 120 
Wavelength (Å) 1.03679 0.97895 
Resolution (Å) 48.41 - 1.3 (1.37 – 
1.3)* 
41.08 - 1.65 (1.68 - 
1.65) 
Rmerge 0.053 (1.043) 0.077 (0.922) 
I/σI 15.7 (1.7) 12.1 (1.3) 
Completeness (%)  99.5 (97.0) 99.1 (89.6) 
Redundancy  8.3 (7.4) 4.8 (3.0) 
Refinement   
Resolution (Å) 30 – 1.3 30 - 1.65 
No reflections 29490 21944 
Rwork / Rfree 0.144 / 0.186 0.261 / 0.297 
Number of atoms   
  Protein 1042 966 
  Ligand/ion 54 38 
  Water 141 63 
B-factors   
  Protein 21.37 26.69 
  Ligand/ion 15.74 18.59 
  Water 34.43 33.91 
R.m.s. deviations   
  Bond length (Å) 0.025 0.011 
  Bond angles (°) 2.350 1.513 
* Values in parenthesis for outer shell. 
 
Crystallization 
 
3: The complex was prepared by mixing FKBP51 (16-140)-A19T protein at 1.75 mM with 20 
mM 3 dissolved in DMSO in 9:1 ratio. Crystallization was performed at 20 °C using the 
hanging drop vapor-diffusion method, equilibrating mixtures of 1 µl protein complex and 1 µl 
reservoir against 500 µl reservoir solution. Rod-shaped crystals were obtained with reservoir 
solution containing 10 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5. 
 
29: The complex was prepared by mixing FKBP51 (16-140)-A19T protein at 1.75 mM with 
30 mM 29 dissolved in DMSO in 9:1 ratio. Crystallization was performed at 20 °C using the 
hanging drop vapor-diffusion method, equilibrating mixtures of 1 µl protein complex and 1 µl 
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reservoir against 500 µl reservoir solution. Needle-shaped crystals were obtained with 
reservoir solution containing 16 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH 
pH 7.5. 
 
Structure Solution and Refinement 
 
The diffraction data were collected at beamlines X10SA (3) of the Swiss Synchrotron Light 
Source (SLS) in Villigen, Switzerland, and ID29 (29) of the European Synchrotron Radiation 
Facility (ESRF) in Grenoble, France.  Diffraction data were integrated with XDS1, and further 
processed with Aimless and Ctruncate2, as implemented in the CCP4i interface3. The crystal 
structures were solved by molecular replacement employing the program Molrep4.  Iterative 
model improvement and refinement were performed with Coot5 and Refmac56. The 
dictionaries for the compounds were generated with the PRODRG server7.  Residues facing 
solvent channels without detectable side chain density were modeled as alanines.  
Large solvent channels running through the crystal lattice of the FKBP5129 complex 
contained considerable density for disordered molecules. The disorder could not be resolved, 
even when the data were processed in spacegroup P1, and was not included into the 
crystallographic model.  The difference density for the ligand in the ordered molecules was 
however clear and readily interpretable.   
Molecular graphics figures were generated with the program Pymol8. (DeLano, 2002). 
 
II. Chemistry 
 
Chromatographic separations were performed either by manual flash chromatography or 
automated flash chromatography using an Interchim Puriflash 430 with an UV detector.  
Merck F-254 (thickness 0.25 mm) commercial plates were used for analytical TLC. 1H NMR 
spectra, 13C NMR spectra, 2D HSQC, HMBC, and COSY of all intermediates were obtained 
from the Department of Chemistry and Pharmacy, LMU, on a Bruker AC 300, a Bruker XL 
400, or a Bruker AMX 600 at room temperature. Chemical shifts for 1H or 13C are given in 
ppm (δ) downfield from tetramethylsilane using residual protio solvent as an internal 
standard.  
Mass spectra (m/z) were recorded on a Thermo Finnigan LCQ DECA XP Plus mass 
spectrometer at the Max Planck Institute of Psychiatry, while the high resolution mass 
spectrometry was carried out at MPI for Biochemistry (Microchemistry Core Facility) on 
Bruker Daltonics MicrOTOF. 
The purity of the compounds was verified by reversed phase HPLC. All gradients were started 
after 1 min of equilibration with starting percentage of solvent mixture. All of the final 
compounds synthesized and tested have a purity of more than 95%.  
 
Analytical HPLC: 
Pump: Beckman System Gold 125S Solvent Module  
Detector: Beckman System Gold Diode Array Detector Module 168 
Column: Phenomenex Jupiter 4µ Proteo 90Å, 250 x 4.6 mm 4 micron 
 
Solvent A: 95% H2O, 5% MeCN, 0.1% TFA 
Solvent B: 95% MeCN, 5% H2O, 0.1% TFA 
 
Methods:  Described for the specific compound 
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Preparative HPLC:  
Pump:  Beckman System Gold Programmable Solvent Module 126 NMP 
Detector:  Beckman Programmable Detector Module 166 
Column:  Phenomenex Jupiter 10µ Proteo 90 Å, 250 x 21.2 mm 10 micron 
Solvent A: 95% H2O, 5% MeOH, 0.1% TFA 
Solvent B: 95% MeOH, 5% H2O, 0.1% TFA 
 
Methods:  Described for the specific compound 
 
(S)-1-((9H-Fluoren-9-yl)methyl)ester-2-((R)-1-(3-(2-(tert-butoxy)-2-oxoethoxy) phenyl)-
3-(3,4-dimethoxyphenyl)propyl) piperidine-2-carboxylate (3-1) 
 
 
3-1 
 
(S)-Fmoc-Pip-OH (0.25 g, 0.71 mmol), DIPEA (0.50 mL, 2.85 mmol) and HATU (410 mg, 
1.07 mmol) were dissolved in DMF (1.5 mL) and stirred for 30 min at RT. Then (R)-tert-
butyl-2-(3-(1-amino-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetate (0.29 g, 0.71 mmol)* 
dissolved in DCM (2.0 mL) was added to the reaction mixture and stirred at RT for 16 h. The 
solvent was removed in vacuo and the crude product was purified by flash chromatography 
(EtOAc/cyclohexane 3:7) to afford the title compound (0.48 g, 0.65 mmol, 92.1 %) as a light 
yellow solid.  
 
* provided by Lead Discovery Center GmbH, Dortmund (LDC046341) 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 20.5 min. 
 
Mass: (ESI+), calculated 531.25 [C44H50N2O8+H]+, found 531.21 [M+H]+. 
 
1H NMR (400 MHz, DMSO) δ 7.83-7.80 (m, 2H), 7.63-7.58 (m, 2H), 7.46 – 7.39 (m, 4H), 
7.32 – 7.20 (m, 2H), 7.04-7.02 (m, 2H), 6.88-6.84 (m, 3H), 6.80 – 6.74 (m, 2H), 5.20-5.17 (m, 
1H), 5.00 – 4.93 (m, 4H), 4.83 (t, J = 6.2 Hz, 1H), 4.17-4.11 (m, 1H), 3.83 (s, 3H), 3.75 (s, 
3H), 3.53-3.47 (m, 1H), 2.82 (t, J = 4.3 Hz, 1H), 2.69 (t, J = 7.9 Hz, 2H), 2.34-2.20 (m, 2H), 
2.08-1.91 (m, 2H), 1.79-1.66 (m, 3H), 1.34 (s, 9H). 
13C NMR (101 MHz, DMSO) δ 170.45, 168.32, 162.49, 158.23, 155.70, 148.71, 147.54, 
145.61, 144.45, 141.16, 134.01, 129.35, 128.18, 127.22, 125.45, 120.40, 119.48, 113.43, 
112.65, 112.08, 81.47, 64.94, 59.93, 55.91, 54.51, 51.97, 46.97, 41.90, 38.41, 36.27, 32.22, 
31.25, 28.31, 26.80, 24.78, 21.20. 
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tert-Butyl-2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-((S)-piperidine-2-
carboxamido)propyl)phenoxy) acetate (3-2) 
 
 
3-2 
 
3-1 (0.43 g, 0.59 mmol) was dissolved in DCM (4.5 mL) and 4-methylpiperidine (0.5 mL). 
After stirring at RT for 16 h, the reaction mixture was concentrated and the crude product 
purified by flash chromatography (0-100 % (EtOAc + 1 % MeOH + 1 % TEA] in 
cyclohexane). The title compound (160 mg, 0.31 mmol, 53.1 %) was obtained as a colourless 
solid.  
 
Mass: (ESI+), calculated 530.30 [C29H40N2O6+H]+, found 530.28 [M+H]+. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.8 min. 
 
1H NMR (300 MHz, CDCl3) δ 7.26 – 7.20 (m, 1H), 7.18 (d, J = 9.4 Hz, 1H), 6.94 – 6.88 (m, 
1H), 6.86 (dd, J = 2.6, 1.5 Hz, 1H), 6.78 – 6.72 (m, 2H), 6.69 – 6.64 (m, 2H), 4.96 (q, J = 7.7 
Hz, 1H), 4.49 (s, 2H), 3.85 (s, 3H), 3.83 (s, 3H), 3.23 – 3.15 (m, 1H), 3.02 – 2.91 (m, 1H), 
2.68 – 2.58 (m, 1H), 2.59 – 2.50 (m, 2H), 2.21 – 2.00 (m, 4H), 1.98 – 1.87 (m, 1H), 1.80 – 
1.70 (m, 1H), 1.59 – 1.49 (m, 1H), 1.47 (s, 9H). 
 
13C NMR (75 MHz, CDCl3) δ 172.71, 167.65, 158.24, 148.73, 146.82, 144.02, 133.90, 
129.60, 120.08, 119.82, 113.37, 112.87, 111.74, 111.20, 82.20, 65.69, 60.12, 55.90, 52.51, 
45.68, 37.93, 32.24, 29.75, 28.02, 25.69, 23.88. 
 
 
 
 
(S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetic acid (5) 
 
OH
O
OMe
OMe
MeO
 
5 
 
Synthesized as previously described.10 
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C. Summary and Outlook 
In the presented thesis the first structure-affinity-relationship analysis on FKBP51-selective 
ligands, after the discovery of SAFit1 and 2, is shown. Using rational drug design methods, 
three different ligand series were designed, synthesized and evaluated. The overall aim was to 
find promising lead structures as starting point for further drug development since the SAFit 
compounds are not suitable for this. Based on the building blocks used for the synthesis we 
developed two “Bottom Group” (BG) and one “Top Group” (BG) series. 
In all series we were able to reproduce the FKBP51 selective binding mode by induced fit that 
was discovered by Gaali et. al.[…]. This was confirmed by solving cocrystal structures of 
representative ligands with FKBP51. Additionally, we could show that neither modifications 
in the TG nor substitutions in the BG affect the selective binding mode. The correct 
conformation of the cyclohexyl ring seems to be the most important factor. Although we were 
not able to retain the high biding affinities of SAFit1 and 2, the developed ligands and 
building blocks exhibit much lower molecular weights. Together with their moderate binding 
affinity and the possibility for further chemical modification, they could serve as promising 
lead structures.  
During our studies we found out that an α-methyl-cyclohexyl group is the minimum 
requirement for selective binding. Inducing a hydroxyl group to the BG building group by an 
aldol reaction does not lead to an additional interaction with the protein but, nevertheless, 
leads to FKBP51 selective compounds with moderate binding affinities. We also recognized 
that rigidification of the cyclohexyl ring can be realized via a trans decalin scaffold as BG and 
that substituents can be positioned in a novel way with this scaffold. In the TG series we 
discovered a pipeolic acid amide containing a geminally substituted cyclopentyl ring as 
promising new scaffold that leads to ligands with much lower molecular weight. Additionally, 
the solid phase-assisted method that was developed for the synthesis of this series is a useful 
novel method for further the rapid generation of FKBP51-focused libraries.   
The chemical synthesis of SAFit1 and SAFit2 was scaled up and adapted in a way that we 
were able to synthesize both compounds in gram scales to provide them for further in vivo and 
in vitro studies. Thereby FKBP51 was confirmed as possible target for the treatment of 
obesity and melanoma and discovered as new target for treating muscoskeletal chronic pain.   
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These findings reinforce further FKBP51 drug development. Within the explored scaffolds 
particularly the decalin series (BG) exhibits a lot of potential for further exploration. Using 
the developed synthesis the 2-position of the bicycle could (9->10) be further substituted, e.g. 
by a dimethyl (11), an isopropyl (12) or a hydroxymethyl (13) group. Affinities could then be 
increased by inducing a carbonyl group (14+15) in the 4-position (that currently represents 
the best ligand of the series). It’s also further worth trying to introduce an oxygen in the 2-
position (8). A possible way would the conversion a hydroxymethyl group, which was 
described by Inoue et al.60. 
Aux
O R2
R1
OAux OAux OAux
HO
O O
OAux
R2R1
9
10
11 12 13
14 15
8
O O
 
Scheme 7: Possible further modifications of the bicyclic scaffold. 
Most exciting will be the combination of the best building blocks that were discovered during 
this work, e.g. the geminally substituted pipecolic ester amide with the best BG from the 
aldol-series (16) and the decalin-series (17). 
 
Fig. 12: Chemical structures of combinated, promising building blocks  
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Although we initially expect a reduction of binding affinity, we postulate that when these low 
molecular weight (< 500 g/mol) compounds still exhibit moderate binding affinity they can 
serve as new lead structure for further optimization.    
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